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Background 
Streptococcus pneumoniae: a concise history 
Streptococcus pneumoniae, or the pneumococcus, is a Gram-positive, catalase-negative, 
alpha-hemolytic facultative anaerobic bacterium. Pneumococcus belongs to the phylum 
Firmicutes, class Bacilli, order Lactobacillales, family Streptococcaceae, genus 
Streptococcus, and species S. pneumoniae. The pneumococcus was first identified in 1881 
when two microbiologists, George Miller Sternberg - a physician in the United States 
Army, and Louis Pasteur - a French chemist, simultaneously and independently isolated 
and described a roughly lancet-shaped pair of coccoid bacteria in human saliva. In their 
experiments, they injected rabbits with saliva from human carriers and subsequently 
recovered diplococci from the blood of these rabbits [1, 2]. The infected rabbits soon died 
from septicemia revealing the pathogenic potential of the newly discovered bacterium in 
mammals. They described a microorganism with characteristic paired cell, diplococcal 
morphology and a distinct capsular layer around each bacterium. Since these discoveries, 
antibiotics and vaccines have been discovered to combat the pneumococcus, but still, 
infection by S. pneumoniae cause up to 1.6 million mortalities globally each year [3]. 
Identification and characterization of the pneumococcus 
Laboratory identification of pneumococci and routine bacteriology continue to rely on 
decades-old culture-based methods [4]. Diagnosis of pneumococci etiology relies on 
recovery, usually verified by a positive culture, of the organism from patients’ diagnostics 
samples (sputum, lungs, spinal fluid, or blood) [5]. S. pneumoniae grows best at 35-37°C 
with ~5% CO2 on blood agar but can also grow on a chocolate agar. Subtle differences 
between pneumococci and other genetically related strains and viridans streptococci can 
be used for accurate diagnostics. S. pneumoniae can be identified using Gram’s stain, 
catalase, and optochin tests simultaneously, and the results confirmed using a bile 
solubility test. If these tests indicate the presence of S. pneumoniae, serological or DNA-
based molecular typing approaches can then be performed to identify the serotype [6-8]. 
This order of analysis, as summarized in Figure 1, is an efficient way to save on time and 
costly serotyping chemicals. It is noteworthy that pneumococcal capsular serotyping is 
not usually required for a clinical response but, it is a crucial part of successful 
pneumococcal disease surveillance efforts especially in the light of pneumococcal 
conjugate vaccines, which targets the highly variable capsule. 
Catalase test: Catalase breaks down hydrogen peroxide (HR2ROR2R) into water (HR2RO) and 
oxygen (OR2R). In catalase-positive microorganisms, the oxygen is exuded as bubbles in the 
liquid, a phenomenon lacking in catalase-negative microorganisms [9]. The catalase test 
is mainly used to distinguish between Gram-positive cocci. Members of the genera 
Streptococcus and Enterococcus are catalase-negative while members of the genus 
Staphylococcus are catalase-positive.  
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Gram’s stain: The method is named after its inventor, Hans Christian Gram, a Danish 
scientist who was experimenting with the techniques for visualizing bacteria in Carl 
Friedländer’s laboratory [10]. By sequentially exposing sections of lung tissues to aniline-
gentian violet; a weak solution of ethanol, iodine, and Bismarck brown or vesuvin, Gram 
observed many pairs of slightly elongated cocci that retained the dark aniline-gentian 
violet stain. Other bacteria in Gram’s specimens failed to retain the aniline-gentian violet 
stain. Gram’s phenomenal discovery [11] that virtually all clinically relevant bacteria are 
either Gram-positive or Gram-negative became one of the foundations of clinical 
microbiology. 
Figure 1. Schematic overview of the steps for identifying and characterizing S. pneumoniae 
Bile solubility test and Optochin Test: When grown aerobically on blood agar, S.
pneumoniae like many other streptococci produce hydrogen peroxide which induces
alpha (α)-hemolysis by oxidizing hemoglobin to green methemoglobin; the characteristic
green coloration observed on blood agar plates [12]. A distinguishing feature between S. 
pneumoniae and other α-hemolytic streptococci is its sensitivity to lysis by bile, in the so-
called ‘bile solubility test’ [13]. The bile salt deoxycholate activates pneumococcal LytA
amidase, an essential autolytic enzyme [14]. Alternatively, S. pneumoniae can be
differentiated based on its susceptibility to optochin (ethylhydrocupreine); optochin
inhibits the pneumococcal FR0RFR1R-ATPase [15]. However, none of these tests are entirely
accurate because resistance of S. pneumoniae to both deoxycholate [16] and optochin [17]
has been observed. 
Serology: Quellung test [8], an immunological reaction with type-specific pneumococcal 
antisera is the gold standard microbiological analysis for identification and typing of S.
pneumoniae. However, serological tests cannot be used to identify pneumococcal strains
lacking a polysaccharide capsule. Cross-reaction may also occur with viridans streptococci
which have an antigen similar to pneumococcal polysaccharide leading to false-positive
results. Furthermore, use of older colonies or mixed cultures may lead to equivocal 
serological reactions.
Polymerase chain reaction (PCR): PCR [18] is a valuable tool for selective amplification of 
particular target DNA sequence(s) within a heterogeneous collection of DNA sequences.
Conventional and real-time PCR assays have been used for diagnosis or surveillance of
pneumococci by detecting specific sequence regions of the pneumolysin (ply), autolysin
(lytA), and pneumococcal surface adhesion (psaA) genes [19, 20]. Several pneumococcal
serospecificities are included in multiplex PCR schemes [6, 7, 21]. Furthermore, PCR can
be combed with partial or targeted genome sequencing [22] or transcriptomics [23] to 
improve the detection of S. pneumoniae. Nonetheless, discrepant results, although rare,
may occur in PCR-based assays due to recombination events that occur between
pneumococci and closely related and viridans streptococci [20, 21]. Furthermore, viridans
streptococci may sometimes also contain the target genes [24].
Molecular typing using MLST: Multilocus sequence typing; MLST [25] relies on
amplification and sequencing of up to seven housekeeping genes (Shikimate 
dehydrogenase; aroE, glucose-6-phosphate dehydrogenase; gdh, glucose kinase; gki, 
xanthine phosphoribosyltransferase; xpt, transketolase; recP, Signal peptidase I; spi, and
D-alanine-D-alanine ligase; ddl), and using the allelic variation in these genes to assign
the pneumococcal isolates to sequence types or clones [26]. The validity of MLST is based
on the paradigm that isolates with identical or closely related allelic profiles typically
express the same serotype [26], but few exceptions have been reported [27]. MLST is
widely used, mainly for epidemiological surveys and population genomics, because it
offers a higher resolution to distinguish isolates at a species level compared to other
techniques such as 16S RNA sequencing [27, 28], and is much cheaper than whole-
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cc r t  c s  r sist c  f . e i e t  t  x c l t  [1 ]  t c i  [17] 
s  s r .  
er l : ll  t st [ ],  i l ic l r cti  it  t -s cific c cc l 
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e i e. r, s r l ic l t sts c t  s  t  i tif  c cc l str i s 
l c i   l s cc ri  c s l . r ss-r cti   ls  cc r it  iri s str t c cci 
ic    ti  si il r t  c cc l l s cc ri  l i  t  f ls - siti  
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s r l ic l r cti s. 
l er se c i  re cti  ( ):  [1 ] is  l l  t l f r s l cti  lific ti  f 
rtic l r t r t  s c (s) it i   t r s c ll cti  f  s c s. 
ti l  r l-ti   ss s   s  f r i sis r s r ill c  f 
c cci  t cti  s cific s c  r i s f t  l si  ( l ), t l si  
(l t ),  c cc l s rf c  si  ( s ) s [1 , ]. r l c cc l 
s r s cificiti s r  i cl  i  lti l x  sc s [ , 7, 1]. rt r r ,  c  
 c  it  rti l r t r t   s ci  [ ] r tr scri t ics [ 3] t  
i r  t  t cti  f . e i e. t l ss, iscr t r s lts, lt  r r , 
 cc r i  - s  ss s  t  r c i ti  ts t t cc r t  
c cci  cl s l  r l t   iri s str t c cci [ , 1]. rt r r , iri s 
str t c cci  s ti s ls  c t i  t  t r t s [ ]. 
lec l r t i  si  : ltil c s s c  t i ;  [ ] r li s  
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r s ; r , l c s - - s t  r s ; , l c s  i s ; ki, 
x t i  s ri s ltr sf r s ; x t, tr s t l s ; rec , i l ti s  I; s i,  
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inhibits the pneumococcal FR0RFR1R-ATPase [15]. However, none of these tests are entirely
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has been observed. 
Serology: Quellung test [8], an immunological reaction with type-specific pneumococcal 
antisera is the gold standard microbiological analysis for identification and typing of S.
pneumoniae. However, serological tests cannot be used to identify pneumococcal strains
lacking a polysaccharide capsule. Cross-reaction may also occur with viridans streptococci
which have an antigen similar to pneumococcal polysaccharide leading to false-positive
results. Furthermore, use of older colonies or mixed cultures may lead to equivocal 
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Polymerase chain reaction (PCR): PCR [18] is a valuable tool for selective amplification of 
particular target DNA sequence(s) within a heterogeneous collection of DNA sequences.
Conventional and real-time PCR assays have been used for diagnosis or surveillance of
pneumococci by detecting specific sequence regions of the pneumolysin (ply), autolysin
(lytA), and pneumococcal surface adhesion (psaA) genes [19, 20]. Several pneumococcal
serospecificities are included in multiplex PCR schemes [6, 7, 21]. Furthermore, PCR can
be combed with partial or targeted genome sequencing [22] or transcriptomics [23] to 
improve the detection of S. pneumoniae. Nonetheless, discrepant results, although rare,
may occur in PCR-based assays due to recombination events that occur between
pneumococci and closely related and viridans streptococci [20, 21]. Furthermore, viridans
streptococci may sometimes also contain the target genes [24].
Molecular typing using MLST: Multilocus sequence typing; MLST [25] relies on
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on the paradigm that isolates with identical or closely related allelic profiles typically
express the same serotype [26], but few exceptions have been reported [27]. MLST is
widely used, mainly for epidemiological surveys and population genomics, because it
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genome sequencing (WGS) which provides superior resolution. Unfortunately, MLST has 
little power in resolving small evolutionary differences and thus not suitable for 
characterizing possible differences in strains within pneumococcal outbreaks. To improve 
the discriminatory power, MLST data can be used in combination with pulsed-field gel 
electrophoresis (PFGE), Multiple-locus variable number tandem repeat analysis (MLVA) 
[29], or sequencing data from more variable genetic loci such as penicillin binding protein 
(pbps) and pneumococcal surface adhesin A (psaA). It will only be a matter of time before 
the robustness of WGS could be put to routine clinical use in the diagnosis of the 
pneumococcus. In fact, WGS is already pivotal in pneumococcal molecular epidemiology 
studies [30], key among them the Global Pneumococcal Sequencing Project [31]. This 
global database will provide a platform to measure the response of S. pneumoniae to 
vaccines and precisely characterize patterns of genetic adaptation on global and regional 
levels, an insight that will significantly inform the designing of future interventions.  
Pneumococcal nasopharyngeal colonization 
Although asymptomatic carriage is common in healthy individuals, nasopharyngeal 
colonization is a prerequisite for pneumococcal disease and a source of the pneumococcal 
spread between individuals [32, 33]. The pneumococci are spread through contact with 
ailing or healthy carriers of the bacteria. Transmission from person to person occurs via 
respiratory droplets/aerosols from the nose or mouth. Children acquire pneumococcal 
approximately twice as much as adults do [34]. The density and duration of 
pneumococcal colonization are mostly influenced by the host age [35] and serotype of the 
colonizing strain [36]. Certain serotypes including type 6B, 9V, 14, 19F and 23F are most 
commonly found in young children [4] whereas type 1, 3, 5, 7F/A, 14 and  19A are most 
commonly found in adults [37, 38]. Overall, common pneumococcal serotypes have been 
observed to be superior in acquisition rate and carriage duration, and they are generally 
non-susceptible to colonization competition [36]. Pneumococcal carriage is usually high 
in children with disproportionately higher rates in developing countries compared 
developed countries [39]. For most serotypes, the prevalence of nasopharyngeal 
colonization peaks around 2-3 three years of life and diminishes after that to <10% in 
adults [4]. The duration of carriage also declines with age [36], probably as a result of the 
mature immunologic response which develops with age. Interestingly, colonization 
remains low in old age > 65 years despite the waning immunity [40]. Children are 
therefore the primary reservoir of pneumococcal strains that circulate within 
communities. The colonization rates in young children associate with the high risk of 
invasive pneumococcal diseases (IPD). However, the incidence of IPD observed in the 
elderly is remarkably high despite the low carriage rates, probably due to the 
heterogeneity in disease susceptibility among the elderly [32].  
Apart from age-dependent colonization, other lifestyle and dietary factors, including 
living in crowded area, or in close-contact like a day care center [33], consumption of, or 
exposure to tobacco [41], and excessive sugar intake in early age [42] are also implicated 
 
 
  
in promoting the acquisition of, and infection by S. pneumoniae. Although probably linked 
to the underlying socioeconomic factors which also affect colonization rates, studies have 
shown that host genetic factors may influence pneumococcal colonization in various 
ethnicities [43, 44]. 
Epidemiology of pneumococcal disease 
The pneumococcus has a dichotomous lifestyle, persisting as a commensal colonizer of 
the nasopharynx in healthy carriers, but can also transition into a ferocious opportunistic 
pathogen in susceptible individuals. Pneumococcal infections mainly consist of superficial 
mucosal infections, such as sinusitis, conjunctivitis, acute otitis media, acute 
exacerbations of chronic bronchitis, and exacerbation of chronic obstructive pulmonary 
disease (COPD). However, when the organism disseminates into deeper, usually sterile 
innate tissue compartments (Figure 2), it can instigate severe invasive pneumococcal 
diseases (IPD), including pneumonia, septic bacteremia, and meningitis [45]. IPD is 
associated with a high degree of morbidity and mortality worldwide.  
Age and gender are important risk factors for pneumococcal infections. Disease risk is 
highest in young children <2 years, the aged >65 years, and individuals with chronic 
illnesses or immune suppression [46]. The incidence of IPD is up to 50 times higher in the 
young (under 5 years old) and the elderly (over 65 years old) than in adolescents [47]. 
Additionally, there is a predominance of pneumococcal disease in males than female [47]. 
This may be because underlying conditions such as cigarette smoking and alcoholism are 
more prevalent among men. An increased risk of IPD is also concomitant with defects in 
the nonspecific or specific defense mechanisms against colonization or invasion of S. 
pneumoniae. Other important risk factors include chronic and immunocompromising 
illnesses such as heart, lung and kidney disease, sickle cell disease, diabetes, cancer, 
HIV/AIDS asplenia, and admission into group childcare or nursing homes [48, 49]. 
Approximately 1.6 million people, including up to a million children under five years old, 
die of IPD every year. IPD is the leading cause of death among vaccine-preventable 
infectious diseases [3]. Developing countries bear the greatest burden of IPD than 
industrialized countries [45], probably due to extensive immunization campaigns and 
socioeconomic status [50]. 
S. pneumoniae is the most common cause of community-acquired pneumonia worldwide 
[51], and together with H. influenzae and M. catarrhalis, they are the major bacterial 
causes of respiratory tract infections [52]. Secondary bacterial infections are thought to 
be the cause majority of the deaths in viral pandemics. Pneumococcal co-infections are 
particularly common in viral pandemics, especially those involving influenza virus [53]. 
Pneumococcal pneumonia is characterized by four stages. First, the lung alveoli are filled 
up with fluids that contain pneumococci. These fluids mediate the spread of the organism 
throughout the lungs. The host immunity recruits neutrophils and red blood cells which 
invade the alveoli inducing an inflammatory immune response. By this stage, most of the 
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adults [4]. The duration of carriage also declines with age [36], probably as a result of the 
mature immunologic response which develops with age. Interestingly, colonization 
remains low in old age > 65 years despite the waning immunity [40]. Children are 
therefore the primary reservoir of pneumococcal strains that circulate within 
communities. The colonization rates in young children associate with the high risk of 
invasive pneumococcal diseases (IPD). However, the incidence of IPD observed in the 
elderly is remarkably high despite the low carriage rates, probably due to the 
heterogeneity in disease susceptibility among the elderly [32].  
Apart from age-dependent colonization, other lifestyle and dietary factors, including 
living in crowded area, or in close-contact like a day care center [33], consumption of, or 
exposure to tobacco [41], and excessive sugar intake in early age [42] are also implicated 
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to the underlying socioeconomic factors which also affect colonization rates, studies have 
shown that host genetic factors may influence pneumococcal colonization in various 
ethnicities [43, 44]. 
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The pneumococcus has a dichotomous lifestyle, persisting as a commensal colonizer of 
the nasopharynx in healthy carriers, but can also transition into a ferocious opportunistic 
pathogen in susceptible individuals. Pneumococcal infections mainly consist of superficial 
mucosal infections, such as sinusitis, conjunctivitis, acute otitis media, acute 
exacerbations of chronic bronchitis, and exacerbation of chronic obstructive pulmonary 
disease (COPD). However, when the organism disseminates into deeper, usually sterile 
innate tissue compartments (Figure 2), it can instigate severe invasive pneumococcal 
diseases (IPD), including pneumonia, septic bacteremia, and meningitis [45]. IPD is 
associated with a high degree of morbidity and mortality worldwide.  
Age and gender are important risk factors for pneumococcal infections. Disease risk is 
highest in young children <2 years, the aged >65 years, and individuals with chronic 
illnesses or immune suppression [46]. The incidence of IPD is up to 50 times higher in the 
young (under 5 years old) and the elderly (over 65 years old) than in adolescents [47]. 
Additionally, there is a predominance of pneumococcal disease in males than female [47]. 
This may be because underlying conditions such as cigarette smoking and alcoholism are 
more prevalent among men. An increased risk of IPD is also concomitant with defects in 
the nonspecific or specific defense mechanisms against colonization or invasion of S. 
pneumoniae. Other important risk factors include chronic and immunocompromising 
illnesses such as heart, lung and kidney disease, sickle cell disease, diabetes, cancer, 
HIV/AIDS asplenia, and admission into group childcare or nursing homes [48, 49]. 
Approximately 1.6 million people, including up to a million children under five years old, 
die of IPD every year. IPD is the leading cause of death among vaccine-preventable 
infectious diseases [3]. Developing countries bear the greatest burden of IPD than 
industrialized countries [45], probably due to extensive immunization campaigns and 
socioeconomic status [50]. 
S. pneumoniae is the most common cause of community-acquired pneumonia worldwide 
[51], and together with H. influenzae and M. catarrhalis, they are the major bacterial 
causes of respiratory tract infections [52]. Secondary bacterial infections are thought to 
be the cause majority of the deaths in viral pandemics. Pneumococcal co-infections are 
particularly common in viral pandemics, especially those involving influenza virus [53]. 
Pneumococcal pneumonia is characterized by four stages. First, the lung alveoli are filled 
up with fluids that contain pneumococci. These fluids mediate the spread of the organism 
throughout the lungs. The host immunity recruits neutrophils and red blood cells which 
invade the alveoli inducing an inflammatory immune response. By this stage, most of the 
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bacteria have been cleared, and the neutrophils packed into the alveoli. Finally, 
macrophages eliminate the remaining residue from the inflammatory response 
effectively dissipating the assault [54]. Much of the damage to the lungs is therefore 
mainly caused by the host’s inflammatory response. 
If it manages to persist in the lungs, the pneumococcus can invade the blood and cause 
bacteremia which could lead to sepsis [46]. When in the blood it can cross the blood-brain 
barrier and infect the meninges causing meningitis [55]. The pneumococcus is also 
implicated in causing milder infections in other parts, including the middle ear; leading to 
otitis media [56], the paranasal sinuses; causing sinusitis [57], the peritoneum; causing 
peritonitis [58], and the joints or bones; causing septic arthritis or osteomyelitis 
respectively [59]. The polysaccharide capsule is thought to be the major virulent factor 
and the primary determinant of the pneumococcal invasive potential [60]. Recent studies, 
however, suggest that other determinants of invasiveness may be localized beneath the 
capsule [61-63]. These factors should be included in evaluating the effects of current 
vaccines and modeling future interventions [64]. 
 
Figure 2. Overview of pneumococcal colonization, transmission and progression to disease. Adapted from 
Henriques-Normark and Tuomanen (2013) 
  
 
 
  
Prevention and treatment of pneumococcal disease 
There are several different prevention and therapeutic options for pneumococcal 
infections. For the prevention of pneumococcal disease, two types of vaccines which 
contain purified capsular polysaccharides of the most common serotypes that cause IPD 
are currently offered. These are pneumococcal polysaccharide vaccine; PPV, and 
pneumococcal conjugate vaccine; PCV [65]. PPV primarily induces a B-cell-dependent 
immune response and require a revaccination after 5-6 years. They are therefore 
recommended for use in adults, because they have a matured immune system, but not 
for children under the age of two [50, 65]. PCV was originally available as a heptavalent, 
containing 7 serotypes (PCV7), but was later extended to include decavalent (PCV10) and 
tridecavalent (PCV13) prescriptions. These PCVs are used for childhood immunization 
programs in most countries around the world. Pneumococcal vaccines have significantly 
reduced episodes of pneumococcal infections caused by protected serotypes, also known 
as vaccine-type serotypes, in children and non-vaccinated adults signifying herd-
immunity [45]. But due to the limited coverage by the PCV (protecting against 7, 10, or 13 
serotypes), and the considerable antigenic variability in S. pneumoniae capsular types; 
with over 90 antigenically distinct serotypes characterized to date [22, 23], a universal 
vaccine has not been developed. ‘Serotype replacement’ with non-vaccine serotypes also 
occurs rapidly under vaccine pressure [30, 66]. The replacement, at least partially, 
abrogates the protective effect of immunization. In rare cases, strains may exchange 
entire capsular loci, in the process commonly referred to as ‘capsule switching’, leading to 
new genotypes capable of evading vaccines or exhibiting resistance to essential antibiotic 
[30, 66]. 
Treatment of pneumococcal infections typically depends on the type of infection and 
disease severity. Routine use of antibiotics to treat minor bacterial infections is not 
recommended as it increases the probability of the bacteria developing drug-resistance 
over time [67]. Mild non-invasive pneumococcal infections such as sinusitis and 
bronchitis, are usually cleared by the host immunity without the need for treatment. 
Antibiotics could be used in rare cases for outpatient treatment or prophylaxis in patients 
with recurrent infections [68], especially those with underlying immunocompromising 
conditions such as HIV/AIDS and sickle cell anemia [69]. For IPD, however, antibiotic 
therapy - primarily with β-lactams - in inpatient medical ward or intensive care units is 
recommended [50, 70]. Nevertheless, the fact that S. pneumoniae is increasingly 
developing resistance to β-lactams [71] and to most other essential antibiotics [52, 70] is a 
greater concern to healthcare management systems globally. S. pneumoniae has a 
natural transformation system that facilitates the exchange of genetic material [67]. 
Therefore, strains that have developed antibiotic resistance can often spread these traits 
to other strains accelerating the problem. Due to the natural attributes of the 
pneumococcus in evading current remedies, proper management of the pneumococcus is 
a growing concern. Therefore, new tools for investigating the pneumococcus and 
developing potent therapies are required. 
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Pneumococcal genomics  
Since its discovery in the 1880s, the pneumococcus has been extensively studied and was 
involved in several historical findings such as Gram staining, serotherapy, the discovery of 
DNA as the hereditary genetic material, and that bacteria can transfer genetic material 
via transformation [72, 73]. Complete sequencing of pneumococcal genomes was first 
completed in 2001 [74]. The genome contains a core set of around 1,500 genes that are 
essential for colonization, or growth and viability [30, 75, 76]. In the accessory or flexible 
genome, considerable plasticity exists between pneumococcal strains; mainly from 
insertional sequences which account for about 5% of the genome, and replete direct-
repeat DNA elements and mobile (integrative and conjugative) genetic elements which 
provide recombinational hotspots for genetic variability [74, 75, 77]. Croucher, et al. for 
example, demonstrated that short-term pneumococcal variations are characterized by 
movement of phages and intragenomic rearrangements, with the slower transfer of 
stable loci distinguishing lineages [75]. The readiness to quickly take up genetic material 
enables the pneumococcus to gain and spread DNA sequences responsible for antibiotic 
resistance and capsular switches that may explain vaccine evasion [30, 66]. Pneumococci 
also encode a plethora of transport systems which, among other functions, help in 
nutrient acquisition, importing carbon and amino acid substrates, and in exporting 
adhesins, degradation enzymes, and components for capsular synthesis. These systems 
are also essential for the genetic competence of the pneumococcus and as drug-efflux 
pumps [74]. About 150 genes of the complement genome contribute to virulence and 
another set of about 170 genes actively maintain the non-invasive phenotype [50, 74], as 
invasion is considered an evolutionary dead-end for the microorganism. In other words, 
invasion does not evolutionarily benefit the pneumococcus since invading strains cannot 
transmit anymore. 
In the recent past, high-throughput genome sequencing technologies (HTGST) have 
emerged as de facto tools that offer unparalleled resolution for microbiology. The 
technologies have significantly contributed to the expansion of dedicated databases such 
as GenBank that collate genome sequencing data. Using bioinformatics and genomics 
tools, information in these databases could be mined and applied to study molecular 
epidemiology, comparative genomics, functional genomics, and population genomics for 
the pneumococcus. For example, the technology has been used in combination with 
other in silico techniques such as homology mapping, comparative genomics, Tn-seq [78], 
and machine learning among others – as reviewed in Chapter 2 - to predict essential 
genes which form potential drug targets [79], discover genetic variants underlying 
relevant phenotypes of antibiotic-resistance [80] and clinical manifestation of IPD [76], 
and to study the molecular epidemiology and evolution of pneumococcal strains [30, 75, 
77]. Bentley and colleagues also utilized HTGST and comparative genomics to identify 
capsular biosynthesis gene clusters for 90 pneumococcal serotypes and explore how 
capsular biosynthesis and the evolution of capsular genes give rise to antigenic diversity 
in the pneumococcus [22]. These studies have advanced the general bacteriology of the 
 
 
  
pneumococcus and provided invaluable knowledge that could steer the design of future 
interventions. Most importantly, they have accelerated the much-anticipated adoption of 
HTGST into routine applications in clinical laboratory microbiology and public health 
surveillance. 
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Research aims and outline of this thesis 
The goal of the research described in this thesis is to understand better the etiology and 
molecular epidemiology of Streptococcus pneumoniae using bioinformatics tools. In silico 
bioinformatics studies were complemented with in vitro and in vivo experiments to 
generate novel insights into the etiology and molecular epidemiology of the 
pneumococcus. The rise of antibiotic-resistant bacteria has led to an urgent need for the 
development of novel diagnostics, drugs and vaccines, rapid detection of drug resistance 
in clinical isolates, and improvements in global surveillance. Given the importance of 
essential bacterial genes in cellular viability, they form promising drug targets for rational 
drug discovery. In Chapter 2, we review current advances and future perspective into the 
discovery of essential genes using computational approaches. Chapter 3 describes a 
proof of concept study that combines high-density transposon mutagenesis, genome 
sequencing and integrative genomics for the identification of potential drug targets in S. 
pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. The chapter explores the 
exhaustive power of transposon insertions sequencing (Tn-seq) complemented with in 
silico tracking to rapidly identify essential genes. Candidate essential genes are further 
subject to comparative selection criteria to identify a subset that is nonconserved in the 
human host and absent in the commensal human gut microbiota. Four new targets in this 
subset were experimentally validated.  
The undesirable trends of post-vaccine ‘serotype replacement’ and ‘capsule switching’ 
which repeal the protective effects of the vaccines have been reported in pediatric 
carriage. Chapter 4 presents the impact of pneumococcal vaccination on whole genome 
epidemiology of adulthood IPD using whole-genome sequencing of 350 pneumococcal 
isolates from Nijmegen. In this chapter, we have established the effect of PCV7 on the 
pneumococcal population epidemiology and present HTGST as a powerful tool for the 
surveillance of circulating and infecting pneumococcal strains. In Chapter 5 and Chapter 
6, we further explore the use of HTGST and genome-wide association studies (GWAS) to 
identify the genetic variants underlying bacterial phenotypes of antibiotics resistance and 
clinical manifestation of invasive disease respectively. Chapter 5 describes an approach 
that uses GWAS of 1680 systematically selected literature and in-house S. pneumoniae 
isolates to compute the ‘distance to antibiotic resistance’ using the cumulative effect of 
antibiotic resistance-conferring SNPs. In Chapter 6, we analyze 349 pneumococcal 
genomes to discover the genetic variants that correlate with clinical manifestation of IPD. 
Some patients have an increased risk of death after the invasion by S. pneumoniae. A 
phage gene that encodes a platelet binding protein, PblB, was identified as one of the 
candidate correlates of all-cause mortality within the first 30 days of hospitalization (30 
day mortality). Chapter 7 reports the biological mechanism behind this association. 
These studies highlight the efficiency of genome sequencing and integrative genomics in 
pneumococcal bacteriology. The thesis concludes (Chapter 8) with a discussion of the 
results of all our studies (Chapters 3-7). The insights gained are integrated with the 
 
 
  
current state of literature to help place our findings in the light of healthcare application 
and provided a primer for future research on the pneumococcus. 
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Abstract 
The minimal subset of genes required for cellular growth, survival, and viability of an 
organism are classified as essential genes. Knowledge of essential genes gives insight into 
the core structure and functioning of a cell. This might lead to more efficient 
antimicrobial drug discovery, to elucidation of the correlations between genotype and 
phenotype, and a better understanding of the minimal requirements for a (synthetic) cell. 
Traditionally, constructing a catalog of essential genes for a given microbe involved costly 
and time-consuming laboratory experiments. While experimental methods have 
produced abundant gene essentiality data for model organisms like Escherichia coli and 
Bacillus subtilis, the knowledge generated cannot automatically be extrapolated to 
predict essential genes in all bacteria. In addition, essential genes identified in the 
laboratory are by definition ’conditionally essential’, as they are essential under the 
specified experimental conditions: these might not resemble conditions in the 
microorganisms’ natural habitat(s). Also, large-scale experimental assaying for essential 
genes is not always feasible due to the time investment required to setup these assays. 
The ability to rapidly and precisely identify essential genes in silico is therefore important 
and has great potential for applications in medicine, biotechnology, and basic biological 
research. Here, we review the advances made in the use of computational methods to 
predict microbial gene essentiality, perspectives for the future of these techniques, and 
the possible practical applications of essential genes. 
 
  
 
 
  
Introduction 
Inactivation of essential genes in an otherwise wild type organism results in lethality. 
These genes therefore represent the foundation of cellular life [1, 2]. Identifying essential 
genes is therefore valuable and important in biology, industrial bioprocessing, and 
medicine. For example, it could aid in comprehending the basic principles behind how 
cells function [3], and the complex relations between genotype and phenotype [4], which 
are fundamental questions in biology and genetics. Understanding the function of 
essential genes is prerequisite to discovering the core components of a minimal cell [5], 
potentially facilitating re-engineering of microorganisms [6] with desired phenotypical 
traits for research and biotechnology. Additionally, since essential genes confer lethal 
phenotypes to microorganisms when deleted or inactivated, they form promising drug 
targets upon which potent antibiotics could be developed [7, 8]. Knowledge of gene 
essentiality has been applied in discovering candidate ‘human disease genes’ (genes with 
disease associated alleles), their mode of inheritance, and contribution to developmental 
abnormalities or disease [9].  
Essential genes have been identified in a number of model organisms [10-15]. However as 
recently reviewed [2], several studies querying gene essentiality in the same organisms 
under similar experimental conditions have produced different catalogs of essential 
genes. This lack of consensus makes it challenging to determine gene essentiality in 
model organisms, let alone in non-model or poorly researched organisms. The differences 
are possibly a result of ’conditional or contextual’ essentiality: the essentiality of a gene 
depends on its context, which might be a defined growth media or conditions, genetic 
context, or a particular developmental stage of a microorganism [16]. Moreover, the 
longer timespans required for conducting experiments also give enough time for 
isozymes to be upregulated significantly affecting essentiality prediction. Most studies 
have consistently deciphered essential genes under rich media conditions 
(Supplementary Table 1); in other words, in the richness of a full complement of vital 
nutrients and devoid of environmental stress [8, 11, 13, 14, 17]. Although laboratory rich 
media conditions are undoubtedly not a proxy of conditions in a microorganism’s natural 
niche, essential genes determined under these conditions provide a near-complete 
representation of genes needed in most in situ niches [11]. Therefore, for the purpose of 
this review, we define the “essentiality” of a gene as its indispensability under rich media 
conditions. 
Gene essentiality studies have advanced significantly in the past few years owing to a 
plethora of in vitro, in vivo (laboratory), and in silico methods. Laboratory methods assess 
gene essentiality by observing lethal phenotypes ensuing from random or systematic 
gene inactivation using transposon mutagenesis [12], gene knockouts [11, 18], genetic 
complementation [19], and RNA interference [20]. However, genomic-scale discovery of 
essential genes using laboratory techniques is often complex, costly, time consuming, 
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and is contextual since it can be influenced by growth conditions as well as genetic 
context [16]. Therefore, to establish accurate results, a consensus of predicted essential 
genes across multiple laboratories is required. To circumvent these complexities, in silico 
techniques have been developed to predict essential genes [21-23]. Computational 
methods have gained popularity over the past years for numerous reasons. First, 
computational methods are less time consuming and they benefit from knowledge 
obtained from other organisms. The essential genes identified from several 
microorganisms provide seed information for training gene essentiality predictors for less 
researched organisms. Second, the abundance of ‘omics’ data from genomic sequencing 
projects provides opportunities for microbial functional genomics. Lastly, bioinformatics 
has greatly developed over recent years, significantly advancing tools available to 
discover essential genes in sequenced genomes. It is noteworthy that computational 
methods cannot (yet) predict conditional essentiality but rather predict whether a gene is 
essential or not.  
In this review, we focus on advances made in genome-wide microbial gene essentiality 
prediction, particularly using computational methods. We discuss the fundamental 
principles of computational gene essentiality prediction tools, and provide an opinion on 
the choice of method. We also explore the possible practical applications of essential 
genes and give a perspective into the future of computational methods in predicting gene 
essentiality.  
 
Computational techniques for gene essentiality prediction 
Many in silico prediction methods have been established to aid in post hoc analysis of 
experimental readouts, or mining ‘omics’ data for encoded signatures to identify essential 
genes. Below we discuss approaches commonly used to predict gene essentiality (Figure 
1). They commonly analyze intrinsic genomic features, such as localization signals, codon 
adaptation indices, GC content, gene orthologs, rate of gene evolution, and phyletic gene 
retention [21, 22, 24]. Other integrated approaches such as network analysis [3, 25] and 
machine learning on combinations of features and approaches [24, 26] are also discussed. 
Transposon sequencing methods 
Transposons have been widely used in techniques like signature tagged mutagenesis [27] 
to manipulate genes in various microorganisms [12, 28, 29] albeit with low resolution. 
Recently however, various high-throughput techniques including Tn-seq [15], INSeq [30], 
HITS [31], TraDIS [32], and variants thereof have harnessed the power of traditional 
transposon mutagenesis, next-generation sequencing (NGS), and post-hoc in silico 
tracking of the insertions, to explore gene function and higher-order genome 
organization [14]. 
 
 
  
Transposon sequencing and analysis (TSA) techniques commonly rely on the construction 
of transposon mutant libraries in which non-essential genes contain transposon 
insertions, followed by growth of the mutant libraries in defined in vitro or in vivo (e.g. 
host infection models) conditions. The relative frequency of each mutant in the 
population at the beginning and the end of the experiment is then determined by means 
of NGS at the transposon junctions. Genes that are essential for growth under a particular 
condition will not accumulate transposon insertions. From this data, the fitness of every 
gene to the experimental conditions to which the transposon libraries were subjected is 
quantified [15, 30-32]. The relatedness and differences between various TSA techniques 
have comprehensively been reviewed [33, 34]. Their main advantages are the high levels 
of accuracy and sensitivity in predicting gene essentiality, and their ability to be adapted 
for analyses in a wide range of species. By using certain regimes to store mutant libraries, 
it is also possible to obtain strains with desired gene knockout(s). In addition, the 
sequencing protocols used generate short sequence reads of millions of DNA molecules 
simultaneously, allowing whole genomes to be investigated in a single experiment. 
Nonetheless, TSA techniques are dependent on strong molecular amenability of an 
organism to allow creation of saturated mutant libraries and accurate deep sequencing 
[8], making them quite expensive for routine use. For this reason, computational 
approaches like homology mapping and machine learning, which may rely solely on 
computer-mined essentiality determinants would be desirable (Figure 1). 
Homology mapping models 
The term ‘homologs’ refers to two or more genes related by descent from a common 
ancestral DNA sequence. This relationship may arise between genes separated by 
speciation (orthologs) or genetic duplication (paralogs). Prediction of essential genes 
based on sequence homology, especially to known essential genes, is arguably the 
simplest and earliest used method in the genomic era. Shortly after the availability of the 
first two completely sequenced bacterial genomes, homology models were employed to 
predict gene essentiality [35], and to establish the minimal genome [17] in Haemophilus 
influenzae and Mycoplasma genitalium. These models rely on heuristic algorithms 
embedded in sequence alignment programs like Muscle [36], Clustal [37-39], T-Coffee 
[40], and database search tools like BLAST, to compare query sequences with a library or 
database of subject sequences whose essentiality is known. Sequences that are similar 
above defined percentage identity and e-value threshold, and length coverage are 
grouped as homologs. Homology models show high confidence levels owing to these 
metric thresholds. 
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Figure 1: Summary of the computational methods used in predicting essential genes. 
#The ability to identify conditionally essential genes is usually specific for the training dataset.  
*Prediction of conditional essentiality is influenced by the quality of the input model, objective function, among 
other factors. 
**In homology models, the query and subject sequences should have maintained enough closeness throughout 
evolution. In ML models, the study subjects should be close enough (e.g. same or close species) to the training 
set, hence disadvantageous while dealing with distantly related species.  
 
Essential genes evolve slowly and tend to be more conserved than non-essential genes in 
bacteria [41]. Selection on essential genes is more stringent than on non-essential genes, 
increasing the average likelihood that orthologues of essential genes are conserved in 
bacteria [1, 42] and almost certainly essential. This allows extrapolation of essentiality 
from one member to an entire group of homologous genes. Many bacterial genomes are 
publicly available from genome sequencing projects (Figure 2). Various homology 
prediction tools and databases that collate homologous proteins (Supplementary Table 
2) are also publicly available. This has greatly simplified determining genes that share 
ancestry, making homology models attractive for predicting gene essentiality based 
solely on genomic sequences. However, they have various limitations. First, they are 
limited to conserved orthologs between species, which often account for a small portion 
of the genome [43]. Moreover, since the model only considers computationally 
determined orthologous genes based on sequence similarity, highly evolving genes may 
 
 
  
be overlooked, consequently leading to underestimation of essential genes in a genome 
[5]. Secondly, orthologues, especially in distantly related species, often show variations in 
gene regulations, post-translational protein modification, divergence in cellular 
pathways, redundancies in processes, gene duplications, and other niche specializations 
[44], leading to potential multiplicity in relative gene essentiality. For example, Hutchison 
and colleagues [28] successfully used transposon insertions to disrupt some of the 256 
essential genes predicted using homology [35], suggesting that they are possibly non-
essential. Yu et al., also identified 787 non-essential S. sanguinis genes, which had 
orthologs in all 48 Streptococcus genomes they analyzed [45]. Additionally, the gene 
encoding alanyl-tRNA synthetase (alaS) is essential in Escherichia coli but not in 
Pseudomonas aeruginosa: probably due to functional redundancy caused by a paralog, 
PA2106, in Pseudomonas [26]. For this reason, absence of paralogs is in generally thought 
to be a strong indicator of essentiality in cross-species homology analyses [8, 46]. 
Although it is more straight-forward to predict essentiality for single copy genes, 
paralogous genes could still be essential: deletion of all copies of a duplicated gene that 
encodes an essential function should lead to lethality. Finally, notwithstanding the 
tendency of essential genes to be highly conserved, genes conserved across species are 
not always essential. Indeed, in model organisms, only less than 25% of all conserved 
genes have experimentally been validated to be essential [29, 47], indicating that 
similarity of sequences does not always warrant extrapolation of the essentiality 
annotation amongst homologs. 
 
Figure 2: The genome project coverage for bacteria. Approximately 39,442 bacterial genome projects are 
documented according to GOLD (Genome OnLine Database; http://www.genomesonline.org) as of June 30, 
2015. 
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Figure 1: Summary of the computational methods used in predicting essential genes. 
#The ability to identify conditionally essential genes is usually specific for the training dataset.  
*Prediction of conditional essentiality is influenced by the quality of the input model, objective function, among 
other factors. 
**In homology models, the query and subject sequences should have maintained enough closeness throughout 
evolution. In ML models, the study subjects should be close enough (e.g. same or close species) to the training 
set, hence disadvantageous while dealing with distantly related species.  
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Protein network topology models 
Two or more proteins can establish physical contact (protein-protein interactions; PPIs) 
as a result of biochemical events and/or electrostatic forces. These interactions are mainly 
determined from quantum chemistry, molecular dynamics, signal transduction, and 
biochemistry assays among others [48-51] and in certain cases can be used to predict 
essentiality. The abundance of experimental data generated from small-scale analyses 
and high-throughput procedures have assisted in defining PPIs within the interactome (all 
possible molecular interactions within a cell). Large-scale exploration of the topological 
properties of these networks is important in understanding the organizational and 
functional principles of individual proteins in biological pathways [25], and consequently 
their essentiality. Various descriptors for centrality of a node in a network have been 
effectively applied to identify essential proteins in PPIs [25, 52, 53]. For example, deletion 
of a hub (highly linked) protein is more likely to lethally perturb the network than deletion 
of a non-hub (peripheral) protein [54]. It is therefore widely agreed that hub proteins 
evolve slowly and are most likely to be essential [53]. However, prediction of gene 
essentiality in less studied genomes using protein networks is expensive and arduous, 
primarily due to the limitations of experimental data (containing missing values, false 
positives, false negatives, or differing between replicates - suggesting that the data is 
erroneous, incomplete, or both) necessary to build and characterize PPIs [55], and the 
complexities in computational inference of PPI networks [56]. Their accuracy also depend 
on the completeness of the network and they cannot be used to predict conditional 
essentiality. Moreover, proteins that lack known interactions with other proteins are 
completely disregarded in PPI models.     
Metabolic network reconstruction and simulation models 
While studying PPI networks gives a basic understanding of gene and protein 
interactions, they are limited in elucidating the complex and dynamic interactions among 
molecular components of cellular networks at genome-scale. Whole genome metabolic 
network reconstruction under constraint-based reconstruction and analysis (COBRA) 
scaffold [57, 58] allows for an in-depth insight into the metabolic capabilities of an 
organism, particularly in correlating the genome with molecular physiology [59]. These 
methods are based on the following fundamental concepts: (1) the burden of 
physicochemical constraints to limit quantifiable phenotypes, (2) identification and 
algebraic account of evolutionary selective pressures, and (3) a genome-scale perception 
of cell metabolism that accounts for all cellular metabolic gene products [60]. Metabolic 
networks for many microorganisms have been reconstructed [61] or can be reconstructed 
and, to some extent, curated using automated systems such as model SEED [62], RAST 
[63], and BiGG [64]. Also, by integrating homology modeling, genome-scale models that 
show substantial predictive power in auxotrophy and essentiality predictions have been 
created for multiple strains of lesser studied organisms by starting with the genome-scale 
model of a well-studied organism like Escherichia coli K12 MG1655 [65]. Nonetheless, 
 
 
  
significant efforts are required to manually curate and ascertain the reliability of 
automatically generated metabolic models to improve their reliability for gene 
essentiality prediction. It is noteworthy that following the immense success in metabolic 
networks reconstruction, significant efforts are being made to model transcriptional 
networks [66], signaling networks [67], and computing of protein expressions needed to 
perform metabolism and proteome synthesis [68]. These efforts are providing crucial 
input to extend gene essentiality prediction using network reconstruction modelling from 
metabolism to incorporate other non-metabolic cellular processes.  
Flux balance analysis (FBA) is the most commonly used constrained-based approach for 
in silico prediction of microbial phenotypes from metabolic models [69, 70]. It integrates 
biochemical constraints with the stoichiometry of metabolic and transport reactions, 
their reversibility and subcellular localization, thereby reducing the intricacy of potential 
dynamic states in order to predict metabolite fluxes at steady state. FBA has been to 
simulate gene knock-out and evaluate the associated lethality on the system, enabling 
the identification of essential genes [70]. For a given objective function and each in silico 
gene deletion, essentiality is evaluated by calculating the optimal production of defined 
biosynthetic precursors: identified auxotrophic requirements and impaired functions 
(indicating simulated gene knockouts which inhibit in silico production of precursors 
contained within the objective function e.g. alanine production) are classified as essential 
for the objective function. FBA relies on stoichiometric characteristics and does not 
require kinetic parameters (which are often difficult to obtain) allowing it to be used on 
any fully sequenced and annotated organism [69]. Nevertheless, FBA has important 
limitations: first, while FBA could be integrated with modal analyses at steady-state, it 
cannot be used to investigate genome-scale metabolic reactions under transient dynamic 
states without including data on enzyme kinetics [71]. Secondly, FBA cannot be used to 
directly predict immediate suboptimal flux states and metabolite concentration following 
a genetic perturbation. Organisms naturally adapt to perturbations by readjusting various 
regulatory mechanisms, enzyme expressions, and fluxes to bypass the effects. Such 
immediate changes and the effect of regulatory mechanisms cannot be explicitly 
specified in FBA. Some of these limitations have been addressed in variants of FBA such 
as MOMA [72], ROOM [73], MEA [74] and dynamic FBA [71]. Lastly, FBA sometimes 
disagrees with experimental data; these discrepancies could be addressed by the addition 
of enzyme reactions through “gap filling” [69, 75]. Overall, given the substantial input 
required and the inability to provide direct readout for conditionally essential genes, 
metabolic network reconstruction models are undesirable first-choice methods for 
exploring gene essentiality in novel genomes. 
Integrated features machine learning models 
Integrative machine learning (ML) models rely on constructing and training a classifier for 
predicting gene essentiality. They integrate multiple characteristics or features encoded 
in an organism’s genomic sequence, which are known to be associated with essentiality 
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While studying PPI networks gives a basic understanding of gene and protein 
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scaffold [57, 58] allows for an in-depth insight into the metabolic capabilities of an 
organism, particularly in correlating the genome with molecular physiology [59]. These 
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of cell metabolism that accounts for all cellular metabolic gene products [60]. Metabolic 
networks for many microorganisms have been reconstructed [61] or can be reconstructed 
and, to some extent, curated using automated systems such as model SEED [62], RAST 
[63], and BiGG [64]. Also, by integrating homology modeling, genome-scale models that 
show substantial predictive power in auxotrophy and essentiality predictions have been 
created for multiple strains of lesser studied organisms by starting with the genome-scale 
model of a well-studied organism like Escherichia coli K12 MG1655 [65]. Nonetheless, 
 
 
  
significant efforts are required to manually curate and ascertain the reliability of 
automatically generated metabolic models to improve their reliability for gene 
essentiality prediction. It is noteworthy that following the immense success in metabolic 
networks reconstruction, significant efforts are being made to model transcriptional 
networks [66], signaling networks [67], and computing of protein expressions needed to 
perform metabolism and proteome synthesis [68]. These efforts are providing crucial 
input to extend gene essentiality prediction using network reconstruction modelling from 
metabolism to incorporate other non-metabolic cellular processes.  
Flux balance analysis (FBA) is the most commonly used constrained-based approach for 
in silico prediction of microbial phenotypes from metabolic models [69, 70]. It integrates 
biochemical constraints with the stoichiometry of metabolic and transport reactions, 
their reversibility and subcellular localization, thereby reducing the intricacy of potential 
dynamic states in order to predict metabolite fluxes at steady state. FBA has been to 
simulate gene knock-out and evaluate the associated lethality on the system, enabling 
the identification of essential genes [70]. For a given objective function and each in silico 
gene deletion, essentiality is evaluated by calculating the optimal production of defined 
biosynthetic precursors: identified auxotrophic requirements and impaired functions 
(indicating simulated gene knockouts which inhibit in silico production of precursors 
contained within the objective function e.g. alanine production) are classified as essential 
for the objective function. FBA relies on stoichiometric characteristics and does not 
require kinetic parameters (which are often difficult to obtain) allowing it to be used on 
any fully sequenced and annotated organism [69]. Nevertheless, FBA has important 
limitations: first, while FBA could be integrated with modal analyses at steady-state, it 
cannot be used to investigate genome-scale metabolic reactions under transient dynamic 
states without including data on enzyme kinetics [71]. Secondly, FBA cannot be used to 
directly predict immediate suboptimal flux states and metabolite concentration following 
a genetic perturbation. Organisms naturally adapt to perturbations by readjusting various 
regulatory mechanisms, enzyme expressions, and fluxes to bypass the effects. Such 
immediate changes and the effect of regulatory mechanisms cannot be explicitly 
specified in FBA. Some of these limitations have been addressed in variants of FBA such 
as MOMA [72], ROOM [73], MEA [74] and dynamic FBA [71]. Lastly, FBA sometimes 
disagrees with experimental data; these discrepancies could be addressed by the addition 
of enzyme reactions through “gap filling” [69, 75]. Overall, given the substantial input 
required and the inability to provide direct readout for conditionally essential genes, 
metabolic network reconstruction models are undesirable first-choice methods for 
exploring gene essentiality in novel genomes. 
Integrated features machine learning models 
Integrative machine learning (ML) models rely on constructing and training a classifier for 
predicting gene essentiality. They integrate multiple characteristics or features encoded 
in an organism’s genomic sequence, which are known to be associated with essentiality 
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[26, 76]. The classifiers are trained and tested using well-annotated genomes, then 
applied to identify putatively essential genes in other (novel) genomes [23-25]. The ever-
increasing number of experimentally determined essential genes has improved the 
understanding of distinguishing properties of essential genes. As a result, it is possible to 
easily select features towards improving the predictive accuracy of machine learning 
models, making them less laborious. Predictive accuracy of ML classifiers resulting from a 
combination of different features may vary but no specific combinations have been 
confirmed to be optimally robust. The reliability of ML models however depend on the 
closeness of the training dataset to the study dataset. Normally, ML models may be 
prone to overfitting, potentially allowing irrelevant information or noise to be presented 
as valid predictions. Domingos and colleagues reviewed overfitting as well as other 
sources of errors in ML, and the possible methods of combating them [77]. These models 
may not be suitable for predicting conditional gene essentiality. Various experimental, 
genomic and protein features have been used to train and build classifier for genes 
essentiality prediction in different studies (Table 1). However, no single study has 
reported use of all the features in a single predictive model to predict gene essentiality. 
The features are often used selectively based on their accuracy and whether they can 
patently be determined for the organism under study.  
 
Applications of essential genes 
Discovering potential drug targets 
Several diseases are becoming increasingly difficult to control due to the emergence of 
drug-resistant pathogenic strains, necessitating a search for new antimicrobials. 
Identification and prioritization of drug targets in novel pathogens is the initial and one of 
the most important steps during drug discovery (Figure 3). Understanding the functions 
of the target proteins, and consequently the mechanisms of action (MOA) are important 
to design putative inhibitors. As such, drug target discovery sets a foundation for 
developing drugs with desired therapeutic properties. Inhibiting essential proteins will 
confer bacteriostatic or bactericidal effects. They therefore form promising targets for 
discovering potent antibiotics against novel pathogens [7].  
  
 
 
  
Table 1: Features that can be used for in silico prediction of gene essentiality  
Feature Rationale Reference 
Gene expression 
profile P a 
Genes that are not expressed under given conditions are less likely to be essential  
Co-expressed genes are often involved in the same pathway or similar cellular 
function  
Interacting proteins are frequently co-expressed 
[95] 
Protein localization 
and biological 
processes 
(enrichment of Gene 
Ontology (GO) Pb 
Essential proteins are enriched in, but not exclusive to the cytoplasm: compared to 
essential genes, significantly higher proportions of non-essential genes are located 
in the cytoplasmic membrane, periplasm, outer membrane, cell wall, and 
extracellularly  
Gene Ontology (GO) term transcriptional regulation annotations is enriched in 
essential genes 
[21, 96] 
Functional domains The functional units of proteins are domains, most of which are highly conserved in 
diverse genera 
[97, 98] 
Total upstream gene 
size Pc 
Genes with larger upstream sizes (promoter regions) are significantly 
underrepresented in indispensable genes  
Genes regulated by multiple transcriptional regulators are likely to have larger 
upstream regions in order to house the various cis-regulatory elements   
Genes with more complex regulation are generally dispensable 
[3, 21, 42, 
99] 
Phyletic retention 
measure Pd 
Essentiality of a gene is extrapolated if the annotated function of that gene can be 
detected in different genera as opposed to sequence similarity 
Specificity increases with inclusion of diverse genera in the analysis  
[21, 45]  
GC content Commonly used to identify genes that are essential under high temperature 
selection.  
The DNA double helix is stabilized primarily by hydrogen bonds between nucleotides 
and base-stacking interactions among aromatic nucleobases: the GC pair contains 
three hydrogen bonds, whereas the AT pairs contain two.  
DNA with high GC-content is believed to be more robust and stable.  
[100] 
Codon usage The probability of a deleterious substitution in essential proteins is expected to be 
negligible, resulting in lower nonsynonymous substitution rates 
[41] 
Orthology and 
paralogy 
In bacteria, essential genes are generally more conserved across species (orthologs) 
than non-essential genes  
Duplicated genes within a genome (paralogues) are also less likely to be essential 
because the duplicate gene serves as a backup and can replace the original copy. 
Inactivation of both copies may however result to lethality. 
[41, 46] 
Protein connectivity  Highly connected proteins in a network evolve slowly and are more likely to be 
essential- see PPI networks  
[53, 54] 
Strand bias Essential genes tend to be encoded on the leading strand of the circular chromosome [101] 
P
a 
PAn organism’s genetic code is interpreted by gene expression into functional gene products: Properties of gene 
expression give rise to a phenotype, often expressed by synthesis of proteins that act as catalytic enzymes in 
specific metabolic pathways, or control the organism’s physical traits [102].  
P
b 
PEssential functional proteins domains have also been identified and used to predict gene essentiality [97, 98]. 
P
c 
PThe connection between regulation complexity, intergenic distance, and gene essentiality has been shown in 
Drosophila melanogaster and Caenorrhabditis elegans [99]. Since transcription factor binding sites in the 
promoter region are discovered using laborious experimental methods, the possibility of using easy-to-
determine upstream region size, as a representation for regulatory complexity in integrative models, is 
advantageous.  
P
d
P Often confused with conservation; a measure of substitution rate, phyletic gene retention is a measure of the 
number of organism in which an ortholog is present [21, 45]. It is therefore assumed that most essential genes 
could be predicted based on the genome annotations. However, the number of essential genes is likely to 
decrease with increased diversity in the genera, subsequently leading to under-prediction [45].  
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reported use of all the features in a single predictive model to predict gene essentiality. 
The features are often used selectively based on their accuracy and whether they can 
patently be determined for the organism under study.  
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Discovering potential drug targets 
Several diseases are becoming increasingly difficult to control due to the emergence of 
drug-resistant pathogenic strains, necessitating a search for new antimicrobials. 
Identification and prioritization of drug targets in novel pathogens is the initial and one of 
the most important steps during drug discovery (Figure 3). Understanding the functions 
of the target proteins, and consequently the mechanisms of action (MOA) are important 
to design putative inhibitors. As such, drug target discovery sets a foundation for 
developing drugs with desired therapeutic properties. Inhibiting essential proteins will 
confer bacteriostatic or bactericidal effects. They therefore form promising targets for 
discovering potent antibiotics against novel pathogens [7].  
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DNA with high GC-content is believed to be more robust and stable.  
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Orthology and 
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In bacteria, essential genes are generally more conserved across species (orthologs) 
than non-essential genes  
Duplicated genes within a genome (paralogues) are also less likely to be essential 
because the duplicate gene serves as a backup and can replace the original copy. 
Inactivation of both copies may however result to lethality. 
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PAn organism’s genetic code is interpreted by gene expression into functional gene products: Properties of gene 
expression give rise to a phenotype, often expressed by synthesis of proteins that act as catalytic enzymes in 
specific metabolic pathways, or control the organism’s physical traits [102].  
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In our recent study, using a high-throughput genome wide screening approach, we 
identified essential genes in bacterial respiratory pathogens [8]. From these essential 
genes, additional criteria were applied to prioritize, and experimentally validate some 
potential target proteins and pathways that can be modulated by bioactive agents. 
Despite the intensifying research efforts, adoption of the biomedical discoveries into 
developmental stages of drug discovery, and subsequently into marketable products has 
been dismal. Indeed, more than 80% of all potential products going into the drug 
development pipeline never make it to the market [78]. The problem might partly be due 
to the lack of comprehensive biochemical knowledge of the drug targets and the MOA of 
their “lead compound” inhibitors; such that, unexpected biological effects are not fully 
assessed prior to clinical trials [79]. Moreover, taking a drug through research and 
development to clinical approval requires immense investments in both time and cost 
further exacerbating the problem.  In fact, only a handful of therapeutic molecules have 
been approved in recent years by the regulatory agencies in the United States and Europe 
[78]. 
 
Figure 3: Schematic representation of the drug discovery pipeline. 
  
 
 
  
Food microbiology and industrial bioprocessing  
Numerous food products, including ripened cheese, pickles, wine, beer, bread, yoghurt 
and other fermented foods, owe their production and characteristics to microorganisms 
[80]. These foods are to some extent naturally preserved due to the fermentation 
process. Concurrently, their shelf-life is prolonged significantly over that of the raw 
materials from which they are manufactured. Several biopolymers produced by 
microorganisms are also used in the food industry [81]. In addition, “generally recognized 
as safe; GRAS” bacteria or probiotics are becoming increasingly vital in the food industry 
[82]. However, microorganisms also constitute potential food and process contaminants, 
and foodborne pathogens [83]. Understanding essential genes is therefore invaluable in 
optimizing various facets of industrial fermentation and bioprocessing.  
First, given a growth medium containing a defined carbon source (raw product), 
metabolic reconstruction can be used to predict the best processing conditions required 
for a given microorganism to maximize production. The ability to evaluate interactions 
between microorganisms and relevant metabolic capabilities in new microbes also 
provides leads for novel and safe starter cultures. Moreover, the knowledge gives an 
insight into all (conditionally) essential metabolic pathways involved in producing a given 
product and co-expressed nonessential pathways which, if feasible, could be inactivated 
to improve efficiency. For example, attempts have been made in using microbes to 
produce alginate, a product conventionally isolated from farmed brown seaweed [84]. 
Knowledge of (conditional) gene essentiality was used to pinpoint the interactions 
between multiple microorganisms during the course of the fermentation. To facilitate 
product optimization strategies, catalogs of (conditionally) essential genes for specific 
microorganisms in specific food products can aid in establishing biobanks and 
biorepositories. The biobanks can be screened for new “safe” microbes with desired 
phenotypic traits and predicted interactions for a given fermentation, or to create novel 
fermented products. 
Secondly, while most foodborne pathogens or food spoilage bacteria and industrial 
contaminants are cleared by standard sterilization, cooking and preservatives, including 
bacterial toxins like nisin, studies have shown that some potentially harmful 
microorganisms can survive these conventional food processing methods [85, 86]. Food 
samples could be tested by PCR for the presence of general spoiler marker genes 
indicating a possible contamination. Such tracking tests are significantly faster than 
conventional techniques. Moreover, unique and essential spoiler genes could be 
considered as prime targets for bespoke decontamination strategies without inversely 
altering the production pipeline. 
Lastly, genomics-based determination of gene essentiality also generates valuable 
knowledge that can be used for metabolic engineering, optimizing cell factories and 
development of novel preservation methods, provided that these solutions are ethically 
acceptable.  
Target
Selection
•Identifying targets using bioinformatics, proteomics, and genomics
•Essential, accessible by inhibitors, and has no off-target effects
Lead
Discovery
•Test libraries of leads for inhibition capability against the selected drug target(s):
•Testing the in vitro potency and ex vivo efficacy, and adverse effects
Lead 
Optimization
•Perform medical chemoproteomics drug affinity profiling for the prioritized lead compounds:
•Testing the in vitro potency, ex vivo efficacy, and adverse effects.
Pre-clinical
Trials
•Perform pan screening, pharmacology, and toxicology tests on lead compounds
•Testing lead clinical candidates in clinical trials
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In our recent study, using a high-throughput genome wide screening approach, we 
identified essential genes in bacterial respiratory pathogens [8]. From these essential 
genes, additional criteria were applied to prioritize, and experimentally validate some 
potential target proteins and pathways that can be modulated by bioactive agents. 
Despite the intensifying research efforts, adoption of the biomedical discoveries into 
developmental stages of drug discovery, and subsequently into marketable products has 
been dismal. Indeed, more than 80% of all potential products going into the drug 
development pipeline never make it to the market [78]. The problem might partly be due 
to the lack of comprehensive biochemical knowledge of the drug targets and the MOA of 
their “lead compound” inhibitors; such that, unexpected biological effects are not fully 
assessed prior to clinical trials [79]. Moreover, taking a drug through research and 
development to clinical approval requires immense investments in both time and cost 
further exacerbating the problem.  In fact, only a handful of therapeutic molecules have 
been approved in recent years by the regulatory agencies in the United States and Europe 
[78]. 
 
Figure 3: Schematic representation of the drug discovery pipeline. 
  
 
 
  
Food microbiology and industrial bioprocessing  
Numerous food products, including ripened cheese, pickles, wine, beer, bread, yoghurt 
and other fermented foods, owe their production and characteristics to microorganisms 
[80]. These foods are to some extent naturally preserved due to the fermentation 
process. Concurrently, their shelf-life is prolonged significantly over that of the raw 
materials from which they are manufactured. Several biopolymers produced by 
microorganisms are also used in the food industry [81]. In addition, “generally recognized 
as safe; GRAS” bacteria or probiotics are becoming increasingly vital in the food industry 
[82]. However, microorganisms also constitute potential food and process contaminants, 
and foodborne pathogens [83]. Understanding essential genes is therefore invaluable in 
optimizing various facets of industrial fermentation and bioprocessing.  
First, given a growth medium containing a defined carbon source (raw product), 
metabolic reconstruction can be used to predict the best processing conditions required 
for a given microorganism to maximize production. The ability to evaluate interactions 
between microorganisms and relevant metabolic capabilities in new microbes also 
provides leads for novel and safe starter cultures. Moreover, the knowledge gives an 
insight into all (conditionally) essential metabolic pathways involved in producing a given 
product and co-expressed nonessential pathways which, if feasible, could be inactivated 
to improve efficiency. For example, attempts have been made in using microbes to 
produce alginate, a product conventionally isolated from farmed brown seaweed [84]. 
Knowledge of (conditional) gene essentiality was used to pinpoint the interactions 
between multiple microorganisms during the course of the fermentation. To facilitate 
product optimization strategies, catalogs of (conditionally) essential genes for specific 
microorganisms in specific food products can aid in establishing biobanks and 
biorepositories. The biobanks can be screened for new “safe” microbes with desired 
phenotypic traits and predicted interactions for a given fermentation, or to create novel 
fermented products. 
Secondly, while most foodborne pathogens or food spoilage bacteria and industrial 
contaminants are cleared by standard sterilization, cooking and preservatives, including 
bacterial toxins like nisin, studies have shown that some potentially harmful 
microorganisms can survive these conventional food processing methods [85, 86]. Food 
samples could be tested by PCR for the presence of general spoiler marker genes 
indicating a possible contamination. Such tracking tests are significantly faster than 
conventional techniques. Moreover, unique and essential spoiler genes could be 
considered as prime targets for bespoke decontamination strategies without inversely 
altering the production pipeline. 
Lastly, genomics-based determination of gene essentiality also generates valuable 
knowledge that can be used for metabolic engineering, optimizing cell factories and 
development of novel preservation methods, provided that these solutions are ethically 
acceptable.  
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Bioremediation 
Compared to conventional physicochemical strategies, microbes provide a safe and 
cheap alternative for environmental remediation, pollution prevention, and waste 
treatment [87]. Although highly diverse and specialized microbial populations present in 
the environment efficiently eliminate many pollutants, the process is normally quite slow, 
potentially permitting pollutants to accumulate above hazardous levels. For example, 
bioremediation of the Exxon Valdez oil spill in Alaska using indigenous microflora was cost 
effective and scientifically rational [88]. However, fertilizers had to be applied in order to 
accelerate the process. The fertilizers present a separate environmental imbalance albeit 
minimal compared to the oil spill. Unlike oil whose constituent hydrocarbons are largely 
biodegradable, most recalcitrant compounds, especially heavy metals, contain structural 
elements or substituents that seldom occur in nature. Because of the rarity of these 
compounds, currently known microorganisms have probably not evolved appropriate 
pathways to bioaccumulate them. While some xenobiotics are inefficiently or 
incompletely biotransformed, or their complex mixtures inhibit degradation by existing 
pathways, for others, derivative pathways have not been described [89]. Knowledge of 
(conditional) gene essentiality can therefore aid in identifying novel biodegradation 
pathways in (new) microorganisms. Additionally, the knowledge could facilitate genetic 
modification of microbes to broaden their substrates range, successfully enhancing 
cleanup while producing specialized (end- or by-) products with less ecological harm. 
Genotype-phenotype correlation 
Mendel’s classical observations of varied phenotypes in peas conjured a paradigm of 
distinct alterations in an organism’s DNA (genotype) that cause disruptions in gene 
function and characteristic phenotype. Ever since, phenotypes have been used to 
systematically discover their plausible genetic background. However, the phenotype of a 
given strain is not only a product of its gene content but also its cellular regulatory 
mechanisms [90] and environmental factors [91]. Although genotype-phenotype 
association studies do not factor in the effects of regulatory mechanisms, they allow for 
straight-forward screening of candidate genotype to phenotype relationships. 
Additionally, the natural diversity and adaptive responses of microbial strains to 
environmental changes could also be investigated using knowledge of conditional gene 
essentiality. For example, using transcriptomic diversity between strains of Lactococcus 
lactis isolated from diary and nondairy niches, the basis of phenotypic differences 
observed in fermented food products at the level of acidification properties has been 
investigated [92].  
  
 
 
  
Perspectives 
Gene essentiality prediction using computational methods will become more important 
with the ongoing advances in biology. Expanding computational methods to predict 
conditionally essential genes, which are currently predicted exclusively using laboratory 
techniques, may soon be realized. Evidently, predicting conditional essentiality requires 
many experimentally determined features that cannot be determined computationally 
yet. In silico reconstruction of microbial genomes with preferred phenotypic traits also 
stands to benefit. In fact, the ab initio assembly of a synthetic cell [6], and genome 
transplantation [93] have been accomplished in Mycoplasma mycoides. Fabricating viable 
cells that harbor housekeeping functions and only genes encoding desired phenotypes is 
therefore achievable and can be perfected in the future. There have been genome 
engineering attempts to improve de novo biosynthesis of vanillin [94]. With the global 
demand for natural food ingredients, flavors, fragrances, biopolymers, and drugs 
increasing rapidly, specialized fabricated microbes that perform “natural-like” 
bioconversions more efficiently might be desirable. Such projects will undoubtedly 
revolutionize processes beyond current technologies when they are scaled up to 
industrial size production. Additionally, by creating, testing and optimizing specialized 
genetic circuits, our understanding of cell biology will also advance significantly. In 
conclusion, it is our believe that future studies could build on the knowledge reviewed 
here, and expand it to improve accuracy and dependability of in silico tools in predicting 
essential genes. 
 
Key points 
• Essential genes are fundamental for cellular growth and viability of an organisms. 
• They form attractive drug targets and essential components of a minimum cell for 
biotechnology and basic biological research. 
• Supplementing or complementing traditional laboratory gene essentiality prediction 
methods with high-throughput computational approaches is gaining interest. 
• Currently, transposon insertion sequencing is the most reliable but quite expensive 
method that combines wet-laboratory and computational tracking to predict gene 
essentiality. 
• Solely computational methods including homology models, machine learning 
models, metabolic network reconstruction, and protein-protein interaction models, 
are reliable but largely influenced by the quality of data and evolutionary distance 
between subjects 
 
.  
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Abstract 
Background: Bacterial respiratory tract infections, mainly caused by Streptococcus 
pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are among the leading 
causes of global mortality and morbidity. Increased resistance of these pathogens to 
existing antibiotics necessitates the search for novel targets to develop potent 
antimicrobials. 
Result: Here, we report a proof of concept study for the reliable identification of potential 
drug targets in these human respiratory pathogens by combining high-density 
transposon mutagenesis, high-throughput sequencing, and integrative genomics. 
Approximately 20% of all genes in these three species were essential for growth and 
viability, including 128 essential and conserved genes, part of 47 metabolic pathways. By 
comparing these essential genes to the human genome, and a database of genes from 
commensal human gut microbiota, we identified and excluded potential drug targets in 
respiratory tract pathogens that will have off-target effects in the host, or disrupt the 
natural host microbiota. We propose 249 potential drug targets, 67 of which are targets 
for 75 FDA-approved antimicrobials and 35 other researched small molecule inhibitors. 
Two out of four selected novel targets were experimentally validated, proofing the 
concept. 
Conclusion: Here we have pioneered an attempt in systematically combining the power 
of high-density transposon mutagenesis, high-throughput sequencing, and integrative 
genomics to discover potential drug targets at genome-scale. By circumventing the time-
consuming and expensive laboratory screens traditionally used to select potential drug 
targets, our approach provides an attractive alternative that could accelerate the much 
needed discovery of novel antimicrobials. 
  
 
 
  
Background 
The World Health Organization (WHO; www.who.int) ranks respiratory tract infections 
(RTI) among the ten leading causes of global mortality. RTI are associated with several 
bacterial species, of which Streptococcus pneumoniae, Haemophilus influenzae, and 
Moraxella catarrhalis are the most prevalent community-acquired respiratory bacterial 
pathogens [1]. In healthy individuals, these species colonize mucosal surfaces of the 
upper airways in a commensal state. Their relevance as pathogens arises when they 
infiltrate and colonize the otherwise sterile spaces in the middle ear, lung or bloodstream, 
progressing to disease [2]. With the mounting inexorable resistance of these pathogens 
against several commonly used antimicrobials [1], discovery of new protein targets 
against which new antibiotics could be developed will highly benefit global healthcare 
management of RTI.  
Elucidation of genes essential for bacterial growth and viability is a prerequisite for 
identifying potential drug targets [3]. Essential genes are highly conserved and are thus 
considered as favourable drug targets for broad-spectrum inhibition [4]. On the other 
hand, some metabolic pathways constitute crucial transport and catalytic proteins which 
could also form attractive drug targets. Furthermore, most pathogens have drastically 
reduced their biosynthetic capabilities, and instead rely on their hosts to provide vital 
nutrients like amino acids, vitamins, and nucleobases [5]. Transport systems for these 
nutrients are generally conserved and indispensable for survival of the pathogen in its 
host [6], making them promising drug targets. In order to qualify as drug targets, 
microbial genes should meet several requirements. First, they should be nonhomologous 
to human genes to avoid drug cytotoxicity [3]. Additionally, targets should either be 
completely absent, or catalytically distinctive from genes found in host gut commensal 
microbiota, whose perturbation is likely to be detrimental to human nutrition, health, and 
physiology [7]. It has been shown that antibiotic killing of commensal microbiota 
facilitates proliferation, and often dominance, of antibiotic-resistant pathogens on 
mucosal surfaces [8]. Lastly, candidate drug targets must be accessible by inhibitors. 
Essential surface/membrane and secreted proteins are particularly promising, having 
been successfully targeted by protein drugs, and representing majority of all known drug 
targets [9, 10]. 
Previous microbial gene essentiality predictions employed techniques generally limited in 
specificity and/or throughput [11, 12]. These shortcomings are alleviated by high-
throughput transposon insertion sequencing strategies, such as Tn-seq, TraDIS, INseq, or 
variants thereof, which have been applied in recent studies to comprehensively essay 
gene essentiality and genetic interactions in various bacteria [13, 14]. Here, we applied 
Tn-seq to reliably identify essential genes in S. pneumoniae, H. influenzae and M. 
catarrhalis. Products of these genes were compared against the human proteome, and 
the catalogue of genes from human gut commensal microbes, to identify and eliminate 
targets likely to have off-target effects in the host or on the host’s gut microbiota. Two 
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out of four of the finally identified novel drug targets have been successfully validated 
using existing inhibitors. This study pioneers an integrative approach for rapid and cost-
effective identification of novel drug targets. Our findings do not only improve the overall 
understanding of respiratory pathogens, but also serve as a proof of concept for the 
robust yet underexploited approaches, combining in silico and wet laboratory analyses in 
identifying antimicrobial drug targets, as recently reviewed [15]. This approach has 
allowed us to identify promising drug target leads, which after experimental validation 
could be potentially advanced to the discovery of novel antimicrobials for the treatment 
of RTI. 
 
Methods 
Bacterial genomes and gene reannotation 
Whole genome sequences for S. pneumoniae TIGR4 uid57857, S. pneumoniae R6 uid57859, 
H. influenzae Rd KW20 uid57771, H. influenzae 86 028NP uid58093 and M. catarrhalis 
BBH18 uid48809 were obtained from the National Centre for Biotechnology Information 
(NCBI) Genbank File Transfer Protocol (FTP) website (ftp://ftp.ncbi.nih.gov/Genbank/). All 
open reading frame (ORF) annotations were updated using Rapid Annotation using 
Subsystem Technology (RAST) [16]. In this analysis, all locus coordinates in original 
Genbank genomes release were retained without adjustments for frame-shifts. 
Orthology and gene essentiality predictions 
We clustered the reannotated protein sequences into putative orthologous groups using 
the OrthoMCL standalone software Version 2.0.2 [17]. Most studies have consistently 
deciphered essential genes under ideal conditions, that is, in the richness of all necessary 
nutrients and without environmental stress. For the purpose of this study, we define the 
“essentiality” of a gene as its indispensability under rich media conditions, unless stated 
otherwise. The caveat with this approach is that essential genes required for metabolism 
within the host may be missed.    
Transposon mutant libraries used were either created in-house for this study, or obtained 
from literature and reanalyzed. The M. catarrhalis BBH18 marinerT7 transposon mutant 
libraries consisting of 28,000 and 7,000 independent transformants were previously 
described [18, 19], and the 12,500 transformants library was generated using the 
previously described protocol [18]. The 40,000 transformants S. pneumoniae R6 and the 
11,000 transformants H. influenzae 86 028NP library were previously described [20, 21]. 
Libraries for the 15,000 transformants S. pneumoniae R6 and H. influenzae Rd KW20 were 
also respectively constructed as previously described [20, 21]. The Tn-seq technology was 
used to profile the relative abundance of each mutant in all libraries after growth as 
described previously [22], except for S. pneumoniae TIGR4. Tn-seq data for S. pneumoniae 
 
 
  
TIGR4 were obtained from literature [23]. We then performed essentiality predictions for 
individual genes using the in-house developed web-tool, ESSENTIALS [24], which 
enabled us calculate a statistical essentiality metric for each ORF, and precisely delineate 
the optimal boundary between essential and nonessential ORFs in each of the 5 strains. 
Analysis data can be found at http://bamics2.cmbi.ru.nl/websoftware/essentials/links.html    
Overrepresented metabolic pathways and subsystems 
Pathways and subsystems for the strains under study were obtained from the Kyoto 
Encyclopedia of Genes and Genomes orthology, and the SEED databases respectively 
[25, 26]. Using a Fisher’s exact test, we performed functional categories enrichment for 
the pathways and subsystems, while incorporating the statistical essentiality value (the 
fold-change value predicted by ESSENTIALS) for each ORF. We corrected for multiple 
testing using Bonferroni correction and obtained q-values for corresponding p-values [27]. 
Proteins subcellular localization (SCL) 
The subcellular localizations (SCL) of all proteins in this study were determined using 
publicly available SCL prediction tools. First, we analyzed all Gram-positive and Gram-
negative strains using pSORTdb version 2.0 [10] and CELLO version 2.5 [28]. Further 
complementation SCL predictions were performed using LocateP and GnegPloc for 
Gram-positive and Gram-negative strains respectively [29, 30]. Additionally, the presence 
of integral Gram-negative outer membrane proteins (OMP) was determined using β-
barrel outer membrane protein predictor (BOMP) [31]. Proteins that showed different 
SCL predictions in the different predictors used were denoted “Unknown”, together with 
those predicted to be of unknown SCL by majority of the predictors used. 
Selecting potential drug targets 
To identify and eliminate essential genes with close undesirable orthologs, we performed 
separate unidirectional blast (BLASTP) searches, using an E-value cut-off of 1e-10, and 
minimum 70% sequence identity over 75% sequence coverage; against the human 
genome, and the metagenomics catalogue of non-redundant human gut microbiome 
genes by Qin et al [7].  
Determination of antimicrobial activity 
Selection of potential drug targets for in vivo validation was mainly based on their 
novelty, that is, they have not been described as targets to existing antimicrobials. 
Commercial availability of inhibitory compounds without resorting to customized 
chemical synthesis was also key; all inhibitory compounds used were supplied by Sigma 
Aldrich. 1-Methyluric acid, 5, 5′-Dithio-bis-(2-nitrobenzoic Acid), and 5'-deoxyadenosine 
were dissolved in water at 5mg/ml. When necessary, the pH was neutralized (to pH7) 
using 10M NaOH solution or 1M HCl. Antimicrobial activity of the compounds was tested 
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Libraries for the 15,000 transformants S. pneumoniae R6 and H. influenzae Rd KW20 were 
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used to profile the relative abundance of each mutant in all libraries after growth as 
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TIGR4 were obtained from literature [23]. We then performed essentiality predictions for 
individual genes using the in-house developed web-tool, ESSENTIALS [24], which 
enabled us calculate a statistical essentiality metric for each ORF, and precisely delineate 
the optimal boundary between essential and nonessential ORFs in each of the 5 strains. 
Analysis data can be found at http://bamics2.cmbi.ru.nl/websoftware/essentials/links.html    
Overrepresented metabolic pathways and subsystems 
Pathways and subsystems for the strains under study were obtained from the Kyoto 
Encyclopedia of Genes and Genomes orthology, and the SEED databases respectively 
[25, 26]. Using a Fisher’s exact test, we performed functional categories enrichment for 
the pathways and subsystems, while incorporating the statistical essentiality value (the 
fold-change value predicted by ESSENTIALS) for each ORF. We corrected for multiple 
testing using Bonferroni correction and obtained q-values for corresponding p-values [27]. 
Proteins subcellular localization (SCL) 
The subcellular localizations (SCL) of all proteins in this study were determined using 
publicly available SCL prediction tools. First, we analyzed all Gram-positive and Gram-
negative strains using pSORTdb version 2.0 [10] and CELLO version 2.5 [28]. Further 
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those predicted to be of unknown SCL by majority of the predictors used. 
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To identify and eliminate essential genes with close undesirable orthologs, we performed 
separate unidirectional blast (BLASTP) searches, using an E-value cut-off of 1e-10, and 
minimum 70% sequence identity over 75% sequence coverage; against the human 
genome, and the metagenomics catalogue of non-redundant human gut microbiome 
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Selection of potential drug targets for in vivo validation was mainly based on their 
novelty, that is, they have not been described as targets to existing antimicrobials. 
Commercial availability of inhibitory compounds without resorting to customized 
chemical synthesis was also key; all inhibitory compounds used were supplied by Sigma 
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by Kirby-Bauer/disk diffusion assay [32], by applying 10 μg of the inhibitory compounds  
to 6mm filter paper discs at concentration ranging from 10000 to 0.05 μg/ml in 10-fold 
stepwise dilutions. As for (R)-6-fluoromevalonate diphosphate 2 μl of (R)-6-
fluoromevalonate diphosphate was diluted in 1ml of Milli-Q (MQ). 10 μl and 100 μl of the 
dilution were used in separate disk diffusion assays. Columbia III agar with 5% sheep 
blood medium was used for S. pneumoniae. Brain heart infusion (BHI) agar medium and a 
combination medium of BHI, hemin, and NAD were used for M. catarrhalis and H. 
influenzae respectively. MIC calculations were performed as described by Wiegand and 
colleagues [33]. Experiments were performed in quadruplicate, and outliers were 
removed using the Grubbs test [34]. 
Toxicity assays on epithelial cell lines 
Cellular toxicity of (R)-6-fluoromevalonate diphosphate was tested using the CellTox 
Green Cytotoxicity Assay (Promega, WI) on Detroit 562 (ATCC CCL-138) and A549 (ATCC 
CCL-185) cell lines according to the manufacturer’s instructions. The two cell lines were 
exposed to (R)-6-fluoromevalonate diphosphate at its effective MIC concentration of 26.6 
μg/ml for 24 hours at 37°C with 5 % CORR2RR. Fluorescence was measured on a Perkin Elmer 
1420 Victor 3V multi-label plate reader. 
 
Results and discussion 
Genome reannotation and gene clustering 
We sought to determine potential drug targets in S. pneumoniae, H. influenzae, and M. 
catarrhalis following the selection criteria outlined in Figure 1. For these species, five 
strains with the required Tn-seq data were available; S. pneumoniae strains R6 and TIGR4, 
H. influenzae strains Rd KW20 and 86 028NP, and M. catarrhalis strain BBH18. Altogether, 
genomes of these strains in their initial annotations constituted of 10,072 open reading 
frames (ORFs). These annotations were updated using RAST to ensure consistency and 
comparability among strains in subsequent analyses. This analysis resulted in putative 
annotations for about 50% of all ORFs originally annotated with a hypothetical function 
(Table 1; Additional file 1). Next, we clustered the updated protein sequences using 
OrthoMCL, producing 1,798 orthologous groups/clusters (OGs) with, and 2,729 without 
singletons respectively (Additional file 1). This clustering of orthologous proteins allowed 
for the determination of species and/or strain specific proteins, as well as determining the 
metabolic potential of the strains. For example, the “Gram-negative specific” periplasmic 
chaperones (SurA) were clustered in OG_756 (cluster 756), while the “Streptococci-
specific” transcriptional regulators (LytR) were clustered in OG_2554. On the other hand, 
300 OGs, including OG_184, OG_186, OG_216, and OG_224, among others, contained 
genes conserved in all the five strains. All protein in individual OGs constituted of similar 
 
 
  
or identical functional annotations. This consistency in grouping and annotation was 
observed across all OGs, suggesting a reliable clustering. Confirmatory clusters and 
respective annotations derived from the clusters of orthologous genes (COGs) database 
were consistent with our OrthoMCL clusters. Additionally, using the OG’s, we were able 
to curate annotations for the HI1586 locus in Haemophilus influenzae Rd KW20, which was 
possibly misannotated in the initial release, as an isoleucyl-tRNA synthetase instead of a 
NaP P+P/HP P+ P  antiporter.  
Essential and conserved protein-coding genes 
Loss of mutant readouts from a transposon library after in vitro transposition and genetic 
transformation of the wild-type isolate is a strong indicator of gene essentiality [35]. 
Although some essential genes tolerate disruptive insertions in the 3’ regions, generally, 
insertions in essential genes lead to lethal phenotypes [36]. For our analysis, mutant 
libraries and/or Tn-seq data were constructed in in-house experiments or obtained from 
literature (Table 1). We separately analyzed the Tn-seq datasets using ESSENTIALS [24]. 
 
Figure 1. Schematic overview of the drug target selection criteria. Genome annotations information for S. 
pneumoniae R6, S. pneumoniae TIGR4, H. influenzae 86 028NP, H. influenzae Rd KW20, and M. catarrhalis BBH18 
were updated using RAST. The proteins with updated annotations were then clustered into putative 
orthologous groups using OrthoMCL, and their subcellular localizations predicted in various publicly available 
tools. ESSENTIALS was used to analyze various transposon mutant libraries and predict the essentiality metric 
for each ORF. Comparing the ensuing essential genes with the catalogue of human gut microbial genes, as well 
as with the human genome helped to eliminate genes with conserved orthologs, and subsequently prioritize 
potential drug targets. 
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This analysis resulted in the identification of 532 essential genes in H. influenzae 86-
028NP, representing 28% of the genome, a higher number as compared to the other 
Gram-negative strains; H. influenzae Rd KW20 and M. catarrhalis BBH18, in which we 
identified 431 and 445 essential genes respectively. In S. pneumonia, we identified 325 and 
414 essential genes for the R6 and TIGR4 strains respectively (Table 1; Additional file 1). 
These values showed that on average, about 20% of all genes in the five strains are 
essential. This is consistent with earlier studies which have reported 15-25% of all genes in 
a genome being essential [23, 36, 37].  
Differences in the number of essential genes could be explained by various factors that 
hamper precision in transposon mutagenesis experiments, including short gene lengths 
and unsaturated transposon libraries; “saturation” being the presence of at least one 
insertion in every gene. In practice, short genes are less susceptible to disruptive 
transposon insertions, hence, more likely to be misclassified as essential. In unsaturated 
transposon mutant libraries, dispensable genes are also more likely to be devoid of 
transposon insertions, and therefore misclassified as being essential genes. The low-
density transposon mutant library (approximately 11,000 colony forming units; CFU) used 
for H. influenzae 86-028NP, and a substantial number of short genes in its genome could, 
therefore, explain the apparently overestimated (532) essential genes. Relatively 
saturated libraries of approximately 20,000 CFU and 40,000 CFU were used for H. 
influenzae Rd KW20 and M. catarrhalis BBH18 respectively (Table 1). A rarefaction 
analysis on our data confirmed that the S. pneumoniae, M. catarrhalis, and H. influenzae 
Rd KW20 transposon libraries approached saturation (Additional file 4). Additionally, 
based on derivations of Poisson’s law, there is a 99.6% probability that genes with a size 
of 1kb are hit in the 1.9Mb H. influenzae 86-028NP genome and an 11,000 CFU mutant 
library. Similar statistics on the 1.79Mb H. influenzae Rd KW20 genome with a 20,000 CFU 
mutant library shows a 99.99% probability. Therefore, H. influenzae 86-028NP could have 
suffered slightly more false positive predictions due to its less saturated mutant libraries.  
We selected 705 OGs containing at least one essential gene from any of the five strains 
for further analysis. These essential OGs mainly consist of proteins with annotated 
functions, participating in diverse core cellular processes, such as DNA replication, DNA 
transcription, protein translation, cell wall biosynthesis, signal transduction, and 
metabolism. Eighteen OGs, however, contained conserved proteins of uncharacterized 
function (Additional file 1). Functional characterization of these genes will aid in achieving 
the optimal set of targets that can be used to develop antimicrobials against RTI causing 
bacteria. The distribution and overlap of the essential genes within the three species is 
outlined in Figure 2. From the 705 OGs, we identified 128 OGs that constituted of genes 
conserved and essential in all five trains, representing targets particularly attractive for 
developing broad-spectrum antimicrobials to treat RTI, since they encode components of 
basal cellular functions in respiratory pathogens. Importantly, collective analysis of the 
five strains revealed species-specific and/or “Gram-category” specific essential genes, 
best suited for narrow-spectrum or specialized inhibition. 
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This analysis resulted in the identification of 532 essential genes in H. influenzae 86-
028NP, representing 28% of the genome, a higher number as compared to the other 
Gram-negative strains; H. influenzae Rd KW20 and M. catarrhalis BBH18, in which we 
identified 431 and 445 essential genes respectively. In S. pneumonia, we identified 325 and 
414 essential genes for the R6 and TIGR4 strains respectively (Table 1; Additional file 1). 
These values showed that on average, about 20% of all genes in the five strains are 
essential. This is consistent with earlier studies which have reported 15-25% of all genes in 
a genome being essential [23, 36, 37].  
Differences in the number of essential genes could be explained by various factors that 
hamper precision in transposon mutagenesis experiments, including short gene lengths 
and unsaturated transposon libraries; “saturation” being the presence of at least one 
insertion in every gene. In practice, short genes are less susceptible to disruptive 
transposon insertions, hence, more likely to be misclassified as essential. In unsaturated 
transposon mutant libraries, dispensable genes are also more likely to be devoid of 
transposon insertions, and therefore misclassified as being essential genes. The low-
density transposon mutant library (approximately 11,000 colony forming units; CFU) used 
for H. influenzae 86-028NP, and a substantial number of short genes in its genome could, 
therefore, explain the apparently overestimated (532) essential genes. Relatively 
saturated libraries of approximately 20,000 CFU and 40,000 CFU were used for H. 
influenzae Rd KW20 and M. catarrhalis BBH18 respectively (Table 1). A rarefaction 
analysis on our data confirmed that the S. pneumoniae, M. catarrhalis, and H. influenzae 
Rd KW20 transposon libraries approached saturation (Additional file 4). Additionally, 
based on derivations of Poisson’s law, there is a 99.6% probability that genes with a size 
of 1kb are hit in the 1.9Mb H. influenzae 86-028NP genome and an 11,000 CFU mutant 
library. Similar statistics on the 1.79Mb H. influenzae Rd KW20 genome with a 20,000 CFU 
mutant library shows a 99.99% probability. Therefore, H. influenzae 86-028NP could have 
suffered slightly more false positive predictions due to its less saturated mutant libraries.  
We selected 705 OGs containing at least one essential gene from any of the five strains 
for further analysis. These essential OGs mainly consist of proteins with annotated 
functions, participating in diverse core cellular processes, such as DNA replication, DNA 
transcription, protein translation, cell wall biosynthesis, signal transduction, and 
metabolism. Eighteen OGs, however, contained conserved proteins of uncharacterized 
function (Additional file 1). Functional characterization of these genes will aid in achieving 
the optimal set of targets that can be used to develop antimicrobials against RTI causing 
bacteria. The distribution and overlap of the essential genes within the three species is 
outlined in Figure 2. From the 705 OGs, we identified 128 OGs that constituted of genes 
conserved and essential in all five trains, representing targets particularly attractive for 
developing broad-spectrum antimicrobials to treat RTI, since they encode components of 
basal cellular functions in respiratory pathogens. Importantly, collective analysis of the 
five strains revealed species-specific and/or “Gram-category” specific essential genes, 
best suited for narrow-spectrum or specialized inhibition. 
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Essential metabolic pathways and subsystems 
Functional category enrichment analyses were performed for all KEGG metabolic 
pathways and the SEED subsystems [25, 26]. As of August 22, 2013, the KEGG database 
describes 448 fully characterized pathways, which are further subcategorized into 
262,304 reference maps for various organisms. All KEGG characterized proteins in the 705 
essential OGs could be assigned to 84 unique pathways. Among these, characterized 
proteins contained in the 128 OGs that are conserved and essential in all five strains could 
be assigned to 47 metabolic pathways (Additional files 1 and 2). As was the case for 
essential genes, the identified essential pathways specify among other functions, core 
bacterial bioprocesses like membrane transport, DNA replication and repair, signal 
transduction, metabolism, transcription and translation, ribosomal functions, and cellular 
processes including cell motility. The SEED, an alternative to KEGG, comprehensively 
groups genes at the level of a biological system and its subsystems. Currently, there are 
approximately 1,009 characterized SEED subsystems. Use of SEED subsystems on the 
essential OGs also revealed overrepresentation of critical system processes, including 
those involved in protein biosynthesis, virulence, disease and defense, as well as 
metabolism of cofactors, vitamins, prosthetic groups, pigments, fatty acids, lipids, and 
isoprenoids (Table 2; Additional file 3).  
Protein subcellular localization 
Out of the 705 OGs selected, the majority (526) consists of cytoplasmic proteins. Cellular 
localization of the other OGs were predicted to be: 96 in the inner membrane, 11 in the 
outer membrane, 12 in the periplasm, and 4 in the extracellular space. In addition, 21 OGs 
are non-categorically predicted to contain membrane proteins, whereas 35 are of 
unknown localizations. Of the 11 outer membrane OGs, 7 contained β-barrels (Additional 
file 1). 
Orthologs in human and human gut microflora 
The human gut is home to microbiota whose proper composition and functioning 
collectively influence human nutrition, protection against pathogens and development of 
disease [7]. Perturbing this microbiota with antibiotics could cause adverse side effects. 
Furthermore, interference with human cell physiology by antibiotics as a consequence of 
non-specific targeting can cause severe cellular cytotoxicity [3], which may result in organ 
failure or even death. We used BLASTP analyses against the human genome (Genome 
Reference Consortium) and the human gut microbial gene catalogue [7], to identify 
targets that would likely have off-target effects. It is noteworthy that targets with as few 
as 10 matches in the non-redundant gut microbial gene catalogue were allowed in the 
final selection, as we hypothesized that these would have no effects on the gut 
microbiome preventing disruption of gut health. This decision was motivated by the 
 
 
  
observation from our analysis that well known targets for both clinically approved 
antimicrobials and experimental small molecule inhibitors collated in DrugBank 
(Additional file 1; column 9) maintained on average fewer than 10 blast hits against the 
human gut microbial gene catalogue (Additional file 1; column 20). On the other hand, 
the majority of the targets with numerous blast hits were aminoacyl-tRNA synthetases 
(aaRSs) and ribosomal protein, including rpsL, a well-known target that had 249 hits for 
pneumococci, 156 for H. influenzae, and 151 for M. catarrhalis. One shortcoming of using 
such filtering criteria is that novel targets that have more than 10 blast hits are not 
effectively retained in the final selection. Nevertheless, we identified 96 OGs with 
orthologs in human, and 127 OGs with orthologs in human gut microflora, that is, with 
>10 blast hits (Additional file 1). All 20 aminoacyl-tRNA synthetases (aaRSs), essential for 
protein synthesis, were particularly conserved in both human and human gut microflora. 
Studies have shown that aaRSs can be selectively targeted as most bacterial aaRSs 
recognize and aminoacylate only cognate tRNA [38]. However, possible side effects are 
expected from drugs targeting aaRSs. RNA molecules and ribosomal proteins were also 
highly conserved in gut microbiota and humans. Additionally, the relatively short lengths 
and the presence of highly repetitive DNA in RNA sequences also rendered their 
essentiality predictions unreliable. All these molecules were therefore not included in the 
final selection of drug targets. Moreover, blast comparison between finally selected 
targets and their human orthologs showed minimal sequence identities (<35%) over short 
sequence coverage. 
 
Figure 2. A Venn diagram showing the overlap of essential orthologous groups among the respiratory 
pathogens. Singletons are shown in brackets. 
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Table 2: Distribution of essential features among respiratory pathogens.  
 Quantity of features in the strains 
 mct hin hit spn spr 
Essential structural and non-coding RNAs  5 49 41 136 47 
    tRNA 4 18 0 12 8 
    rRNA 1 31 41 44 30 
    sRNA n/a n/a n/a 80 9 
Essential Protein-coding ORFs 445 431 532 414 325 
    Protein of unknown functions 159 172 225 186 127 
    Metabolism 173 142 182 124 100 
    Genetic Information Processing 93 95 101 95 93 
    Environmental Information Processing 20 24 24 9 5 
Overrepresented/essential KEGG pathways 236 437 196 307 356 
    Metabolism 136 221 95 171 213 
    Genetic Information Processing 74 177 74 128 129 
    Environmental Information Processing 26 38 26 8 14 
    Cellular Processes 0 1 1 0 0 
Overrepresented/essential SEED subsystems 449 513 602 450 355 
    Protein metabolism 84 85 99 100 93 
    Cofactors, Vitamins, Prosthetic Groups, Pigments 75 61 80 29 25 
    Cell Wall and Capsule 47 60 78 47 30 
    Amino Acids and Derivatives 41 59 58 14 11 
    Respiration 41 16 34 8 7 
    Fatty Acids, Lipids, and Isoprenoids 29 36 40 26 21 
    RNA Metabolism 25 59 71 60 39 
    Carbohydrates 24 30 46 47 35 
    DNA Metabolism 19 37 35 45 41 
    Stress Response 18 17 9 10 8 
    Nucleosides and Nucleotides biosynthesis 17 13 11 25 9 
    Virulence, Disease and Defense 16 18 18 16 15 
    Regulation and Cell signaling 8 4 8 6 5 
    Cell Division and Cell Cycle 5 18 15 17 16 
The strains under study are abbreviated: mct; Moraxella catarrhalis BBH18, hin; Haemophilus influenzae Rd 
KW20, hit; H. influenzae 86 028NP, spn; Streptococcus pneumoniae TIGR4, and spr; S. pneumoniae R6. Untested 
categories are denoted by “n/a”. 
Drug targets selection and validation 
We identified 249 potential drug targets in the five strains (Additional file 5), including key 
enzymes in pathways such as fatty acid biosynthesis [39-41], vitamin biosynthesis [42-
45], and isoprenoid biosynthesis pathways [46-48], which have gained interest in drug 
discovery research, as well as 67 known targets inhibited by 75 FDA-approved 
antimicrobial drugs and 35 other researched small molecule inhibitors collated in the 
DrugBank database [49]. To validate our target prediction, we selected four novel targets 
with commercially available novel inhibitors of their predicted essential functions, that is, 
inhibitors not yet approved as clinical drugs and don’t require to be custom synthesized: 
We tested whether exposure to these compounds inhibited growth of the target 
organisms.  
Vitamin biosynthetic pathways constitute an attractive and largely untapped source of 
potential drug targets [42, 45]. For instance, thiamine (vitamin B1) in its active form 
 
 
  
thiamine diphosphate is indispensable for the activity of the carbohydrate and branched-
chain amino acid metabolic enzymes [42]. Most bacteria synthesize thiamine de novo, 
whereas humans depend on dietary uptake, making the thiamine biosynthetic pathway 
an attractive selective drug target. Folic acid (vitamin B9) is another indispensable 
cofactor, whose biosynthetic pathway was a target for sulfamidochrysoidine (prontosil); 
later replaced by an improved sulphonamide drug sulfanilamide, the first ever antibiotic 
used in humans [50]. The pathway is also targeted by trimethoprim [45], another clinically 
acknowledged chemotherapeutic agent that acts on dihydrofolate reductase. Niacin 
(vitamin B3; alternatively known as nicotinamide or nicotinic acid) is also essential to all 
living cells and is biosynthetically converted to nicotinamide adenine dinucleotide 
(NAD P+ P), a coenzyme involved in electron transport reactions in cell metabolism processes 
[51]. After it was described that niacin has therapeutic effects and it modulates various 
biological effects as well as NAD P+ Pmetabolism, there has been an increased interest in the 
role of NAD P+ P biosynthetic pathway in health and disease [52]. Prospects of targeting the 
pathway are also being explored. We used 5, 5′-Dithiobis, 2-nitrobenzoic acid (CAS: 69-
78-3) to inhibit NAD P+ P kinase (EC:  2.7.1.23) - a key enzyme in the NADP biosynthesis which 
catalyzes the phosphorylation of NAD P+ P into NADPP+ P. Inhibition of growth was expected in 
both Gram-positive and Gram-negative strains. However, inhibition of growth was only 
observed in the disk diffusion assays for S. pneumoniae. MIC calculations were 
inconclusive as they ranged from 319 to 2500 μg/ml with a large variability between 
assays (Table 3).  
As an essential amino acid, methionine is not synthesized de novo in humans, who must 
rely on dietary intake. Enzymes involved in microbial methionine biosynthesis therefore 
offer highly specific and selective drug targets. We used 1-methyluric acid (CAS: 708-79-2) 
to target S-adenosylmethionine synthetase (EC: 2.5.1.6); a key enzyme in methionine 
biosynthesis, whose drug target potential has been explored in various pathogens [53, 
54]. Contrary to expectations, no growth inhibition was observed in Gram-negative 
strains (Table 3; Figure 3): growth inhibition was only observed in S. pneumoniae. Since 1-
methyluric acid formed a precipitate in concentrations above 312 μg /ml, no MIC values 
could be calculated. This lack of growth inhibition in Gram-negative strains may possibly 
be due to their double layered cell walls which are less penetrable [55], or the bacteria 
have expanded their resistance mechanisms to evade killing by antimicrobials [55, 56]. It 
is also possible that the two Gram-negative species have alternative mechanisms for 
methionine biosynthesis, further complicating screening for effective drugs. 
The microbial fatty acid synthesis (FAS) pathway is an attractive target for drug discovery 
[41, 57]. This pathway is subdivided into type I and II, whereby human FAS proteins 
predominantly belong to type I FAS, and the bacterial ones are predominantly type II 
FAS. Proteins from the two FAS types generally possess distinctive molecular 
organization of the active site allowing for selective targeting [39, 40]. Although Gram-
positive pathogens could compensate FASII inhibition by assimilating environmental 
fatty acids; particularly unsaturated fatty acids [58, 59], several clinical and household 
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Table 2: Distribution of essential features among respiratory pathogens.  
 Quantity of features in the strains 
 mct hin hit spn spr 
Essential structural and non-coding RNAs  5 49 41 136 47 
    tRNA 4 18 0 12 8 
    rRNA 1 31 41 44 30 
    sRNA n/a n/a n/a 80 9 
Essential Protein-coding ORFs 445 431 532 414 325 
    Protein of unknown functions 159 172 225 186 127 
    Metabolism 173 142 182 124 100 
    Genetic Information Processing 93 95 101 95 93 
    Environmental Information Processing 20 24 24 9 5 
Overrepresented/essential KEGG pathways 236 437 196 307 356 
    Metabolism 136 221 95 171 213 
    Genetic Information Processing 74 177 74 128 129 
    Environmental Information Processing 26 38 26 8 14 
    Cellular Processes 0 1 1 0 0 
Overrepresented/essential SEED subsystems 449 513 602 450 355 
    Protein metabolism 84 85 99 100 93 
    Cofactors, Vitamins, Prosthetic Groups, Pigments 75 61 80 29 25 
    Cell Wall and Capsule 47 60 78 47 30 
    Amino Acids and Derivatives 41 59 58 14 11 
    Respiration 41 16 34 8 7 
    Fatty Acids, Lipids, and Isoprenoids 29 36 40 26 21 
    RNA Metabolism 25 59 71 60 39 
    Carbohydrates 24 30 46 47 35 
    DNA Metabolism 19 37 35 45 41 
    Stress Response 18 17 9 10 8 
    Nucleosides and Nucleotides biosynthesis 17 13 11 25 9 
    Virulence, Disease and Defense 16 18 18 16 15 
    Regulation and Cell signaling 8 4 8 6 5 
    Cell Division and Cell Cycle 5 18 15 17 16 
The strains under study are abbreviated: mct; Moraxella catarrhalis BBH18, hin; Haemophilus influenzae Rd 
KW20, hit; H. influenzae 86 028NP, spn; Streptococcus pneumoniae TIGR4, and spr; S. pneumoniae R6. Untested 
categories are denoted by “n/a”. 
Drug targets selection and validation 
We identified 249 potential drug targets in the five strains (Additional file 5), including key 
enzymes in pathways such as fatty acid biosynthesis [39-41], vitamin biosynthesis [42-
45], and isoprenoid biosynthesis pathways [46-48], which have gained interest in drug 
discovery research, as well as 67 known targets inhibited by 75 FDA-approved 
antimicrobial drugs and 35 other researched small molecule inhibitors collated in the 
DrugBank database [49]. To validate our target prediction, we selected four novel targets 
with commercially available novel inhibitors of their predicted essential functions, that is, 
inhibitors not yet approved as clinical drugs and don’t require to be custom synthesized: 
We tested whether exposure to these compounds inhibited growth of the target 
organisms.  
Vitamin biosynthetic pathways constitute an attractive and largely untapped source of 
potential drug targets [42, 45]. For instance, thiamine (vitamin B1) in its active form 
 
 
  
thiamine diphosphate is indispensable for the activity of the carbohydrate and branched-
chain amino acid metabolic enzymes [42]. Most bacteria synthesize thiamine de novo, 
whereas humans depend on dietary uptake, making the thiamine biosynthetic pathway 
an attractive selective drug target. Folic acid (vitamin B9) is another indispensable 
cofactor, whose biosynthetic pathway was a target for sulfamidochrysoidine (prontosil); 
later replaced by an improved sulphonamide drug sulfanilamide, the first ever antibiotic 
used in humans [50]. The pathway is also targeted by trimethoprim [45], another clinically 
acknowledged chemotherapeutic agent that acts on dihydrofolate reductase. Niacin 
(vitamin B3; alternatively known as nicotinamide or nicotinic acid) is also essential to all 
living cells and is biosynthetically converted to nicotinamide adenine dinucleotide 
(NAD P+ P), a coenzyme involved in electron transport reactions in cell metabolism processes 
[51]. After it was described that niacin has therapeutic effects and it modulates various 
biological effects as well as NAD P+ Pmetabolism, there has been an increased interest in the 
role of NAD P+ P biosynthetic pathway in health and disease [52]. Prospects of targeting the 
pathway are also being explored. We used 5, 5′-Dithiobis, 2-nitrobenzoic acid (CAS: 69-
78-3) to inhibit NAD P+ P kinase (EC:  2.7.1.23) - a key enzyme in the NADP biosynthesis which 
catalyzes the phosphorylation of NAD P+ P into NADPP+ P. Inhibition of growth was expected in 
both Gram-positive and Gram-negative strains. However, inhibition of growth was only 
observed in the disk diffusion assays for S. pneumoniae. MIC calculations were 
inconclusive as they ranged from 319 to 2500 μg/ml with a large variability between 
assays (Table 3).  
As an essential amino acid, methionine is not synthesized de novo in humans, who must 
rely on dietary intake. Enzymes involved in microbial methionine biosynthesis therefore 
offer highly specific and selective drug targets. We used 1-methyluric acid (CAS: 708-79-2) 
to target S-adenosylmethionine synthetase (EC: 2.5.1.6); a key enzyme in methionine 
biosynthesis, whose drug target potential has been explored in various pathogens [53, 
54]. Contrary to expectations, no growth inhibition was observed in Gram-negative 
strains (Table 3; Figure 3): growth inhibition was only observed in S. pneumoniae. Since 1-
methyluric acid formed a precipitate in concentrations above 312 μg /ml, no MIC values 
could be calculated. This lack of growth inhibition in Gram-negative strains may possibly 
be due to their double layered cell walls which are less penetrable [55], or the bacteria 
have expanded their resistance mechanisms to evade killing by antimicrobials [55, 56]. It 
is also possible that the two Gram-negative species have alternative mechanisms for 
methionine biosynthesis, further complicating screening for effective drugs. 
The microbial fatty acid synthesis (FAS) pathway is an attractive target for drug discovery 
[41, 57]. This pathway is subdivided into type I and II, whereby human FAS proteins 
predominantly belong to type I FAS, and the bacterial ones are predominantly type II 
FAS. Proteins from the two FAS types generally possess distinctive molecular 
organization of the active site allowing for selective targeting [39, 40]. Although Gram-
positive pathogens could compensate FASII inhibition by assimilating environmental 
fatty acids; particularly unsaturated fatty acids [58, 59], several clinical and household 
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antimicrobials targeting key FAS enzymes, e.g. Platensimycin and Platencin have been 
successfully developed [41, 60]. 
In our analysis, we identified various genes conserved in all five strains, for example genes 
in OGs 085, 143, and 653, whose products play key roles in the FAS pathway. With 5'-
Deoxyadenosine (CAS: 4754-39-6), we targeted lipoate synthase (LipA; EC: 2.8.1.8), a key 
enzyme in the lipoic acid metabolism [61], using product-level inhibition. Surprisingly, we 
observed growth inhibition in all three species (Figure 3; Table 3), despite the target 
cluster (OG_653) comprising of orthologs from only Gram-negative strains (Additional file 
1). This observations are also reflected in the MIC, which ranged from 29.3 to 205.1 μg/ml 
(Table 3). A blastP comparison showed that the closest ortholog of the Gram-negative 
LipA in S. pneumoniae is the non-lipoic pathway enzyme fructose-6-phosphate aldolase I, 
sharing about 32% sequence identity. Moreover, a comparison between LipA and lipoate-
protein ligase (LplA), the key lipoylation enzyme in S. pneumoniae [61], revealed that the 
two proteins are non-orthologous, as they share very low sequence identity (<25%). They 
however have conserved domain which may explain the observed growth inhibition. 
 
Table 3. Drug target in vivo validation summary. Diameter of the clearance zone after normal incubation 
represents the inhibition area on disk. Concentrations showing delayed growth are denoted by an asterisk (*). 
Compound 
Amount 
on disc 
(µg) 
MIC μg/ml; Std. Dev. [Inhibition area on disk 
diffusion assay] 
S. pneumoniae H. influenzae M. catarrhalis 
5,5'-dithiobis(2-nitrobenzoate) (CAS 69-78-
3) 
1,000 
2,500; 0 [4 
mm*] 
781; 313 
[none] 
319; 303 
[none] 
1-methyluric acid (CAS  708-79-2) 1,000 >312.5 [6 mm] >312.5 [none] >312.5 [none] 
5′deoxyadenosine (CAS 4754-39-6) 1,000 78.1; 0 [6 mm] 
205; 132 [5 
mm*] 
29.3; 11 [12 
mm] 
(R)-6-fluoromevalonate diphosphate (CAS  
2822-77-7) 
1,000 
26.6; 11.5 [12 
mm] 
4,167; 1443 
[none] 
>5,000; 0 
[none] 
(R)-6-fluoromevalonate diphosphate (CAS  
2822-77-7) 
100 
26.6; 11.5 [4 
mm*] 
4,167; 1443 
[none] 
>5,000; 0 
[none] 
Std. Dev. = Standard deviation 
 
 
Figure 3. Validation of growth inhibition using disk diffusion essays. Cell culture plate cross-sectional images 
showing the area of growth inhibition for: a. M. catarrhalis in 5′deoxyadenosine, and S. pneumoniae in; b. (R)-6-
fluoromevalonate diphosphate, c. I methyl, d. 5, 5’-dithiobis (2-nitrobenzoate), and e. 5′deoxyadenosine 
respectively.  
edcba
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Isoprenoids are natural products involved in many biochemical functions, such as 
supplying quinones for the electron transport chains, components of membranes, and 
subcellular targeting and regulation [47]. Humans employ the mevalonate pathway, 
whereas most microbes follow a non-mevalonate (1-deoxy-d-xylulose 5-phosphate/2-C-
methyl-d-erythritol 4-phosphate) pathway. Functional roles of key enzymes in the 
isoprenoid biosynthesis pathway are well characterized, opening prospects for the 
discovery of novel drug targets [46, 48]. Fosmidomycin is a promising isoprenoid-based 
anti-malarial drug which is currently in clinical trials [48]. Using 6-fluoromevalonate (CAS: 
2822-77-7) to target diphosphomevalonate decarboxylase (EC: 4.1.1.33), we observed 
selective growth inhibition only in S. pneumoniae as expected (Additional file 1; Figure 3; 
Table 3). Additionally, no effects on growth were observed in the Gram-negative strains, 
which was also as expected. We determined an average MIC of value 26.6 μg/ml for the S. 
pneumoniae growth inhibition (Table 3). At 26.6 μg/ml, no toxicity was observed in cell 
toxicity assays on epithelial cell lines (data not shown). Moreover, in patent WO 
1995013058 A1, no cytotoxic effects of 6-fluoromevalonate were observed on T-
lymphocytes. Previous literature also shown that 6-fluoromevalonate could potentially 
function the same as statins, as they inhibit the same pathway [62]. 
Diphosphomevalonate decarboxylase could therefore be a promising target for 
developing novel antibiotics against S. pneumoniae [63]. 
Conclusion 
We have combined Tn-seq with in silico approaches to obtain an insight into many 
essential and conserved molecular functions, which we predicted to be unique among 
respiratory pathogens. With this combinatorial approach, we have reliably identified 249 
potential drug targets, 67 of which are acknowledged targets for 75 FDA-approved 
antimicrobial drugs and 35 other researched small molecule inhibitors [49]; we 
successfully validated two of the four tested targets. Here, we propose a number of novel 
potential drug targets that are a concrete lead for experimental validation. We anticipate 
that future research based on this study will eventually provide interesting targets that 
can be successfully moved to drug development. In conclusion, we have pioneered a 
powerful approach, which combines gene essentiality data with robust computational 
techniques, to comprehensively screen for antimicrobial drug targets at genome-scale. 
This approach circumvents the complex and costly laboratory screens, thus, facilitating 
directed drugs discovery. 
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Abstract 
The 7-valent pneumococcal conjugated vaccine (PCV7) has affected the genetic 
population of Streptococcus pneumoniae in pediatric carriage. Little is known however 
about pneumococcal population genomics in adult invasive pneumococcal disease (IPD) 
under vaccine pressure. We sequenced and serotyped 349 strains of S. pneumoniae 
isolated from IPD patients in Nijmegen between 2001 and 2011. Introduction of PCV7 in 
the Dutch National Immunization Program in 2006 preluded substantial alterations in the 
IPD population structure caused by serotype replacement. No evidence could be found 
for vaccine induced capsular switches. We observed that after a temporary bottleneck in 
gene diversity after the introduction of PCV7, the accessory gene pool re-expanded 
mainly by genes already circulating pre-PCV7. In the post-vaccine genomic population a 
number of genes changed frequency, certain genes became overrepresented in vaccine 
serotypes, while others shifted towards non-vaccine serotypes. Whether these dynamics 
in the invasive pneumococcal population have truly contributed to invasiveness and 
manifestations of disease remains to be further elucidated. We suggest the use of whole 
genome sequencing for surveillance of pneumococcal population dynamics that could 
give a prospect on the course of disease, facilitating effective prevention and 
management of IPD. 
  
 
 
  
Introduction 
The bacterial pathogen Streptococcus pneumoniae remains an important cause of 
pneumonia and meningitis worldwide, causing an estimated 1.6 million deaths annually 
[1] Immunization with a 7-valent pneumococcal conjugated vaccine (PCV), both in young 
children [2] and the elderly [3], has been demonstrated to be highly efficacious in 
preventing invasive pneumococcal disease (IPD) caused by vaccine serotypes. Moreover, 
after the introduction of routine pediatric vaccination, an additional decrease in vaccine-
type pneumococcal infections occurred, both in pediatric carriage [4, 5] as well as in IPD 
at all ages [6], indicative of a herd immunity effect. However, in all regions where routine 
PCV vaccination has been introduced, we see replacement in pneumococcal carriage and 
disease by non-vaccine serotypes [7-9], which at least partially abrogates the preventive 
effect of vaccination. In the Netherlands, the number of reported cases of IPD has not 
decreased after vaccination due to full replacement by non-vaccine serotypes [10] 
Currently available pneumococcal vaccines target the pneumococcal polysaccharide 
capsule. Although over 90 antigenically distinct pneumococcal capsules (denominated as 
serotypes) are known to date, only a selection of 7 serotypes (later extended to 10 and 13) 
is included in the PCV, based on modelling vaccination effects by the frequency and the 
propensity for invasiveness for each serotype [11, 12]. Whereas the polysaccharide 
capsule is essential for the pneumococcus to cause IPD [13], recent publications suggest 
that true determinants of invasiveness may lay underneath the pneumococcal capsule, 
represented by variations on the pneumococcal genome [14-18], which should be 
included in modelling vaccine effects [19].  
Since the introduction of routine pediatric immunization with PCV, several studies have 
detailed pneumococcal genomic epidemiology in pediatric carriage and otitis media 
under vaccine pressure. They all demonstrated that the pneumococcal genomic structure 
of pediatric carriage remained fairly stable, and that serotype replacement occurred 
mainly through expansion of previously existent clones [20-25]. The single study that 
examined whole pneumococcal genomes, including virulence factors, reported little 
effect on the accessory genome at the overall pneumococcal carriage population level 
despite massive serotype replacement [26]. However, the effect of pneumococcal 
vaccination on whole genome epidemiology of invasive pneumococcal disease remains 
unexplored, although it may hold invaluable information on understanding the long term 
effects of mass vaccination, especially with regard to changes in clinical manifestation of 
disease due to the changing prevalence of virulence factors in the pneumococcal 
population.  
PCV7 was introduced in the Dutch National Immunization Program in April 2006 while 
PCV10 was introduced in May 2011. In this study, we have sequenced 349 invasive 
pneumococcal isolates from 2001 to June 2011, in order to investigate the herd-immunity 
effect of PCV7 on pneumococcal population genomics in IPD.  
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Abstract 
The 7-valent pneumococcal conjugated vaccine (PCV7) has affected the genetic 
population of Streptococcus pneumoniae in pediatric carriage. Little is known however 
about pneumococcal population genomics in adult invasive pneumococcal disease (IPD) 
under vaccine pressure. We sequenced and serotyped 349 strains of S. pneumoniae 
isolated from IPD patients in Nijmegen between 2001 and 2011. Introduction of PCV7 in 
the Dutch National Immunization Program in 2006 preluded substantial alterations in the 
IPD population structure caused by serotype replacement. No evidence could be found 
for vaccine induced capsular switches. We observed that after a temporary bottleneck in 
gene diversity after the introduction of PCV7, the accessory gene pool re-expanded 
mainly by genes already circulating pre-PCV7. In the post-vaccine genomic population a 
number of genes changed frequency, certain genes became overrepresented in vaccine 
serotypes, while others shifted towards non-vaccine serotypes. Whether these dynamics 
in the invasive pneumococcal population have truly contributed to invasiveness and 
manifestations of disease remains to be further elucidated. We suggest the use of whole 
genome sequencing for surveillance of pneumococcal population dynamics that could 
give a prospect on the course of disease, facilitating effective prevention and 
management of IPD. 
  
 
 
  
Introduction 
The bacterial pathogen Streptococcus pneumoniae remains an important cause of 
pneumonia and meningitis worldwide, causing an estimated 1.6 million deaths annually 
[1] Immunization with a 7-valent pneumococcal conjugated vaccine (PCV), both in young 
children [2] and the elderly [3], has been demonstrated to be highly efficacious in 
preventing invasive pneumococcal disease (IPD) caused by vaccine serotypes. Moreover, 
after the introduction of routine pediatric vaccination, an additional decrease in vaccine-
type pneumococcal infections occurred, both in pediatric carriage [4, 5] as well as in IPD 
at all ages [6], indicative of a herd immunity effect. However, in all regions where routine 
PCV vaccination has been introduced, we see replacement in pneumococcal carriage and 
disease by non-vaccine serotypes [7-9], which at least partially abrogates the preventive 
effect of vaccination. In the Netherlands, the number of reported cases of IPD has not 
decreased after vaccination due to full replacement by non-vaccine serotypes [10] 
Currently available pneumococcal vaccines target the pneumococcal polysaccharide 
capsule. Although over 90 antigenically distinct pneumococcal capsules (denominated as 
serotypes) are known to date, only a selection of 7 serotypes (later extended to 10 and 13) 
is included in the PCV, based on modelling vaccination effects by the frequency and the 
propensity for invasiveness for each serotype [11, 12]. Whereas the polysaccharide 
capsule is essential for the pneumococcus to cause IPD [13], recent publications suggest 
that true determinants of invasiveness may lay underneath the pneumococcal capsule, 
represented by variations on the pneumococcal genome [14-18], which should be 
included in modelling vaccine effects [19].  
Since the introduction of routine pediatric immunization with PCV, several studies have 
detailed pneumococcal genomic epidemiology in pediatric carriage and otitis media 
under vaccine pressure. They all demonstrated that the pneumococcal genomic structure 
of pediatric carriage remained fairly stable, and that serotype replacement occurred 
mainly through expansion of previously existent clones [20-25]. The single study that 
examined whole pneumococcal genomes, including virulence factors, reported little 
effect on the accessory genome at the overall pneumococcal carriage population level 
despite massive serotype replacement [26]. However, the effect of pneumococcal 
vaccination on whole genome epidemiology of invasive pneumococcal disease remains 
unexplored, although it may hold invaluable information on understanding the long term 
effects of mass vaccination, especially with regard to changes in clinical manifestation of 
disease due to the changing prevalence of virulence factors in the pneumococcal 
population.  
PCV7 was introduced in the Dutch National Immunization Program in April 2006 while 
PCV10 was introduced in May 2011. In this study, we have sequenced 349 invasive 
pneumococcal isolates from 2001 to June 2011, in order to investigate the herd-immunity 
effect of PCV7 on pneumococcal population genomics in IPD.  
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Results 
Cohort and serotype dynamics 
We serotyped and sequenced 349 strains of S. pneumoniae isolated from an unbiased 
cohort of IPD patients in Nijmegen, the Netherlands, between 2001 and 2011. In the 
Netherlands, the elderly are not routinely vaccinated against pneumococcal disease, 
pediatric pneumococcal vaccination coverage has been high (>94%) [27], and penicillin 
resistance was below 3% during the entire study period [28]. These facts increase the 
probability that in this cohort, major changes in adult IPD epidemiology are due to herd 
immunity after pediatric immunization. Moreover, risk factors for acquiring a 
pneumococcal infection have not changed for the IPD patients in our study cohort, 
suggesting that replacement has been a merely pneumococcus-mediated phenomenon. 
According to our analysis, since the 7-valent PCV (PCV7) was introduced in the pediatric 
Dutch National Immunization Program in April 2006, the invasive pneumococcal 
population structure has altered substantially. Its introduction preluded a steady decrease 
in adult IPD cases caused by the seven serotypes it protects against (vaccine types, VTs): 
4, 6B, 9V, 14, 18C, 19F, and 23F, supporting a herd immunity effect of PCV7, concordant 
with a previous nationwide study [29]. In addition, the absolute increase in IPD cases 
caused by non-PCV7 protected serotypes (non-vaccine types, nVTs) observed in the 
Netherlands [30], as well as within our cohort [31] is suggestive of serotype replacement 
or capsular switching. Similarly to the pediatric pneumococcal carriage study by Croucher 
et al [26], in our non-vaccinated IPD cohort we observed an increase of subtype variants 
of VTs: 6A, 19A, 23A, and 23B. However, the post PCV7 nVT IPD cases were dominated by 
serotypes 1, 3, 7F, and 8 which may be seen less frequently in carriage cohorts [11]. 
Core genome phylogeny  
Phylogeny of the 349 IPD isolates was reconstructed based on a ‘superalignment’ of 
concatenated alignments of genes in 786 out of the 1075 core orthologous groups (OGs) 
containing genes present in a single copy in all isolates. 289 OGs with a dissimilar tree 
topology and branch distance as compared to ribosomal protein encoding genes were 
excluded as their phylogeny may be influenced by recombination or homoplasies. A tight 
clustering of isolates by serotype was observed (Figure 1). Similar to the carriage study by 
Croucher et al [26], in our IPD study, serotype replacement was responsible for the 
increase in nVTs. The rare cases of capsular switch were probably extant before 
immunization and did not increase upon the introduction of PCV7. It is therefore unlikely 
that capsular switching was induced by vaccine pressure, although larger numbers of 
isolates may be needed to confirm this. Compared to their closest neighbors in the 
phylogenetic tree, capsular switched strains accumulated only between 1 and 10 single 
nucleotide polymorphisms (SNPs) in their core genome. 
 
 
  
Figure 1. Structure of the invasive pneumococcal population. The maximum likelihood phylogeny was 
generated using 59,682 polymorphic sites within a 970,559 bp codon alignment of 755 core OGs with similar 
phylogenetic profiles as ribosomal protein encoding genes in order to exclude genes that were acquired by, for 
example, horizontal gene transfer. The inner bars each represent a pneumococcal strain (I) and are colored by 
capsular serotype. The second circle displays the sequence clusters (II). The year of collection is marked by the 
color (red: pre-PCV7, blue: post-PCV7) and intensity of coloration per year, for PCV7 vaccine serotypes (III) and 
non-vaccine serotypes (IV). 
The majority of these SNPs occurred in regions centered on genes involved in resistance 
to and efflux of antibiotics, synthesis of cell wall proteins, as well as transposases, pili and 
phage elements (Supplementary Table 1). A similar situation with regard to gene 
insertions or deletions was observed in the capsule switched isolates, suggesting phages 
and transposing elements play a major role in shaping the pneumococcal genome on 
relatively short timescales (Supplementary Table 2). The sequence clusters were based on 
BAPS analyses, and were determined to study if serotype replacement within a serogroup 
would involve closely related core genomes. Although this holds true for serogroup 23, 
replacement in serogroups 6 and 19 is scattered over the phylogenetic tree.  
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The majority of these SNPs occurred in regions centered on genes involved in resistance 
to and efflux of antibiotics, synthesis of cell wall proteins, as well as transposases, pili and 
phage elements (Supplementary Table 1). A similar situation with regard to gene 
insertions or deletions was observed in the capsule switched isolates, suggesting phages 
and transposing elements play a major role in shaping the pneumococcal genome on 
relatively short timescales (Supplementary Table 2). The sequence clusters were based on 
BAPS analyses, and were determined to study if serotype replacement within a serogroup 
would involve closely related core genomes. Although this holds true for serogroup 23, 
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Figure 2. Annual diversity among 
accessory genomes. The diversity was 
calculated between strains collected 
within the same year. Using a binary 
measure of the presence (1) or 
absence (0) of a gene in each 
accessory OG, diversity among 
strains was calculated by applying the 
distance measure described by Dutilh 
et al [50]. Core OG diversity was 
determined by comparing the 
pairwise distances between isolates 
from the phylogenetic tree per year. 
Circles: denote accessory distance; 
diamonds: denote core OG distance; 
whiskers: 95% confidence intervals.  
Genome diversity 
Analysis of the diversity of the accessory genome among strains revealed a significant 
drop in OG diversity in 2007 shortly after the introduction of PCV7 (p < 0.0001), and a re-
expansion in subsequent years (Figure. 2); a similar trend is seen for the core OG diversity, 
however here the 95% CI overlap. This illustrates that vaccination had an early temporary 
bottleneck effect on IPD gene diversity. In concordance with the decreased diversity after 
vaccination, a considerable number of OGs were significantly altered in prevalence, but 
most of them returned towards equilibrium afterwards (Figure. 3). Majority of the OGs 
that contributed to the re-expansion of diversity in the accessory genome after 2007 was 
comparable to those circulating pre PCV7. The decreased diversity after vaccination when 
VT stains were steadily removed from the population seems to represent the 
simultaneous decrease of certain sets of VT-related genes. However, the re-expansion of 
diversity with similar genes, suggests that those might now be carried by replacing nVT 
strains. Such a phenomenon has recently been predicted by modeling from 
pneumococcal carriage genome data [32]. Aside from this tendency to recover, certain 
OGs dispersed from their prevalence in the original gene pool. Both dynamics will be 
detailed below. A second gradual decrease in accessory genome diversity was observed 
towards 2011. This was not due to a distinct decreasing diversity among VT strains post 
vaccination, as the diversity in the accessory genomes remained similar between VT and 
nVT strains (see Supplementary Figure 1). 
Gene dynamics 
For the entire cohort, 506 pneumococcal genes were significantly overrepresented in the 
group of VTs, and 223 in nVTs (see Supplementary Table 3). This observation suggests 
that the distribution of particular genes over strains is more clustered in the VT group. 
Given the low number of serotypes in the VT group, it may indicate that also the 
phylogeny of the accessory genome clusters by serotype. Whereas 97 genes were 
Figure 3. Temporal stability of accessory gene pool. Odds ratios for prevalence of individual OGs in the
accessory genome whose frequency significantly altered at bottleneck shortly post PCV7 (2007) or during re-
expansion (2008-2011), compared to pre PCV7 (2001-2006) The X-axis indicates the proportion of isolates
carrying each OG in 2001 while the Y-axis indicates the log transformed odds ratio of strains carrying each OG in
2007 (green dots), and post PCV7 (blue dots), relative to pre PCV7.
exclusively found in the VTs and 331 genes were unique to the nVTs, the average number
of unique genes per serotype was equal.
Post PCV7, 105 genes significantly decreased in frequency, among which many phage-
related genes and transposons that went down along with VTs carrying them. Only 33
genes expanded significantly, including mainly ABC-transporters, zinc metallopeptidases
and genes facilitating recombination. The fact that VT strains had more OGs associated
with phages throughout the course of the study may relate to the ‘kill the winner’
strategy employed by phages as VT strains had a higher prevalence and would therefore
be more likely to be a target for phage predation.
Under the selective pressure of herd immunity post PCV7, the rate of adult IPD caused by
VTs decreased. Those VT strains that still caused IPD after the PCV7 bottleneck more
often carried OG0185 DNA methylase (1.8 fold increase, p=0.008), OG1539 flippase wzx
associated with serogroup 6 (2.3 fold increase, p=0.037), and a cluster consisting of 13 
Tn5253-related genes (3.7 fold increase, p=0.02). Although the latter are often related to
acquisition of antibiotic resistance, all strains concerned were fully susceptible to
tetracycline and clindamycin, and only 1 was resistant against erythromycin and
clarithromycin. The patients involved had no notable history indicative of increased
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expansion in subsequent years (Figure. 2); a similar trend is seen for the core OG diversity, 
however here the 95% CI overlap. This illustrates that vaccination had an early temporary 
bottleneck effect on IPD gene diversity. In concordance with the decreased diversity after 
vaccination, a considerable number of OGs were significantly altered in prevalence, but 
most of them returned towards equilibrium afterwards (Figure. 3). Majority of the OGs 
that contributed to the re-expansion of diversity in the accessory genome after 2007 was 
comparable to those circulating pre PCV7. The decreased diversity after vaccination when 
VT stains were steadily removed from the population seems to represent the 
simultaneous decrease of certain sets of VT-related genes. However, the re-expansion of 
diversity with similar genes, suggests that those might now be carried by replacing nVT 
strains. Such a phenomenon has recently been predicted by modeling from 
pneumococcal carriage genome data [32]. Aside from this tendency to recover, certain 
OGs dispersed from their prevalence in the original gene pool. Both dynamics will be 
detailed below. A second gradual decrease in accessory genome diversity was observed 
towards 2011. This was not due to a distinct decreasing diversity among VT strains post 
vaccination, as the diversity in the accessory genomes remained similar between VT and 
nVT strains (see Supplementary Figure 1). 
Gene dynamics 
For the entire cohort, 506 pneumococcal genes were significantly overrepresented in the 
group of VTs, and 223 in nVTs (see Supplementary Table 3). This observation suggests 
that the distribution of particular genes over strains is more clustered in the VT group. 
Given the low number of serotypes in the VT group, it may indicate that also the 
phylogeny of the accessory genome clusters by serotype. Whereas 97 genes were 
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exclusively found in the VTs and 331 genes were unique to the nVTs, the average number 
of unique genes per serotype was equal. 
Post PCV7, 105 genes significantly decreased in frequency, among which many phage-
related genes and transposons that went down along with VTs carrying them. Only 33 
genes expanded significantly, including mainly ABC-transporters, zinc metallopeptidases 
and genes facilitating recombination. The fact that VT strains had more OGs associated 
with phages throughout the course of the study may relate to the ‘kill the winner’ 
strategy employed by phages as VT strains had a higher prevalence and would therefore 
be more likely to be a target for phage predation. 
Under the selective pressure of herd immunity post PCV7, the rate of adult IPD caused by 
VTs decreased. Those VT strains that still caused IPD after the PCV7 bottleneck more 
often carried OG0185 DNA methylase (1.8 fold increase, p=0.008), OG1539 flippase wzx 
associated with serogroup 6 (2.3 fold increase, p=0.037), and a cluster consisting of 13 
Tn5253-related genes (3.7 fold increase, p=0.02). Although the latter are often related to 
acquisition of antibiotic resistance, all strains concerned were fully susceptible to 
tetracycline and clindamycin, and only 1 was resistant against erythromycin and 
clarithromycin. The patients involved had no notable history indicative of increased 
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antibiotic pressure (antibiotics use before admission, comorbidities associated with 
frequent antibiotics use, nursing home residency). Therefore, presence of the Tn5253 
cluster may have facilitated maintenance in IPD through a different mechanism. 
After 2007 the number of adult IPD cases caused by non-vaccine serotypes expanded. 
Among nVT IPD, the proportion of strains carrying OG1150 (toxin antitoxin component 
HicA) increased post PCV7 (p=0.032). Genes that were first observed in nVTs after PCV7 
(n=115) were infrequent. They coded for phages, transposons and membrane structures, 
but also included OG2585 (endonuclease), and OG2354 (multidrug resistance transporter 
MdtK). Although the latter is homologous to the MepA multidrug transporter of S. 
aureus, here a different antibiotic resistance pattern was observed. Of the two strains 
carrying MdtK, one isolate was fully susceptible in vitro, while the other was resistant to 
clarithromycin, and intermediately susceptible to doxycycline and ofloxacin, but not 
resistant to fluoroquinolones - the substrate of MepA in S. aureus [31].  
Although capsular switching has been rare, theoretically, individual pneumococcal genes 
may also benefit from translocation to strains with a polysaccharide capsule not targeted 
by vaccination. We studied whether individual genes shifted from VT to nVT strains by 
comparing the odds ratios for linkage to VT versus nVT strains before and after the PCV7 
bottleneck. Of the 86 genes that displayed increased odds for being related to nVTs after 
PCV7, 72% were previously related to VTs, indicative of a certain originality to nVT 
strains. Whether these genes actually benefit from a transition towards nVT strains, or 
contribute to severity of infection remains to be elucidated. 
Although after the introduction of PCV7 the overall severity of IPD cases (measured by 
pneumonia severity index) remained stable, higher rates of pleural effusion and 
empyema have been reported [31, 34], which may be attributed to a changed frequency 
of virulence factors in the pneumococcal population. For instance zinc metalloproteinase 
C (zmpC), mainly present in nVTs, has been associated with a more severe clinical 
manifestation of IPD and was shown to be expanding [17]. This illustrates that elimination 
of VTs may result in substitution by nVT strains that potentially confer more severe 
disease. Modeling of vaccination-induced changes in frequency of disease associated 
genes may therefore be of interest to optimize target selection in new generations of 
pneumococcal vaccines. Such an approach would require further exploration of the role of 
pneumococcal genotypes in the manifestation of human infection. 
 
Conclusions 
Despite serotype replacement in pneumococcal disease, after pediatric pneumococcal 
vaccination with PCV7 we observed a temporary bottleneck in gene diversity, which re-
expanded mainly by genes already present in the original gene pool. Our observations 
suggest that the introduction of PCV7 has only temporarily affected the pneumococcal 
population, like disease frequency, with the effects lasting up to one year. Certain genes 
 
 
  
in IPD have dispersed from their original prevalence, while others became 
overrepresented in VT, or shifted towards nVT. These changes may influence clinical 
manifestation of disease if these genes are associated with disease. We suggest whole 
genome sequencing to investigate pneumococcal dynamics after vaccination and as such 
maintain close surveillance of strains in a population; information that could give a 
prospect on an altered course and severity of disease, facilitating effective prevention and 
management of invasive pneumococcal disease. 
 
Methods 
Pneumococcal strain collection, DNA isolation and serotyping 
Pneumococcal strains were isolated from adults hospitalized with a bacteremic 
pneumococcal infection at two Dutch hospitals between January 2000 and June 2011 as 
described by Cremers et al [31]. The candidates were retrospectively included in the 
Pneumococcal Bacteremia Collection Nijmegen (PBCN). This observational cohort study 
was approved by the Local Medical Ethics Committees of both participating hospitals. 
The cohort was divided in pre and post PCV-7 strains as defined by their collection from 
blood before or after January 1 2007. The pneumococcal serotypes were determined 
using the multiplex PCR analysis [35]. In case multiplex PCR was inconclusive, serotyping 
was complemented with the Quellung reaction using Pneumococcus Neufeld Antisera 
(Statens Serum Institute, Copenhagen, Denmark) according to the manufacturer’s 
instructions [31]. All pneumococcal serotypes were then confirmed using an in-house 
implementation of the Sanger Institute molecular capsular typing (MCT) system [36, 37]. 
Genomic DNA preparation and whole genome sequencing 
The strains were grown statically in 10ml of Todd Hewitt broth (Merck, Darmstadt, 
Germany) with 5% yeast extract at 37°C and 5% COR2R to an optical density at 620nm of 
0.2-0.3. The bacterial pellet was washed with 1ml PBS and DNA was extracted using 
QIAGEN Genomic-tips 20/G and Genomic DNA Buffer Set (both Qiagen, Venlo, The 
Netherlands) according to the manufacturer's instructions for mini DNA preparations. 
The concentration of extracted genomic DNA was determined using Quant-iT™ 
PicoGreen® dsDNA Reagent (LifeTechnologies, Bleiswijk, The Netherlands) and the 
TECAN GENios plate reader with Magellan software (Tecan, Giessen, The Netherlands) 
and its intactness was confirmed with gel electrophoresis. Genomic DNA was sequenced 
on an Illumina HiSeq 2000 as paired-end reads of 100 nucleotides. 
Genome assembly, mapping and annotation  
The strains were assembled using the Sanger Institute genomes assembly pipeline. For 
each strain, Velvet [38] was used to create multiple assemblies by varying the kmer size 
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pneumococcal infection at two Dutch hospitals between January 2000 and June 2011 as 
described by Cremers et al [31]. The candidates were retrospectively included in the 
Pneumococcal Bacteremia Collection Nijmegen (PBCN). This observational cohort study 
was approved by the Local Medical Ethics Committees of both participating hospitals. 
The cohort was divided in pre and post PCV-7 strains as defined by their collection from 
blood before or after January 1 2007. The pneumococcal serotypes were determined 
using the multiplex PCR analysis [35]. In case multiplex PCR was inconclusive, serotyping 
was complemented with the Quellung reaction using Pneumococcus Neufeld Antisera 
(Statens Serum Institute, Copenhagen, Denmark) according to the manufacturer’s 
instructions [31]. All pneumococcal serotypes were then confirmed using an in-house 
implementation of the Sanger Institute molecular capsular typing (MCT) system [36, 37]. 
Genomic DNA preparation and whole genome sequencing 
The strains were grown statically in 10ml of Todd Hewitt broth (Merck, Darmstadt, 
Germany) with 5% yeast extract at 37°C and 5% COR2R to an optical density at 620nm of 
0.2-0.3. The bacterial pellet was washed with 1ml PBS and DNA was extracted using 
QIAGEN Genomic-tips 20/G and Genomic DNA Buffer Set (both Qiagen, Venlo, The 
Netherlands) according to the manufacturer's instructions for mini DNA preparations. 
The concentration of extracted genomic DNA was determined using Quant-iT™ 
PicoGreen® dsDNA Reagent (LifeTechnologies, Bleiswijk, The Netherlands) and the 
TECAN GENios plate reader with Magellan software (Tecan, Giessen, The Netherlands) 
and its intactness was confirmed with gel electrophoresis. Genomic DNA was sequenced 
on an Illumina HiSeq 2000 as paired-end reads of 100 nucleotides. 
Genome assembly, mapping and annotation  
The strains were assembled using the Sanger Institute genomes assembly pipeline. For 
each strain, Velvet [38] was used to create multiple assemblies by varying the kmer size 
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between 66% and 90% of the read length. From these assemblies, the one with the 
highest N50 was chosen and contigs that were shorter than the insert size length were 
removed. The resulting assembly was improved by the following steps: The contigs of the 
assembly were scaffolded by iteratively running SSPACE using default settings [39]. 
Then, gaps identified as 1 or more N’s, were targeted for closure by running 120 iterations 
of GapFiller [40]. Genomes were annotated using an in-house implementation of Prokka 
[41]. The genome assemblies were deposited at the European Nucleotide Archive under 
study number ERP001789. 
Gene clustering and phylogenetic analysis 
All putative coding sequences were translated and analyzed by an all-versus-all blastP 
employing a 10E-15 e-value cut-off and BLOSUM90 matrix. TribeMCL [42] was used to 
cluster orthologs by an inflation value of 4 to implement the MCL step, which resulted 
into a total of 3021 OGs. Of these OGs, 1075 were denominated as core OGs as they 
consisted of proteins present in single copies in each of the 349 strains. Protein sequences 
of these core OGs were aligned with MUSCLE [43], and subsequently codon translated 
into nucleotide alignments [44]. Genes of OGs encoding ribosomal proteins from each 
strain were concatenated into a single ‘ribosomal’ alignment. A reference maximum 
likelihood phylogeny was generated based on this ribosomal alignment using RAxML 
[45]. Phylogenies for each of the remaining core OGs were also generated separately. 
Plotting the Euclidian distances (EuD) of each OG tree with the ribosomal protein 
encoding tree resulted in three distributions of distances. To reach an alignment with 
high phylogenetic resolution, the sequences from OGs whose phylogenies were similar to 
the ribosomal phylogeny (EuD ≤ 0.03) were concatenated to the ribosomal alignment to 
give a single reduced ‘core’ super-alignment. Finally, polymorphic regions of this super-
alignment were extracted and re-analyzed with RAxML using a general time-reversible 
(GTR) nucleotide substitution model. Core OG diversity was determined by comparing 
the average of the pairwise distances between the isolates per year. The reduced core 
super-alignment was also analyzed using BAPS; Bayesian Analysis of Population 
Structure software [46] to determine the sequence clusters. Two runs of 40 and 50 
maximum clusters were performed, each creating 12 largely monophyletic sequence 
clusters and an extra ‘sink’ cluster that incorporated all unclassified isolates. Visualization 
of the tree was performed using iTOL [47]. 
Analysis of the population structure 
Core genomes and whole genomes of strains with a capsule switched serotype were 
separately aligned in Mauve [48], along with their closest neighbors (Supplementary File 
1). SNP coordinates were isolated and characterized in Artemis [49].  
 
 
 
  
Genomic diversity and dynamics 
The genomic diversity was determined based on the strains’ accessory genomes. For each 
OG a binary measure of presence (1) or absence (0) of a representative protein from a 
given strain was generated. The contribution of each strain to an OG was therefore 
denoted by a single numeric value (1 or 0) to represent the presence or absence of a gene, 
or a group of paralogs in a certain strain. This information was collated into a gene 
presence/absence matrix (Supplementary File 2). Using the method described by Dutilh 
et al [50], the genomic variations among strains collected within each year were 
calculated. Core OGs (those constituted of a single gene from each of the analyzed 
isolates) were excluded from this analysis. 
The time frames applied to detect changes in the proportion of strains carrying a certain 
OG post PCV7 compared to before were 2001 to 2006; pre-vaccine, and 2008 to 2011; 
post-vaccine respectively. 
Statistical analysis 
The difference in phylogenetic distance among strains collected between 2001 to 2006 
and 2007 was tested by an unpaired t-test. Differences in pre- and post-vaccine gene 
frequencies were tested by Fisher Exact test. For all analyses, the significance level was 
set at 0.05. 
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Abstract 
Advances in genome sequencing technologies and genome-wide association studies 
(GWAS) have provided unprecedented insights into the molecular basis of microbial 
phenotypes and enabled the identification of the underlying genetic variants in real 
populations. However, utilization of genome sequencing in clinical phenotyping of 
bacteria is challenging due to the lack of reliable and accurate approaches. Here, we 
report a method for predicting microbial resistance patterns using genome sequencing 
data. We analyzed whole genome sequences of 1,680 Streptococcus pneumoniae isolates 
from four independent populations using GWAS and identified probable hotspots of 
genetic variation which correlate with phenotypes of resistance to essential classes of 
antibiotics. With the premise that accumulation of putative resistance-conferring SNPs, 
potentially in combination with specific resistance genes, precedes full resistance, we 
retrogressively surveyed the hotspot loci and quantified the number of SNPs and/or 
genes, which if accumulated would confer full resistance to an otherwise susceptible 
strain. We name this approach the ‘distance to resistance’. It can be used to identify the 
creep towards complete antibiotics resistance in bacteria using genome sequencing. This 
approach serves as a basis for the development of future sequencing-based methods for 
predicting resistance profiles of bacterial strains in hospital microbiology and public 
health settings. 
Introduction
Streptococcus pneumoniae, or the pneumococcus, is part of the normal bacterial flora of 
the human nasopharynx, but can occasionally infiltrate sterile sites of the body
progressing to disease [1]. An estimated 1.6 million deaths associated with S. pneumoniae
are reported every year worldwide, mostly affecting children under five years [2]. Despite 
the immunization efforts reducing pneumococcal disease, there is merely a marginal 
prospect of eliminating the pneumococcal disease. This is because the available
pneumococcal conjugate vaccines (PCV) only protect against a handful vaccine-type 
serotypes [3], and their removal facilitates rapid replacement by the non-vaccine 
serotypes, which consequently increase in carriage prevalence, disease, and antibiotic 
resistance [4, 5]. The burden of pneumococcal disease is intensified by the mounting
resistance of the pneumococcus to essential antibiotics in clinical use.
Since the first case of penicillin-resistant pneumococcus was reported [6] followed by
outbreaks of disease caused by multidrug-resistant pneumococci [7], the antibiotic
resistance patterns of S. pneumoniae have drastically evolved and escalated worldwide 
[8]. The pneumococcus is known to be highly recombinogenic [9], allowing sequences
that confer antimicrobial non-susceptibility to be readily introduced into the genome.
Discovery of the genetic determinants underlying microbial phenotypes such as
transmission, antimicrobial resistance, and virulence is an important question in
microbiology. Traditionally, changes in DNA which are associated with antibiotic
resistance in S. pneumoniae were identified using sequence comparison [10, 11], 
laboratory mutagenesis [10], and identification of horizontally transferred sequences [12]. 
These techniques are limited in specificity and sensitivity necessary for clinical 
laboratories. They only reveal common genomic regions where change has occurred in
the so-called ‘mosaic’ genes and are narrow in their application to study actual
populations and may miss out on situations where multiple mutations occurring in
different genomic loci are required for full antibiotic resistance [12]. Significant advances
in high-throughput genome sequencing technologies and bacterial genome-wide
association studies (GWAS) now allow identification of statistical association between
plausible causal genetic variants and microbial phenotypes in real populations [13]. This
approach was recently used to identify the single nucleotide polymorphisms (SNPs) in 
DNA that may confer beta-lactam resistance in S. pneumoniae [14]. 
However, the understanding of how genetic variations contribute to antibiotics resistance
remains underexplored. Here we report the use of genome sequencing and GWAS to
investigate SNPs and genes associated with resistance to four essential classes of
antibiotics; collectively referred to as antibiotic resistance hereafter. We name the 
cumulative odds ratio of these resistance-conferring variants the “distance to resistance”
for the pneumococcus. We analyzed 1,680 invasive and carriage pneumococcal isolates
from Nijmegen, the Netherlands [15], Massachusetts, USA [16], Maela, Thailand [14, 17], 
and isolates from Sickle-cell anemic children (hereafter referred to as SCD; sickle cell
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Abstract
Advances in genome sequencing technologies and genome-wide association studies
(GWAS) have provided unprecedented insights into the molecular basis of microbial
phenotypes and enabled the identification of the underlying genetic variants in real
populations. However, utilization of genome sequencing in clinical phenotyping of
bacteria is challenging due to the lack of reliable and accurate approaches. Here, we 
report a method for predicting microbial resistance patterns using genome sequencing
data. We analyzed whole genome sequences of 1,680 Streptococcus pneumoniae isolates
from four independent populations using GWAS and identified probable hotspots of
genetic variation which correlate with phenotypes of resistance to essential classes of
antibiotics. With the premise that accumulation of putative resistance-conferring SNPs,
potentially in combination with specific resistance genes, precedes full resistance, we
retrogressively surveyed the hotspot loci and quantified the number of SNPs and/or
genes, which if accumulated would confer full resistance to an otherwise susceptible
strain. We name this approach the ‘distance to resistance’. It can be used to identify the
creep towards complete antibiotics resistance in bacteria using genome sequencing. This
approach serves as a basis for the development of future sequencing-based methods for
predicting resistance profiles of bacterial strains in hospital microbiology and public
health settings.
Introduction 
Streptococcus pneumoniae, or the pneumococcus, is part of the normal bacterial flora of 
the human nasopharynx, but can occasionally infiltrate sterile sites of the body 
progressing to disease [1]. An estimated 1.6 million deaths associated with S. pneumoniae 
are reported every year worldwide, mostly affecting children under five years [2]. Despite 
the immunization efforts reducing pneumococcal disease, there is merely a marginal 
prospect of eliminating the pneumococcal disease. This is because the available 
pneumococcal conjugate vaccines (PCV) only protect against a handful vaccine-type 
serotypes [3], and their removal facilitates rapid replacement by the non-vaccine 
serotypes, which consequently increase in carriage prevalence, disease, and antibiotic 
resistance [4, 5]. The burden of pneumococcal disease is intensified by the mounting 
resistance of the pneumococcus to essential antibiotics in clinical use. 
Since the first case of penicillin-resistant pneumococcus was reported [6] followed by 
outbreaks of disease caused by multidrug-resistant pneumococci [7], the antibiotic 
resistance patterns of S. pneumoniae have drastically evolved and escalated worldwide 
[8]. The pneumococcus is known to be highly recombinogenic [9], allowing sequences 
that confer antimicrobial non-susceptibility to be readily introduced into the genome. 
Discovery of the genetic determinants underlying microbial phenotypes such as 
transmission, antimicrobial resistance, and virulence is an important question in 
microbiology. Traditionally, changes in DNA which are associated with antibiotic 
resistance in S. pneumoniae were identified using sequence comparison [10, 11], 
laboratory mutagenesis [10], and identification of horizontally transferred sequences [12]. 
These techniques are limited in specificity and sensitivity necessary for clinical 
laboratories. They only reveal common genomic regions where change has occurred in 
the so-called ‘mosaic’ genes and are narrow in their application to study actual 
populations and may miss out on situations where multiple mutations occurring in 
different genomic loci are required for full antibiotic resistance [12]. Significant advances 
in high-throughput genome sequencing technologies and bacterial genome-wide 
association studies (GWAS) now allow identification of statistical association between 
plausible causal genetic variants and microbial phenotypes in real populations [13]. This 
approach was recently used to identify the single nucleotide polymorphisms (SNPs) in 
DNA that may confer beta-lactam resistance in S. pneumoniae [14].  
However, the understanding of how genetic variations contribute to antibiotics resistance 
remains underexplored. Here we report the use of genome sequencing and GWAS to 
investigate SNPs and genes associated with resistance to four essential classes of 
antibiotics; collectively referred to as antibiotic resistance hereafter. We name the 
cumulative odds ratio of these resistance-conferring variants the “distance to resistance” 
for the pneumococcus. We analyzed 1,680 invasive and carriage pneumococcal isolates 
from Nijmegen, the Netherlands [15], Massachusetts, USA [16], Maela, Thailand [14, 17], 
and isolates from Sickle-cell anemic children (hereafter referred to as SCD; sickle cell 
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disease) in the USA [18]. The genotypic and phenotypic diversity in these independent 
cohorts, whose draft genomes and phenotypes for antibiotic resistance are available, 
represent a unique paradigm for identifying probable genetic variants underlying 
pneumococcal antibiotic resistance. With the premise that presence of particular genes or 
accumulation of specific SNPs precedes full drug resistance of a fit clone, whole genome 
sequencing and GWAS could be used to evaluate the rate of accumulation of candidate 
resistance-conferring variants and provide an early warning sign of increasing antibiotic 
resistance. We hypothesize that the SNPs and/or resistance associated genes separating 
the phenotypes of antibiotic resistance are the plausible maximum number of mutations, 
which if accumulated could render high antibiotic resistance to otherwise susceptible 
bacteria. As the clinics gradually embrace genome sequencing for microbiological 
analyses, the ability to use genomic sequencing data to predict relevant phenotypes such 
as antibiotic resistance will be essential and desirable. This study serves as a foundation 
for the development of future technologies that could utilize genomic sequencing to 
analyze the molecular epidemiological trends for bacterial strains reliably, and provide an 
early-warning measure for the edge towards antimicrobial resistance, crucially informing 
on clinical intervention strategies. 
Result and discussion 
Pneumococcal strains and phenotypes of antibiotic resistance 
We analyzed 1,680 S. pneumoniae isolates systematically selected from diverse sources as 
follows: 350 invasive isolates from Nijmegen, the Netherlands [19]; a collection of 680 and 
332 systematically selected nasopharyngeal carriage (NP) isolates from Massachusetts, 
USA [16] and Maela, Thailand respectively [14, 17]; and 318 isolates from pediatric 
suffering from SCD in the USA [18]. Minimum inhibitory concentration breakpoints from 
the Clinical and Laboratory Standards Institute (CLSI) 2008; and where CLSI breakpoints 
were unavailable, guidelines from the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) were applied to separate the resistant and susceptible 
isolates accordingly. Compared to the general population, SCD patients are usually at 
high risk of contracting potentially fatal IPD. Therefore, they receive long-term antibiotic 
prophylaxis and frequent empiric antibiotic treatment. In response to the antibiotic 
selective pressure, pneumococci isolated from SCD patients have been shown to exhibit 
high rates of antibiotic resistance [18, 20]. For carriage isolates from Maela and 
Massachusetts, 54 of the 1,012 were resistant to trimethoprim, penicillin, erythromycin 
and cotrimoxazole, representing about 0.054% resistance to four classes of essential 
antibiotics (multidrug resistance; MDR). Additionally, all 263 carriage isolates that 
showed full resistance to penicillin were also resistant to at least one other antibiotic of a 
different class (~26% resistance to penicillin and one other antibiotic). In contrast, only 
one isolate from Nijmegen (10208_2#41) showed resistance to all antibiotics tested 
except for tobramycin (~ 0.0029% MDR). Of the three penicillin-resistant isolates from 
Nijmegen, one (9953_7#71) also exhibited resistance to tobramycin. A total of 1,012
pneumococcal carriage isolates (Massachusetts and Maela), and 350 IPD isolates
(Nijmegen) were included in the variants screening GWAS. The 318 SCD isolates were 
included in the post-association evaluation of SNPs to determine the distance to
resistance because SCD patients are frequently treated with antimicrobials and were
expected to exhibit substantial resistance that could skew the associations. Generally, the
Nijmegen cohort had the lowest percentage proportion of isolates showing antibiotic
resistance; penicillin 0.86% (3 isolates), trimethoprim 4.29% (15),  erythromycin 2.28%
(8), and cotrimoxazole 4.29% (15), as compared to the selection of Maela and
Massachusetts isolates; penicillin 25.99% (263), trimethoprim 14.13% (143 isolates),
erythromycin 35.57% (360), and cotrimoxazole 27.76% (281). Surprisingly, the proportions
of resistance to fluoroquinolones; ciprofloxacin 22.86% (80) and ofloxacin 50% (175), as
well as the aminoglycoside tobramycin 49.14% (172) were remarkably high in the
Nijmegen IPD isolates (Figure 1; Supplementary Table 1). Tobramycin could especially be
used as a combination drug for selective decontamination of the digestive tract in
critically ill patients [21] but not for IPD control in the Netherlands. That large selection
for pneumococcal resistance to tobramycin may, therefore, be due to extensive use of the
antibiotic or as a result of pleiotropy or linked resistance with other classes of antibiotics.
Correcting for population stratification in bacterial GWAS
S. pneumoniae is highly recombinogenic leading to strains with very diverse genomes [17,
22]. Besides exchanging DNA fragments within pneumococci and other viridian
Streptococci, the nasopharynx also houses other commensal microorganisms, such as
Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus, which could
readily provide genetic material for recombination. Although affecting smaller parts of
the genome and not occurring in every generation, the high frequency of homologous
recombination is advantageous in creating genetic admixture into bacterial populations
in a manner similar to sexual reproduction in humans. This breaks up the strong linkage
disequilibrium (LD; large haplotype blocks) which usually muddle bacterial GWAS and
help to identify associations unlikely to have occurred by chance [14]. The confounding
effect of the clonal population structure is, in this sense, restrained in highly
recombinogenic bacteria like S. pneumoniae. However, the different cohorts we sampled
provided strains with multi-lineage clonal backgrounds whose population structure may
lead to false associations [13], particularly since resistant clones may have a fitness
advantage in settings where antibiotics use is frequent. Therefore, we corrected for 
population stratification using the genetic subpopulations (represented by the sequence
clusters; SCs) determined using BAPS and/or the method proposed by Prosperi et al. [23] 
(see Materials and methods), allowing for precise discrimination of causal variants from
linked variants. This approach and the large dataset we sampled enabled for reliable
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disease) in the USA [18]. The genotypic and phenotypic diversity in these independent
cohorts, whose draft genomes and phenotypes for antibiotic resistance are available,
represent a unique paradigm for identifying probable genetic variants underlying
pneumococcal antibiotic resistance. With the premise that presence of particular genes or 
accumulation of specific SNPs precedes full drug resistance of a fit clone, whole genome 
sequencing and GWAS could be used to evaluate the rate of accumulation of candidate
resistance-conferring variants and provide an early warning sign of increasing antibiotic
resistance. We hypothesize that the SNPs and/or resistance associated genes separating
the phenotypes of antibiotic resistance are the plausible maximum number of mutations,
which if accumulated could render high antibiotic resistance to otherwise susceptible
bacteria. As the clinics gradually embrace genome sequencing for microbiological
analyses, the ability to use genomic sequencing data to predict relevant phenotypes such
as antibiotic resistance will be essential and desirable. This study serves as a foundation
for the development of future technologies that could utilize genomic sequencing to
analyze the molecular epidemiological trends for bacterial strains reliably, and provide an
early-warning measure for the edge towards antimicrobial resistance, crucially informing
on clinical intervention strategies.
Result and discussion
Pneumococcal strains and phenotypes of antibiotic resistance
We analyzed 1,680 S. pneumoniae isolates systematically selected from diverse sources as
follows: 350 invasive isolates from Nijmegen, the Netherlands [19]; a collection of 680 and
332 systematically selected nasopharyngeal carriage (NP) isolates from Massachusetts,
USA [16] and Maela, Thailand respectively [14, 17]; and 318 isolates from pediatric
suffering from SCD in the USA [18]. Minimum inhibitory concentration breakpoints from 
the Clinical and Laboratory Standards Institute (CLSI) 2008; and where CLSI breakpoints
were unavailable, guidelines from the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) were applied to separate the resistant and susceptible 
isolates accordingly. Compared to the general population, SCD patients are usually at
high risk of contracting potentially fatal IPD. Therefore, they receive long-term antibiotic
prophylaxis and frequent empiric antibiotic treatment. In response to the antibiotic 
selective pressure, pneumococci isolated from SCD patients have been shown to exhibit
high rates of antibiotic resistance [18, 20]. For carriage isolates from Maela and
Massachusetts, 54 of the 1,012 were resistant to trimethoprim, penicillin, erythromycin
and cotrimoxazole, representing about 0.054% resistance to four classes of essential
antibiotics (multidrug resistance; MDR). Additionally, all 263 carriage isolates that
showed full resistance to penicillin were also resistant to at least one other antibiotic of a
different class (~26% resistance to penicillin and one other antibiotic). In contrast, only
one isolate from Nijmegen (10208_2#41) showed resistance to all antibiotics tested
except for tobramycin (~ 0.0029% MDR). Of the three penicillin-resistant isolates from 
Nijmegen, one (9953_7#71) also exhibited resistance to tobramycin. A total of 1,012 
pneumococcal carriage isolates (Massachusetts and Maela), and 350 IPD isolates 
(Nijmegen) were included in the variants screening GWAS. The 318 SCD isolates were 
included in the post-association evaluation of SNPs to determine the distance to 
resistance because SCD patients are frequently treated with antimicrobials and were 
expected to exhibit substantial resistance that could skew the associations. Generally, the 
Nijmegen cohort had the lowest percentage proportion of isolates showing antibiotic 
resistance; penicillin 0.86% (3 isolates), trimethoprim 4.29% (15),  erythromycin 2.28% 
(8), and cotrimoxazole 4.29% (15), as compared to the selection of Maela and 
Massachusetts isolates; penicillin 25.99% (263), trimethoprim 14.13% (143 isolates), 
erythromycin 35.57% (360), and cotrimoxazole 27.76% (281). Surprisingly, the proportions 
of resistance to fluoroquinolones; ciprofloxacin 22.86% (80) and ofloxacin 50% (175), as 
well as the aminoglycoside tobramycin 49.14% (172) were remarkably high in the 
Nijmegen IPD isolates (Figure 1; Supplementary Table 1). Tobramycin could especially be 
used as a combination drug for selective decontamination of the digestive tract in 
critically ill patients [21] but not for IPD control in the Netherlands. That large selection 
for pneumococcal resistance to tobramycin may, therefore, be due to extensive use of the 
antibiotic or as a result of pleiotropy or linked resistance with other classes of antibiotics. 
Correcting for population stratification in bacterial GWAS 
S. pneumoniae is highly recombinogenic leading to strains with very diverse genomes [17,
22]. Besides exchanging DNA fragments within pneumococci and other viridian
Streptococci, the nasopharynx also houses other commensal microorganisms, such as
Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus, which could
readily provide genetic material for recombination. Although affecting smaller parts of
the genome and not occurring in every generation, the high frequency of homologous
recombination is advantageous in creating genetic admixture into bacterial populations
in a manner similar to sexual reproduction in humans. This breaks up the strong linkage
disequilibrium (LD; large haplotype blocks) which usually muddle bacterial GWAS and
help to identify associations unlikely to have occurred by chance [14]. The confounding
effect of the clonal population structure is, in this sense, restrained in highly
recombinogenic bacteria like S. pneumoniae. However, the different cohorts we sampled
provided strains with multi-lineage clonal backgrounds whose population structure may
lead to false associations [13], particularly since resistant clones may have a fitness
advantage in settings where antibiotics use is frequent. Therefore, we corrected for
population stratification using the genetic subpopulations (represented by the sequence
clusters; SCs) determined using BAPS and/or the method proposed by Prosperi et al. [23] 
(see Materials and methods), allowing for precise discrimination of causal variants from
linked variants. This approach and the large dataset we sampled enabled for reliable
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Table 1. Single nucleotide polymorphisms that are determining of penicillin resistance
BP 
Position
RF
importance
RF p-value
CMH p-
value
Annotation Gene
1613086 20.62957785 0 3.308E-99 penicillin-binding protein 2b penA
1612897 19.83961807 0 6.649E-85 penicillin-binding protein 2b penA
333792 11.86365577 8.69E-98 1.234E-99 Holliday junction-specific endonuclease recU
333282 11.70867819 1.55E-18 5.304E-55 penicillin-binding protein 1A pbp1A
334107 11.29654702 7.83E-162 9.151E-72 Holliday junction-specific endonuclease recU
334639 10.42365322 0 1.203E-68 hypothetical protein -
294991 10.24670847 0 5.276E-60
phospho-N-acetylmuramoyl-pentapeptide-
transferase mraY
335104 8.53526957 3.3E-17 2.659E-68 DivIVA protein -
333345 7.379638353 6.46E-16 8.607E-24 penicillin-binding protein 1A pbp1A
1613422 7.320298527 9.51E-56 4.344E-55 penicillin-binding protein 2b penA
292563 7.167180495 8.14E-08 1.294E-55 penicillin binding protein 2x pbpX
332247 6.771832321 4.27E-26 3.671E-55 penicillin-binding protein 1A pbp1A
335955 6.631966798 8.25E-35 9.742E-45 RNA methylase family protein -
1613770 6.108715366 7.27E-87 2.023E-78 penicillin-binding protein 2b penA
333386 5.891738108 4.68E-13 8.607E-24 penicillin-binding protein 1A pbp1A
1532326 5.159428663 2.95E-11 4.143E-72 dihydrofolate reductase dyr
1531915 5.154251817 1.21E-11 1.717E-20 ATP-dependent protease ATP-binding subunit ClpX clpX
295737 4.619274035 1.67E-75 7.271E-49 ATP-dependent protease ATP-binding subunit ClpL clpL
296748 4.473732826 4.15E-08 2.701E-36 ATP-dependent protease ATP-binding subunit ClpL clpL
2193975 4.432372852 3.41E-61 8.905E-27 elongation factor Ts tsf
tobramycin. Penicillin and other β-lactams have for long been the primary means of
treating pneumococcal infections and are perhaps the most widely used group of
antibiotics that work by inhibiting bacterial cell wall biosynthesis [24]. Resistance arises
when the organism produces beta-lactamases, which are enzymes that cleave the beta-
lactam ring, or modifies the drug targets; ‘penicillin binding proteins’; PBPs [25].
Published research implicates changes in PBPs as the primary determinants of β-lactams
resistance [26-30]. Variations in PBP2b and PBP2x modulate low-level (intermediate) β-
lactams resistance with additional changes in PBP1a leading to extreme resistance.
Growth inhibition assays have also shown that β-lactams primarily kill the pneumococcus
by inhibiting PBPs, particularly PBP2x [31]. PBP transpeptidase signatures have also been
shown to be significant indicators of resistance levels in various β-lactams [32]. SNPs
associated with beta-lactam resistance were previously reported using GWAS [14]. In our
analysis, however, we identified a significantly higher number of SNPs that confer 
resistance to penicillin (4,137) than Chewapreecha and colleagues (858 and 1,721 in Maela
and Massachusetts cohorts respectively - 301 common SNPs). The difference could be 
explained by the fact that Chewapreecha et al replicated their associations in two 
independent cohorts and only collated candidate SNPs that were identified to be
common between the two groups subsequently minimizing false positives. In contrast,
we selected all SNPs showing significant statistical association with the phenotype after
correction for multiple testing (p-value <0.01). 
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Figure 1. A maximum likelihood phylogeny of the concatenated variant regions from the core genome of 1682 
pneumococcal isolates. The clades are colored according to the sequence clusters. The circular stripes represent 
the antibiotic resistance phenotypes starting from the inside: pink; penicillin, green; erythromycin, blue;
trimethoprim, gold; cotrimoxazole, red; tobramycin, purple; ofloxacin, and navy-blue; ciprofloxacin.
Specific polymorphisms and genes strongly associated with antibiotic resistance 
Initial candidate putative causal variants were selected as SNPs showing statistically 
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Bonferroni-adjusted for multiple testing. Separate associations were tested for resistance 
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Position 
RF 
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RF p-value 
CMH p-
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Annotation Gene 
1613086 20.62957785 0 3.308E-99 penicillin-binding protein 2b penA 
1612897 19.83961807 0 6.649E-85 penicillin-binding protein 2b penA 
333792 11.86365577 8.69E-98 1.234E-99 Holliday junction-specific endonuclease recU 
333282 11.70867819 1.55E-18 5.304E-55 penicillin-binding protein 1A pbp1A 
334107 11.29654702 7.83E-162 9.151E-72 Holliday junction-specific endonuclease recU 
334639 10.42365322 0 1.203E-68 hypothetical protein - 
294991 10.24670847 0 5.276E-60 
phospho-N-acetylmuramoyl-pentapeptide-
transferase mraY 
335104 8.53526957 3.3E-17 2.659E-68 DivIVA protein - 
333345 7.379638353 6.46E-16 8.607E-24 penicillin-binding protein 1A pbp1A 
1613422 7.320298527 9.51E-56 4.344E-55 penicillin-binding protein 2b penA 
292563 7.167180495 8.14E-08 1.294E-55 penicillin binding protein 2x pbpX 
332247 6.771832321 4.27E-26 3.671E-55 penicillin-binding protein 1A pbp1A 
335955 6.631966798 8.25E-35 9.742E-45 RNA methylase family protein - 
1613770 6.108715366 7.27E-87 2.023E-78 penicillin-binding protein 2b penA 
333386 5.891738108 4.68E-13 8.607E-24 penicillin-binding protein 1A pbp1A 
1532326 5.159428663 2.95E-11 4.143E-72 dihydrofolate reductase dyr 
1531915 5.154251817 1.21E-11 1.717E-20 ATP-dependent protease ATP-binding subunit ClpX clpX 
295737 4.619274035 1.67E-75 7.271E-49 ATP-dependent protease ATP-binding subunit ClpL clpL 
296748 4.473732826 4.15E-08 2.701E-36 ATP-dependent protease ATP-binding subunit ClpL clpL 
2193975 4.432372852 3.41E-61 8.905E-27 elongation factor Ts tsf 
tobramycin. Penicillin and other β-lactams have for long been the primary means of 
treating pneumococcal infections and are perhaps the most widely used group of 
antibiotics that work by inhibiting bacterial cell wall biosynthesis [24]. Resistance arises 
when the organism produces beta-lactamases, which are enzymes that cleave the beta-
lactam ring, or modifies the drug targets; ‘penicillin binding proteins’; PBPs [25]. 
Published research implicates changes in PBPs as the primary determinants of β-lactams 
resistance [26-30]. Variations in PBP2b and PBP2x modulate low-level (intermediate) β-
lactams resistance with additional changes in PBP1a leading to extreme resistance. 
Growth inhibition assays have also shown that β-lactams primarily kill the pneumococcus 
by inhibiting PBPs, particularly PBP2x [31]. PBP transpeptidase signatures have also been 
shown to be significant indicators of resistance levels in various β-lactams [32]. SNPs 
associated with beta-lactam resistance were previously reported using GWAS [14]. In our 
analysis, however, we identified a significantly higher number of SNPs that confer 
resistance to penicillin (4,137) than Chewapreecha and colleagues (858 and 1,721 in Maela 
and Massachusetts cohorts respectively - 301 common SNPs). The difference could be 
explained by the fact that Chewapreecha et al replicated their associations in two 
independent cohorts and only collated candidate SNPs that were identified to be 
common between the two groups subsequently minimizing false positives. In contrast, 
we selected all SNPs showing significant statistical association with the phenotype after 
correction for multiple testing (p-value <0.01).  
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Moreover, we potentially introduced more genotypic variance by analyzing a mixture of 
isolates, especially the disease isolates, from different geographical areas. The divergent 
genotypes in practice resulted into more sequence clusters (used for population 
substructure stratification) further partitioning the phylogenetic clusters/clades that may 
have been considered similar in the Chewapreecha study. Therefore, our approach 
allowed for identification of more SNPs. Of the 4,137 SNPs associated with resistance to 
penicillin, 3,589 were in coding or intragenic sequences and 548 in non-coding or 
intergenic sequences (Figure 2; Supplementary Table 2). Interestingly, a q-q plot of the 
GWAS results shows a sharp deviation above an expected p-value indicating the presence 
of unusually high linkage disequilibrium and strong association of the phenotype with 
SNPs in heavily genotyped loci. 
To further control for inflation and increase confidence in verity, a more stringent p-value 
cut-off was applied. We generated a q-q plot of the penicillin association p-values and 
placed a limit threshold at the point of deviation of the observed p-values from the 
expected p-values. This new cut-off (p-value<1.5E-20) yielded a smaller subset of 426 
SNPs associating to the penicillin resistance phenotype. These SNPs are localized 
primarily in genes which have been previously reported to be involved in development of 
penicillin resistance, including genes involved in the peptidoglycan biosynthesis pathway 
like penicillin binding proteins; PBPs (pbp1A, pbp1B, pbpX, pbp2A, penA), peptidoglycan 
biogenesis transferases (mraW, mraY) and synthesis of peptidoglycan precursors (murM, 
murN), pneumococcal surface protein (pspA, pspC), recombination pathway (recU), cell 
division pathway (gpsB, ftsL), MDR proteins and drug efflux pumps (pmrA), drug 
antiporters [14], heat shock proteins/chaperones (ClpL) [33], and genes implicated in 
resistance to other essential classes of antibiotics like dihydrofolate reductase (dyr); 
involved in trimethoprim resistance [34, 35]. 
 In the case of penicillin resistance, a single SNP is not enough to confer full resistance. 
Therefore, we employed a machine learning method, Random Forest (RF) to investigate 
the combinatorial effect of certain SNPs. The RF model identified a subset of 34 unique 
SNPs that are predictive of penicillin resistance (Table 1). A GWAS on presence or 
absence of individual genes also revealed that presence of variants of the cell division 
initiation protein, gpsB (og_2891 and og_1645; p-values 4.73E-44 and 4.06E-43 
respectively- Bonferroni-adjusted for multiple testing) significantly correlates with 
penicillin resistance. Despite being putatively essential and thus expected to be present in 
all isolates [36], there appears to be two variants of the gpsB gene og_1645; n=1457, and 
og_2891; n=215, judging from their different amino acid sequences. A separate RF 
analysis on both SNPs and OGs also determined that og_2891 and og_1645 are the only 
genes among the top 20 features that are predictive of penicillin resistance (Table 2). 
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penicillin resistance. Despite being putatively essential and thus expected to be present in 
all isolates [36], there appears to be two variants of the gpsB gene og_1645; n=1457, and 
og_2891; n=215, judging from their different amino acid sequences. A separate RF 
analysis on both SNPs and OGs also determined that og_2891 and og_1645 are the only 
genes among the top 20 features that are predictive of penicillin resistance (Table 2). 
  
 
 
  
Table 2. Single nucleotide polymorphisms and genes that confer penicillin resistance in the pneumococcus 
Feature 
RF 
importance 
RF p-value CMH p-value Annotation Gene 
1613086 17.19240972 0 3.308E-99 Penicillin-binding protein 2b penA 
1612897 16.25074593 0 6.649E-85 Penicillin-binding protein 2b penA 
og_2891 10.99276087 0 4.73E-44 Cell division initiation protein (SP_0372) gpSB 
og_1645 10.67477573 0 4.06E-43 Cell division initiation protein (SP_0372) gpSB 
333792 9.977205881 8.69E-98 1.234E-99 Holliday junction-specific endonuclease recU 
334107 9.725165692 7.83E-162 9.151E-72 Holliday junction-specific endonuclease recU 
333282 9.339362915 1.55E-18 5.304E-55 Penicillin-binding protein 1A pbp1A 
334639 8.058415682 0 1.203E-68 Hypothetical protein - 
294991 8.007530946 0 5.276E-60 
Phospho-N-acetylmuramoyl-pentapeptide-
transferase 
mraY 
335104 7.818192276 3.3E-17 2.659E-68 DivIVA protein - 
292563 6.279875395 8.14E-08 1.294E-55 Penicillin binding protein 2x pbpX 
1613422 5.834807369 9.51E-56 4.344E-55 Penicillin-binding protein 2b penA 
332247 5.797588876 4.27E-26 3.671E-55 Penicillin-binding protein 1A pbp1A 
333345 5.576828511 6.46E-16 8.607E-24 Penicillin-binding protein 1A pbp1A 
1613770 5.573167922 7.27E-87 2.023E-78 Penicillin-binding protein 2b penA 
333386 5.202912551 4.68E-13 8.607E-24 Penicillin-binding protein 1A pbp1A 
335955 5.175277829 8.25E-35 9.742E-45 RNA methylase family protein - 
1531915 4.829698691 1.21E-11 1.717E-20 ATP-dependent protease ATP-binding subunit ClpX clpX 
1532326 4.61272854 2.95E-11 4.143E-72 Dihydrofolate reductase dyr 
296748 4.294101416 4.15E-08 2.701E-36 ATP-dependent protease ATP-binding subunit ClpL clpL 
296367 4.031726526 7.28E-23 8.841E-38 ATP-dependent protease ATP-binding subunit ClpL clpL 
 
This observation is perhaps a reinforcement that resistance to β-lactams is primarily 
driven mutations in key genes, and possibly by the presence of certain resistance genes. 
GpsB is thought to be vital for peripheral and septal peptidoglycan synthesis in S. 
pneumoniae, particularly in the recruitment of PBP1 to the division complex and its 
removal from the cell pole soon after pole maturation is completed [36]. It shows 
overlapping, although non-identical, pattern of co-localization with FtsZ during cell 
division. Depletion of gpsB causes division defect characterized by significant cell 
elongation and enlargement, several unconstricted rings of division proteins Pbp2x, 
Pbp1a, FtsZ, and MreC, cessation of growth, and eventually cell lysis in S. pneumoniae 
D39 [36]. These phenotypes are similar to those observed in Pbp2x depletion [37] or 
inhibition of Pbp2x by the β-lactam antibiotic methicillin [36]. Therefore, the observed 
association is most likely a secondary effect of the functions of gpsB in peptidoglycan 
synthesis during cell division which may have fitness and pleiotropic consequences in 
maintaining cell integrity rather than a direct role in resistance. 
Penicillin-resistant pneumococcus exhibit varying patterns of resistance to other β-
lactams and are generally resistant to other classes of antibiotics that are usually active 
against pneumococci [38-40]. We evaluated resistance to trimethoprim, cotrimoxazole, 
erythromycin, tobramycin, ofloxacin and ciprofloxacin. Trimethoprim and cotrimoxazole 
(a combination of trimethoprim and sulfamethoxazole) reduce the ability of some 
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bacteria to utilize folic acid for growing [34], by blocking folate metabolism via dhfR or dyr 
(encoding dihydrofolate reductase) and folP/sulA (encoding dihydropteroate synthase) 
respectively. These drugs interrupt two crucial steps required in the biosynthesis of 
bacterial proteins. Mutational or recombinational changes on the target enzymes; dhfR 
and folP or their promoter regions have been reported to enhance resistance to 
trimethoprim and cotrimoxazole [34, 35, 41, 42]. We identified SNPs associated with 
resistance to trimethoprim and cotrimoxazole in various genes encoding enzymes 
involved in folate metabolism, including dyr, folE, and folP (Figure 2; Supplementary 
Tables 3-4), and SNPs in genes implicated in resistance to other essential antibiotics like 
penicillin. RF analysis revealed that only mutations in folate metabolism (dyr, folC, folE, 
folP, and 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine diphosphokinase; HPPK 
(EC 2.7.6.3) encoded by folK or sulD), and chaperones/ATP-dependent proteases (clpL, 
clpX) [43], as well as linked mutations in PBPs (pbp1A, pbpX, penA), recombination 
proteins (recR, recU), and peptidoglycan biogenesis transferases (mraW, mraY), were 
predictive of cotrimoxazole and trimethoprim resistance (Tables 3 and 4). Also, there is a 
very strong co-selection for resistance to other classes of antibiotics, especially β-
lactams. However, it is not clear whether this is because of frequent simultaneous use of 
these antibiotics, or an epistatic effect on linked compensatory pathways. 
Erythromycin and other macrolides inhibit protein synthesis by penetrating the bacterial 
cell membrane and binding to the ribosomal RNA molecules, particularly in the 50S 
subunit, of the bacterial ribosome blocking the exit of the growing peptide chain. 
Macrolides remain an important class of antibiotics for pneumococcal disease. In the 
USA, macrolides are used as monotherapy for outpatient pneumonia and in combination 
with β-lactams for more severe pneumonia [44]. The macrolide azithromycin is combined 
with ceftriaxone as empiric therapy for severe pneumonia, and clarithromycin is a second 
line treatment for mild community-acquired pneumonia in Australia [45]. However, the 
prevalent use of these antibiotics in other indications like non-pneumococcal respiratory 
tract infections [46], trachoma and sexually transmitted diseases [47], and chronic 
obstructive pulmonary disease (COPD) [48] may be the primary driver of selection for 
macrolide resistance in pneumococci. Pneumococcal resistance to macrolides is caused 
by drug efflux or alteration of the target site [49-53]. The phenotypic expression of target-
site modification can be inducible or constitutive [49], and can be confirmed with the 
presence of mefA/E and ermB genes. MefA and mefE share >90% sequence homology and 
are carried in transposons which are comprised of additional open reading frames [54]. 
Before correcting for multiple testing, we observe a statistically significant association 
between the presence of ermB (og_1123) and resistance to erythromycin (p-value 3.137E-
05).  
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Table 3. Single nucleotide polymorphisms and genes that confer cotrimoxazole resistance in the pneumococcus 
Feature 
RF 
importance 
RF p-value CMH p-value Annotation Gene 
1531915 12.06447624 0 3.65E-32 
ATP-dependent protease ATP-binding 
subunit ClpX 
clpX 
293661 10.58122979 2.05E-112 1.3E-75 penicillin binding protein 2x pbpX 
267233 10.09698603 0 5.656E-82 GTP cyclohydrolase I folE 
1532245 9.521815356 0 2.616E-81 dihydrofolate reductase dyr 
1613086 9.414234472 5.99E-237 8.051E-62 penicillin-binding protein 2b penA 
264912 8.905643954 0 1.032E-75 dihydropteroate synthase folP 
1531651 7.923116586 0 4.595E-60 
ATP-dependent protease ATP-binding 
subunit ClpX 
clpX 
265536 7.247622768 5.56E-86 3.638E-67 dihydropteroate synthase folP 
291557 6.341493841 3.03E-43 3.097E-61 cell division protein ftsL 
292017 5.849575748 7.35E-31 4.103E-50 penicillin binding protein 2x pbpX 
1532054 5.822732316 0 1.203E-28 hypothetical protein - 
1612897 5.726042635 8.3E-102 1.213E-49 penicillin-binding protein 2b penA 
262352 5.671693703 0 1.208E-38 - - 
263885 5.610620269 9.89E-132 7.608E-41 permease - 
332799 5.455168203 5.73E-56 1.758E-48 penicillin-binding protein 1A pbp1A 
262539 5.429029061 0 2.304E-33 - - 
263190 5.333550128 9.15E-144 4.673E-26 permease - 
1613770 5.331345531 3.4E-65 2.497E-51 penicillin-binding protein 2b penA 
291982 5.096429153 4.18E-34 3.797E-47 penicillin binding protein 2x pbpX 
335104 4.434933551 0.000000165 1.249E-40 DivIVA protein - 
 
The OG comprises of two variants of the “23S-rRNA (adenine(2058)-N(6)) 
methyltransferase” (ermB): one variant is of the Staphylococcus aureus origin (ungapped 
blastP alignment with 100% sequence identity over 100% sequence coverage and an e-
value of 3e-176). Surprisingly, this association significance wanes after correcting for 
multiple testing (p-value 0.09; Bonferroni-corrected for multiple testing), perhaps due to 
the low prevalence of ermB (n=124). Nonetheless, we identified polymorphisms in the 16S 
rRNA; rsmE, 50S rRNA; rplM/S/B/T, rpmA/E2/F/H, rplE/L/I, and 30S rRNA; rpsA/M/N/P/D/H 
molecules among others, that significantly associate with erythromycin resistance (Figure 
2; Supplementary Table 5). In the RF analysis, the presence of various genes was 
associated with resistance to erythromycin (Table 5). They include the macrolide efflux 
pump mefA (og_1312): [54]; ImpB/MucB/SamB family protein (og_1652): a family of error-
prone DNA polymerases involved in DNA repair [55]; the YolD-like protein (og_1379), a 
group of functionally uncharacterized proteins predicted to be functionally alike to the 
UmuD subunit of polymerase V from Gram-negative bacteria [56] and the ribose import 
ATP-binding protein (og_791; SP_1114). The functional protein interaction network 
STRING shows that the ribose import ATP-binding protein (og_791; SP_1114) directly 
interacts with various efflux pumps associated with antibiotic resistance: the drug efflux 
ABC transporter ATP-binding protein/permease (SP_1342), the MATE efflux pump 
(SP2065), and the MATE family DinF transport system (SP1939) [57]. UmuD [58] is  
 
 
  
Table 4. Single nucleotide polymorphisms and genes that confer trimethoprim resistance in the pneumococcus 
Feature RF p-value CMH p-value Annotation Gene 
267970 4.39E-262 2.51E-13 
2-amino-4-hydroxy-6-hydroxymethyldihydropteridine 
pyrophosphokinase 
- 
291557 4.19E-57 6.03E-15 Cell division protein ftsL 
292017 4.99E-52 2.89E-16 Penicillin binding protein 2x pbpX 
291982 9.37E-47 1.34E-16 Penicillin binding protein 2x pbpX 
cog_1652 3.01E-198 3.54E-08 ImpB/MucB/SamB family protein - 
cog_1312 1.79E-58 0.00000173 Macrolide efflux pump - 
cog_1379 4.39E-85 0.000000119 YolD-like protein - 
cog_791 3.88E-48 0.00000049 Ribose import ATP-binding protein rbsA - 
cog_2061 1.41E-90 0.000000119 Hypothetical protein - 
291286 3.39E-15 7.68E-17 S-adenosyl-methyltransferase MraW mraW 
290545 3.38E-26 6.7E-12 - - 
1558235 4.29E-19 4.69E-11 Cytidylate kinase cmk 
cog_1645 0 0.001967 Cell division initiation protein - 
cog_2891 0 0.000622 Cell division initiation protein - 
cog_182 1.49E-25 0.001306 
Binding-protein-dependent transport systems inner membrane 
component 
- 
2002234 2.83E-28 6.6E-15 PTS system ascorbate-specific transporter subunit IIC - 
1459029 5.58E-30 4.56E-12 Asparaginyl-tRNA synthetase asnC 
887794 1.4E-27 4.56E-12 DNA polymerase III subunit epsilon - 
1800425 0.0000387 1.73E-21 DegT/DnrJ/EryC1/StrS family amino sugar synthetase - 
 
involved in UV protection and mutation in Gram-negative strains. It may modify the DNA 
replication machinery to allow bypass synthesis across a damaged template. ImpB copies 
undamaged DNA at stalled replication forks, which arise in vivo from mismatched or 
misaligned primer ends. These misaligned primers could be extended by DNA 
polymerase IV subunit (polIV). 
Fluoroquinolones; Ofloxacin and ciprofloxacin inhibit bacterial DNA synthesis by 
promoting cleavage of bacterial DNA in the DNA-enzyme complexes of DNA gyrase and 
type IV topoisomerase; more specifically, the gyrA and gyrB subunits of DNA gyrase, and 
parC and parE subunits of topoisomerase IV, resulting in rapid bacterial death. 
Fluoroquinolone activity in Gram-positive bacteria usually results from inhibition of DNA 
type IV topoisomerase whereas activity in Gram-negative bacteria corresponds with 
inhibition of DNA gyrase. Ciprofloxacin binds exclusively with topoisomerase IV whereas 
ofloxacin binds more avidly with topoisomerase IV and also binds gyrase. Resistance in S. 
pneumoniae to fluoroquinolone is caused predominantly by mutations in gyrA or parC, 
and occasionally in parE, which reduces binding of the drug to the site of activity [59-63]. 
Pneumococcal resistance to fluoroquinolone is thought to be a stepwise process; most 
intermediately resistant strains accumulate first-step mutations, which usually involve 
only a single mutation in the target genes [59], although, these strains do tend to go on to 
develop subsequent second-step mutations which significantly diminishes the activity of 
most fluoroquinolones and renders the strains highly resistant [64]. 
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methyltransferase” (ermB): one variant is of the Staphylococcus aureus origin (ungapped 
blastP alignment with 100% sequence identity over 100% sequence coverage and an e-
value of 3e-176). Surprisingly, this association significance wanes after correcting for 
multiple testing (p-value 0.09; Bonferroni-corrected for multiple testing), perhaps due to 
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associated with resistance to erythromycin (Table 5). They include the macrolide efflux 
pump mefA (og_1312): [54]; ImpB/MucB/SamB family protein (og_1652): a family of error-
prone DNA polymerases involved in DNA repair [55]; the YolD-like protein (og_1379), a 
group of functionally uncharacterized proteins predicted to be functionally alike to the 
UmuD subunit of polymerase V from Gram-negative bacteria [56] and the ribose import 
ATP-binding protein (og_791; SP_1114). The functional protein interaction network 
STRING shows that the ribose import ATP-binding protein (og_791; SP_1114) directly 
interacts with various efflux pumps associated with antibiotic resistance: the drug efflux 
ABC transporter ATP-binding protein/permease (SP_1342), the MATE efflux pump 
(SP2065), and the MATE family DinF transport system (SP1939) [57]. UmuD [58] is  
 
 
  
Table 4. Single nucleotide polymorphisms and genes that confer trimethoprim resistance in the pneumococcus 
Feature RF p-value CMH p-value Annotation Gene 
267970 4.39E-262 2.51E-13 
2-amino-4-hydroxy-6-hydroxymethyldihydropteridine 
pyrophosphokinase 
- 
291557 4.19E-57 6.03E-15 Cell division protein ftsL 
292017 4.99E-52 2.89E-16 Penicillin binding protein 2x pbpX 
291982 9.37E-47 1.34E-16 Penicillin binding protein 2x pbpX 
cog_1652 3.01E-198 3.54E-08 ImpB/MucB/SamB family protein - 
cog_1312 1.79E-58 0.00000173 Macrolide efflux pump - 
cog_1379 4.39E-85 0.000000119 YolD-like protein - 
cog_791 3.88E-48 0.00000049 Ribose import ATP-binding protein rbsA - 
cog_2061 1.41E-90 0.000000119 Hypothetical protein - 
291286 3.39E-15 7.68E-17 S-adenosyl-methyltransferase MraW mraW 
290545 3.38E-26 6.7E-12 - - 
1558235 4.29E-19 4.69E-11 Cytidylate kinase cmk 
cog_1645 0 0.001967 Cell division initiation protein - 
cog_2891 0 0.000622 Cell division initiation protein - 
cog_182 1.49E-25 0.001306 
Binding-protein-dependent transport systems inner membrane 
component 
- 
2002234 2.83E-28 6.6E-15 PTS system ascorbate-specific transporter subunit IIC - 
1459029 5.58E-30 4.56E-12 Asparaginyl-tRNA synthetase asnC 
887794 1.4E-27 4.56E-12 DNA polymerase III subunit epsilon - 
1800425 0.0000387 1.73E-21 DegT/DnrJ/EryC1/StrS family amino sugar synthetase - 
 
involved in UV protection and mutation in Gram-negative strains. It may modify the DNA 
replication machinery to allow bypass synthesis across a damaged template. ImpB copies 
undamaged DNA at stalled replication forks, which arise in vivo from mismatched or 
misaligned primer ends. These misaligned primers could be extended by DNA 
polymerase IV subunit (polIV). 
Fluoroquinolones; Ofloxacin and ciprofloxacin inhibit bacterial DNA synthesis by 
promoting cleavage of bacterial DNA in the DNA-enzyme complexes of DNA gyrase and 
type IV topoisomerase; more specifically, the gyrA and gyrB subunits of DNA gyrase, and 
parC and parE subunits of topoisomerase IV, resulting in rapid bacterial death. 
Fluoroquinolone activity in Gram-positive bacteria usually results from inhibition of DNA 
type IV topoisomerase whereas activity in Gram-negative bacteria corresponds with 
inhibition of DNA gyrase. Ciprofloxacin binds exclusively with topoisomerase IV whereas 
ofloxacin binds more avidly with topoisomerase IV and also binds gyrase. Resistance in S. 
pneumoniae to fluoroquinolone is caused predominantly by mutations in gyrA or parC, 
and occasionally in parE, which reduces binding of the drug to the site of activity [59-63]. 
Pneumococcal resistance to fluoroquinolone is thought to be a stepwise process; most 
intermediately resistant strains accumulate first-step mutations, which usually involve 
only a single mutation in the target genes [59], although, these strains do tend to go on to 
develop subsequent second-step mutations which significantly diminishes the activity of 
most fluoroquinolones and renders the strains highly resistant [64]. 
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Table 5. Single nucleotide polymorphisms and genes that confer erythromycin resistance in the pneumococcus 
Feature RF importance RF p-value 
CMH p-
value 
Annotation Gene 
og_1652 7.180656298 0 3.701E-14 ImpB/MucB/SamB family protein - 
og_1379 7.175992284 0 6.409E-15 YolD-like protein - 
og_2061 7.097377018 0 6.409E-15 hypothetical protein - 
og_1312 6.485953794 1.71E-217 2.683E-14 Macrolide efflux pump mefA 
og_791 6.017699918 1.03E-210 6.671E-14 Ribose import ATP-binding protein rbsA - 
1741683 4.904707263 8.7E-52 3.01E-23 Nudix-related transcriptional regulator NrtR - 
og_243 4.114250972 0.00000718 0.0002367 IS1380-Spn1 transposase - 
og_10 3.24238261 0.000118 0.01343 3-ketoacyl-ACP reductase - 
290545 3.240769624 1.2E-76 6.7E-12 Tn916 ORF16 ATP/GTP-binding protein - 
297653 3.016787219 4.01E-28 2.24E-16 methyltransferase small domain superfamily - 
og_53 2.971456253 5.89E-142 4.8E-09 UDP-glucose 6-dehydrogenase - 
og_129 2.962230108 0.000564 4.443E-07 chlorohydrolase - 
678325 2.695815692 1.6E-53 2.15E-15 transposase, ISSmi4 - 
136082 2.412872116 2.23E-15 7.73E-14 cytidine deaminase cdd 
637379 2.41015196 6.07E-44 1.36E-10 nucleotidyl transferase WchZ - 
987093 2.253968194 7.1E-12 4.43E-23 Abi-alpha protein - 
2058103 1.964208468 8.09E-10 5.51E-18 transposase - 
og_4190 1.95393053 0.385 0.4235 IS630-Spn1, transposase Orf1 - 
1593956 1.93060019 8.68E-09 1.62E-10 Ribose import ATP-binding protein rbsA - 
794795 1.754564135 0.000000235 1.62E-10 hypothetical protein - 
This increasing mutational heterogeneity makes it harder to use GWAS in precisely 
identifying the role of each mutation in disseminating antibiotic resistance. Surprisingly, 
we did not find any associations between SNPs in fluoroquinolone target proteins (DNA 
topoisomerase and DNA gyrase) and fluoroquinolone resistance (Supplementary Table 
5). However, we observed a significant statistical association between mutations in a 
multi-drug resistance efflux pump (pmrA) and resistance to ofloxacin (p-value 5.06E-05). 
PmrA is homologous to other well-studied efflux pumps like NorA and Bmr, whose 
expression leads to reduced susceptibility against several diverse compounds [65], and 
has previously been shown to be associated with fluoroquinolone resistance in the 
pneumococcus [66]. More research will be required to ascertain the role of this efflux 
pump in propagating ofloxacin resistance in the pneumococcus. We also observed that 
mutations in the heme exporter protein A (ccmA) and the recombination factor protein 
(rarA) associated with resistance to the fluoroquinolone ciprofloxacin.  
For pathogenic bacteria, heme is the main source of nutritional iron [67]. Being an 
essential cofactor for many enzymes, iron is found in all kingdoms of life. The 
pneumococcus mainly uses iron from hemoglobin and heme to support growth [68]. 
Paradoxically, heme at high concentrations is toxic because of its high redox potential, 
thus making it a liability to bacteria [69]. Therefore, bacteria control heme uptake by 
employing various sequestration, degradation, and efflux mechanisms. While the direct 
role of CcmA in quinolone-resistance is unclear, archetypes of heme-exporter systems 
that also modulate other phenotypes have been identified in Gram-positive bacteria [70-
 
 
  
72]. In Group A streptococci the heme exporter confers multi-drug resistance [73]. Apart 
from the ABC-transporter protein PmrA [74], efflux mechanisms of fluoroquinolone 
resistance are poorly characterized in the pneumococcus. However, efflux could reduce 
intracellular fluoroquinolone concentrations to sublethal levels furthering the 
development of resistance-conferring mutations [75]. More experimentation will, 
therefore, be required to deduce the exact mechanisms behind this novel association. 
Recombination is the primary source of genome plasticity, generating phenotypic and 
genetic diversification in bacteria. Unlike in β-lactam resistance where recombination 
plays an important role [76], fluoroquinolone resistance arises from very specific 
resistance-determining mutations within the target proteins [77]. Horizontal transfer of 
fluoroquinolone resistance loci between viridans group streptococci and the 
pneumococcus has been shown to occur in vitro but not in vivo [78], with significantly 
higher rates during asymptomatic carriage than during invasive isolates [79, 80]. Studies 
have reported a link between fluoroquinolone resistance and evolution of resistance to 
penicillin and macrolides [81]; both of which could be fostered by recombination. These 
studies suggest that the observed association between ciprofloxacin resistance and 
mutations in rarA could be an artifact of the linked resistance with other antibiotics. 
However, since we cannot rule out a novel mechanism involving these mutations, more 
studies are required to ascertain this observation. 
Predicting antibiotic resistance profiles using genome sequencing data 
We presupposed that accumulation of particular SNPs leads to a creep towards antibiotic 
resistance and subsequently full-resistance, we aimed to categorize the strains according 
to their phenotype of antibiotic resistance using the putative resistance-conferring SNPs 
identified by GWAS. This analysis helped determine how far the antibiotic susceptible 
strains are from attaining full-resistance, and what the creep pattern towards resistance 
is. We identified the partition between isolates by summing up the logarithmic 
derivatives of odds ratios (sOR) for antibiotic resistance-conferring SNPs. This measure 
was dubbed the “distance to resistance”. Antibiotic resistance profiles differed 
significantly between sampled populations, and between invasive and nasopharyngeal 
carriage isolates. Rates of antibiotic resistance were generally low in the Netherlands 
isolates compared to those from Thailand and USA (Figure 3), probably due to the more 
stringent antibiotic control policies observed in the Netherlands. The WHO provides 
defined daily dose (DDD) guidelines for antibiotics use in adults [82]. Research has shown 
that aggregate hospital antibiotic use by DDD in the United States is discordant with the 
WHO standards [83]. Most studies established that majority of antibiotics were 
administered in primary care settings to treat infections for which antibiotic therapy is 
hardly indicated [84-88]. Such trends are likely to have accelerated the pneumococcal 
selection for resistance in the US population, and could explain the expected higher levels 
of resistance as compared to, for example, the Dutch population where antibiotic use is 
vastly prudent. 
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Table 5. Single nucleotide polymorphisms and genes that confer erythromycin resistance in the pneumococcus 
Feature RF importance RF p-value 
CMH p-
value 
Annotation Gene 
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og_2061 7.097377018 0 6.409E-15 hypothetical protein - 
og_1312 6.485953794 1.71E-217 2.683E-14 Macrolide efflux pump mefA 
og_791 6.017699918 1.03E-210 6.671E-14 Ribose import ATP-binding protein rbsA - 
1741683 4.904707263 8.7E-52 3.01E-23 Nudix-related transcriptional regulator NrtR - 
og_243 4.114250972 0.00000718 0.0002367 IS1380-Spn1 transposase - 
og_10 3.24238261 0.000118 0.01343 3-ketoacyl-ACP reductase - 
290545 3.240769624 1.2E-76 6.7E-12 Tn916 ORF16 ATP/GTP-binding protein - 
297653 3.016787219 4.01E-28 2.24E-16 methyltransferase small domain superfamily - 
og_53 2.971456253 5.89E-142 4.8E-09 UDP-glucose 6-dehydrogenase - 
og_129 2.962230108 0.000564 4.443E-07 chlorohydrolase - 
678325 2.695815692 1.6E-53 2.15E-15 transposase, ISSmi4 - 
136082 2.412872116 2.23E-15 7.73E-14 cytidine deaminase cdd 
637379 2.41015196 6.07E-44 1.36E-10 nucleotidyl transferase WchZ - 
987093 2.253968194 7.1E-12 4.43E-23 Abi-alpha protein - 
2058103 1.964208468 8.09E-10 5.51E-18 transposase - 
og_4190 1.95393053 0.385 0.4235 IS630-Spn1, transposase Orf1 - 
1593956 1.93060019 8.68E-09 1.62E-10 Ribose import ATP-binding protein rbsA - 
794795 1.754564135 0.000000235 1.62E-10 hypothetical protein - 
This increasing mutational heterogeneity makes it harder to use GWAS in precisely 
identifying the role of each mutation in disseminating antibiotic resistance. Surprisingly, 
we did not find any associations between SNPs in fluoroquinolone target proteins (DNA 
topoisomerase and DNA gyrase) and fluoroquinolone resistance (Supplementary Table 
5). However, we observed a significant statistical association between mutations in a 
multi-drug resistance efflux pump (pmrA) and resistance to ofloxacin (p-value 5.06E-05). 
PmrA is homologous to other well-studied efflux pumps like NorA and Bmr, whose 
expression leads to reduced susceptibility against several diverse compounds [65], and 
has previously been shown to be associated with fluoroquinolone resistance in the 
pneumococcus [66]. More research will be required to ascertain the role of this efflux 
pump in propagating ofloxacin resistance in the pneumococcus. We also observed that 
mutations in the heme exporter protein A (ccmA) and the recombination factor protein 
(rarA) associated with resistance to the fluoroquinolone ciprofloxacin.  
For pathogenic bacteria, heme is the main source of nutritional iron [67]. Being an 
essential cofactor for many enzymes, iron is found in all kingdoms of life. The 
pneumococcus mainly uses iron from hemoglobin and heme to support growth [68]. 
Paradoxically, heme at high concentrations is toxic because of its high redox potential, 
thus making it a liability to bacteria [69]. Therefore, bacteria control heme uptake by 
employing various sequestration, degradation, and efflux mechanisms. While the direct 
role of CcmA in quinolone-resistance is unclear, archetypes of heme-exporter systems 
that also modulate other phenotypes have been identified in Gram-positive bacteria [70-
 
 
  
72]. In Group A streptococci the heme exporter confers multi-drug resistance [73]. Apart 
from the ABC-transporter protein PmrA [74], efflux mechanisms of fluoroquinolone 
resistance are poorly characterized in the pneumococcus. However, efflux could reduce 
intracellular fluoroquinolone concentrations to sublethal levels furthering the 
development of resistance-conferring mutations [75]. More experimentation will, 
therefore, be required to deduce the exact mechanisms behind this novel association. 
Recombination is the primary source of genome plasticity, generating phenotypic and 
genetic diversification in bacteria. Unlike in β-lactam resistance where recombination 
plays an important role [76], fluoroquinolone resistance arises from very specific 
resistance-determining mutations within the target proteins [77]. Horizontal transfer of 
fluoroquinolone resistance loci between viridans group streptococci and the 
pneumococcus has been shown to occur in vitro but not in vivo [78], with significantly 
higher rates during asymptomatic carriage than during invasive isolates [79, 80]. Studies 
have reported a link between fluoroquinolone resistance and evolution of resistance to 
penicillin and macrolides [81]; both of which could be fostered by recombination. These 
studies suggest that the observed association between ciprofloxacin resistance and 
mutations in rarA could be an artifact of the linked resistance with other antibiotics. 
However, since we cannot rule out a novel mechanism involving these mutations, more 
studies are required to ascertain this observation. 
Predicting antibiotic resistance profiles using genome sequencing data 
We presupposed that accumulation of particular SNPs leads to a creep towards antibiotic 
resistance and subsequently full-resistance, we aimed to categorize the strains according 
to their phenotype of antibiotic resistance using the putative resistance-conferring SNPs 
identified by GWAS. This analysis helped determine how far the antibiotic susceptible 
strains are from attaining full-resistance, and what the creep pattern towards resistance 
is. We identified the partition between isolates by summing up the logarithmic 
derivatives of odds ratios (sOR) for antibiotic resistance-conferring SNPs. This measure 
was dubbed the “distance to resistance”. Antibiotic resistance profiles differed 
significantly between sampled populations, and between invasive and nasopharyngeal 
carriage isolates. Rates of antibiotic resistance were generally low in the Netherlands 
isolates compared to those from Thailand and USA (Figure 3), probably due to the more 
stringent antibiotic control policies observed in the Netherlands. The WHO provides 
defined daily dose (DDD) guidelines for antibiotics use in adults [82]. Research has shown 
that aggregate hospital antibiotic use by DDD in the United States is discordant with the 
WHO standards [83]. Most studies established that majority of antibiotics were 
administered in primary care settings to treat infections for which antibiotic therapy is 
hardly indicated [84-88]. Such trends are likely to have accelerated the pneumococcal 
selection for resistance in the US population, and could explain the expected higher levels 
of resistance as compared to, for example, the Dutch population where antibiotic use is 
vastly prudent. 
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Figure 3. Penicillin, erythromycin, trimethoprim, and cotrimoxazole resistance profiles for isolates from 
individual geographical locations. Each point represents the cumulative odds ratio effect of SNPs that 
significantly associate with resistance on each isolate. 
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Figure 4. The difference in resistance profiles between invasive and carriage isolates. 
 
Figure 5. A. A box whisker plot of the random forest votes increasing for resistance relative to the increase in 
MIC per isolate for penicillin. B. A Receiver Operating Characteristic (ROC) curve showing the discrimination 
power of the random forest model in predicting penicillin resistance (Area under curve; AUC min= 0.9417 and 
max= 0.9882 at 99.9% CI). 
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From this data, it is possible to evaluate the resistance profile of new clinical isolates and 
to predict strains that are approaching extreme antibiotic resistance using sequence-
based approach. We observed that carriage (non-invasive) strains exhibited more 
resistance to antibiotics than invasive strains: they mostly contained resistance-
associated SNPs with high odds ratios (Figure 4). Indeed, there is ample opportunity for 
pneumococci in carriage to benefit from multiple co-colonizing strains of same or closely 
related species that provide new genetic material for homologous gene transformation. 
This phenomenon be could be explained by the fact that rates of pneumococcal 
transformation are also much higher during colonization than during planktonic growth in 
sepsis [89]. 
Pneumococci exhibiting decreased susceptibility to regular penicillin doses are on the rise 
[38, 39]. Many European guidelines recommend high-dose empirical treatments for 
systemic infections caused by such strains showing atypical susceptibility. Analyzing the 
strains for an effective dose, however, relies on laboratory assays. A recent publication 
reports the use of PBPs transpeptidase signatures (TPDs) from 2,528 clinical 
pneumococcal isolates to predict the MICs for various β-lactam antibiotics [32]. Li and 
colleagues constructed predictive models that link amino acid sequence variations in the 
TPDs of PBP1a, PBP2b, and PBP2x to β-lactam MIC levels among invasive pneumococcal 
isolates. They identified 68, 78, and 118 unique TPD amino acid sequences for PBP1a, 
PBP2b, and PBP2x, respectively.  Using 307 unique combinations of these sequences 
which defined the PBP types, they observed that isolates whose PBP types exhibited 
more than 10% amino acid sequence divergence from a usual susceptible PBP type were 
associated with increased β-lactam MICs. Such studies raise the optimism that genomic 
sequencing-based approaches could soon be used as alternatives to phenotypic 
susceptibility testing. We observed that increase in minimum inhibitory concentrations 
(MIC) is characterized by an increase in sORs (Figure 5). Additionally, the antibiotics-
susceptible isolates (MIC <0.016 μg/ml) have also acquired some level of mutation that 
brings them closer to low-MIC penicillin resistance, which in clinical practice can be 
managed by increased penicillin dose. Overall, we could reliably test for decreasing 
sensitivity to high doses of penicillin treatment based only on genome sequences with 
this approach.  
Prospective value of the distance to resistance 
In response to environmental stress over time, bacteria evolve genetic adaptations such 
as the acquisition of resistance genes or accumulation of critical mutation that confer 
antibiotic resistance. Figure 6 shows the resistance profiles for four antibiotics over time 
in different cohorts. There seems to be an increase, however subtle, in the number of 
isolates that have accumulated more resistance-conferring SNPs in each cohort every 
year. The IPD isolates from Nijmegen have particularly accumulated combinations of 
SNPs that confer resistance but are more close to susceptibility as compared to carriage 
isolates. The onset of these SNPs is perhaps indicative of the development of antibiotic
resistance. However, more studies will be required to confirm this observations. Put
together, these results show that by starting with a curated reference database of genes
and SNPs/alleles that confer resistance in historical and contemporary isolates; it is
possible to model a framework that predicts a creep towards resistance over time and
extreme antimicrobial resistance for various antibiotics in new bacterial isolate.
Prospecting these changes by looking solely at genome sequence data provides an early
warning sign that could significantly benefit public health surveillance.
In conclusion, this study establishes a proof of concept measure for the ‘distance to
antimicrobial resistance.' Although causality cannot always be drawn from associations,
bacterial GWAS provide the means of identifying genomic variants, of a rational basis for
functional validation, for important microbial phenotypes like antibiotic resistance. By
quantifying the aggregate effects of individual resistance-conferring SNPs on the
phenotype, we have demonstrated that prediction of advancing antimicrobial resistance
could be achieved in silico using genomic sequencing data. Therefore, this study invokes a
change of perspective for future research to focus on detecting genetic variants and
variations in genetic loci responsible for heralding the creep towards antibiotic resistance
in pathogenic bacteria. Such sequencing-based frameworks are not only affordable and
consistent but also allow for simultaneous discovery of essential pneumococcal features
such as serotype and sequence type. Altogether, this knowledge will greatly inform the
choice of clinical intervention and improve public health surveillance thus precluding
outbreaks caused by emerging multidrug resistant strains.
Materials and methods
Strains and phenotypes in study
This study included 1,680 pneumococcal isolates and corresponding antibiotic resistance
phenotypes; 349 from adults admitted with invasive pneumococcal disease between 2001
and 2011 in two hospitals in Nijmegen, The Netherlands, [19], a systematic selection
(three from each  “secondary BAPS” cluster) of published carriage isolates from 
Massachusetts, USA [16] and Maela, Thailand [14, 17], and 318 isolates from children
suffering from sickle-cell disease (SCD) in the USA [18] which included isolates from the
CDC ABC bacterial surveillance core and published collections [90, 91].
Phenotypes of antimicrobial susceptibility were determined in vitro as previously
described [15], following the guidelines for antimicrobial susceptibility and minimum
inhibitory concentration breakpoints stipulated by the Clinical and Laboratory Standards
Institute (CLSI) 2008. Where CLSI guidelines were lacking, the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) guidelines were used. Intermediately
42613 maati, Frederick.indd   106 04-10-16   16:08
Distance to resistance | 107
5
 
 
  
From this data, it is possible to evaluate the resistance profile of new clinical isolates and 
to predict strains that are approaching extreme antibiotic resistance using sequence-
based approach. We observed that carriage (non-invasive) strains exhibited more 
resistance to antibiotics than invasive strains: they mostly contained resistance-
associated SNPs with high odds ratios (Figure 4). Indeed, there is ample opportunity for 
pneumococci in carriage to benefit from multiple co-colonizing strains of same or closely 
related species that provide new genetic material for homologous gene transformation. 
This phenomenon be could be explained by the fact that rates of pneumococcal 
transformation are also much higher during colonization than during planktonic growth in 
sepsis [89]. 
Pneumococci exhibiting decreased susceptibility to regular penicillin doses are on the rise 
[38, 39]. Many European guidelines recommend high-dose empirical treatments for 
systemic infections caused by such strains showing atypical susceptibility. Analyzing the 
strains for an effective dose, however, relies on laboratory assays. A recent publication 
reports the use of PBPs transpeptidase signatures (TPDs) from 2,528 clinical 
pneumococcal isolates to predict the MICs for various β-lactam antibiotics [32]. Li and 
colleagues constructed predictive models that link amino acid sequence variations in the 
TPDs of PBP1a, PBP2b, and PBP2x to β-lactam MIC levels among invasive pneumococcal 
isolates. They identified 68, 78, and 118 unique TPD amino acid sequences for PBP1a, 
PBP2b, and PBP2x, respectively.  Using 307 unique combinations of these sequences 
which defined the PBP types, they observed that isolates whose PBP types exhibited 
more than 10% amino acid sequence divergence from a usual susceptible PBP type were 
associated with increased β-lactam MICs. Such studies raise the optimism that genomic 
sequencing-based approaches could soon be used as alternatives to phenotypic 
susceptibility testing. We observed that increase in minimum inhibitory concentrations 
(MIC) is characterized by an increase in sORs (Figure 5). Additionally, the antibiotics-
susceptible isolates (MIC <0.016 μg/ml) have also acquired some level of mutation that 
brings them closer to low-MIC penicillin resistance, which in clinical practice can be 
managed by increased penicillin dose. Overall, we could reliably test for decreasing 
sensitivity to high doses of penicillin treatment based only on genome sequences with 
this approach.  
Prospective value of the distance to resistance 
In response to environmental stress over time, bacteria evolve genetic adaptations such 
as the acquisition of resistance genes or accumulation of critical mutation that confer 
antibiotic resistance. Figure 6 shows the resistance profiles for four antibiotics over time 
in different cohorts. There seems to be an increase, however subtle, in the number of 
isolates that have accumulated more resistance-conferring SNPs in each cohort every 
year. The IPD isolates from Nijmegen have particularly accumulated combinations of 
SNPs that confer resistance but are more close to susceptibility as compared to carriage 
 
 
  
isolates. The onset of these SNPs is perhaps indicative of the development of antibiotic 
resistance. However, more studies will be required to confirm this observations. Put 
together, these results show that by starting with a curated reference database of genes 
and SNPs/alleles that confer resistance in historical and contemporary isolates; it is 
possible to model a framework that predicts a creep towards resistance over time and 
extreme antimicrobial resistance for various antibiotics in new bacterial isolate. 
Prospecting these changes by looking solely at genome sequence data provides an early 
warning sign that could significantly benefit public health surveillance. 
In conclusion, this study establishes a proof of concept measure for the ‘distance to 
antimicrobial resistance.' Although causality cannot always be drawn from associations, 
bacterial GWAS provide the means of identifying genomic variants, of a rational basis for 
functional validation, for important microbial phenotypes like antibiotic resistance. By 
quantifying the aggregate effects of individual resistance-conferring SNPs on the 
phenotype, we have demonstrated that prediction of advancing antimicrobial resistance 
could be achieved in silico using genomic sequencing data. Therefore, this study invokes a 
change of perspective for future research to focus on detecting genetic variants and 
variations in genetic loci responsible for heralding the creep towards antibiotic resistance 
in pathogenic bacteria. Such sequencing-based frameworks are not only affordable and 
consistent but also allow for simultaneous discovery of essential pneumococcal features 
such as serotype and sequence type. Altogether, this knowledge will greatly inform the 
choice of clinical intervention and improve public health surveillance thus precluding 
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Materials and methods 
Strains and phenotypes in study  
This study included 1,680 pneumococcal isolates and corresponding antibiotic resistance 
phenotypes; 349 from adults admitted with invasive pneumococcal disease between 2001 
and 2011 in two hospitals in Nijmegen, The Netherlands, [19], a systematic selection 
(three from each  “secondary BAPS” cluster) of published carriage isolates from 
Massachusetts, USA [16] and Maela, Thailand [14, 17], and 318 isolates from children 
suffering from sickle-cell disease (SCD) in the USA [18] which included isolates from the 
CDC ABC bacterial surveillance core and published collections [90, 91]. 
Phenotypes of antimicrobial susceptibility were determined in vitro as previously 
described [15], following the guidelines for antimicrobial susceptibility and minimum 
inhibitory concentration breakpoints stipulated by the Clinical and Laboratory Standards 
Institute (CLSI) 2008. Where CLSI guidelines were lacking, the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) guidelines were used. Intermediately 
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resistant (IR) isolates were grouped as resistant (non-susceptible) when testing for 
associations. 
Determining SNPs and orthologous sequences 
Bases were called from mapped sequences using kSNP v2 software [92] against a single 
reference genome: multidrug-resistant S. pneumoniae ATCC 700669; Spain 23F ST81 [93]. 
A total of 124,310 SNP calls were generated. Filtering for SNPs present in more than ~ 
90% of the isolates, (1,500 strains) resulted in 76,429 SNP calls that we used for further 
analysis. To determine clusters of orthologous sequences, all coding sequences (CDS) 
from the 1,680 isolates were predicted using Prodigal [94]. All coding sequences were 
analyzed using USEARCH [95] and aligned in the ‘large-scale BLAST score ratio’ (LS-BSR) 
pipeline [96] allowing 10% amino acid difference within clusters. The resulting 
representative sequences per group (“centroids”) were clustered through a Markov 
Clustering Algorithm (TRIBE-MCL) [97] with an inflation factor of 2.5, resulting into 4687 
orthologous groups (OGs). For each OG, we generated a binary metric of the presence (1) 
or absence (0) of a representative coding sequence(s) (CDS) from each strain. Each 
strain’s contribution of CDS to an OG was subsequently denoted by a single numeric 
value (1 or 0) to designate the presence or absence of a distinct gene, gene variants, or a 
group of paralogs. These groups were collated into a binary matrix and formatted for 
PLINK association analyses [98]. 
Determining the population structure and performing statistical association 
Resistance phenotypes were grouped according to antibiotic classes and analyzed 
separately for each population, and together in the final association analysis. The 
population clusters used to control for the effect of clonal inheritance of genetic variants 
and population stratification were determined using the Bayesian Analysis of Population 
Structure (BAPS) software [99], and a phylogeny-based partitioning approach as 
proposed by Prosperi et al. [23], which employs ‘ape, geiger, igraph, and phytools’ 
packages in R software [100]. An alignment of concatenated SNPs from the core or non-
repetitive DNA of each of the isolates were analyzed in BAPS as previously described [15]. 
For the Prosperi clustering, a maximum-likelihood phylogenetic tree was constructed 
using RAxML version 8.2.0 [101] and an alignment of all the concatenated SNPs from the 
core genome of all isolates as described before [15]. The general time-reversible model 
was used to calculate the maximum-likelihood ratios with a γ adjustment for site variation 
as the nucleotide substitution model. The support for nodes on the tree was tested using 
a hundred unsystematic bootstrap replicates. Resulting phylogenetic tree was visualized 
using iTOL version 2.1 [102].  
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We used the Cochran-Mantel-Haenszel (CMH) correlation statistic to test for associations 
between antibiotic resistance phenotype and SNPs conditional on the population 
structure. Stratification for population structure minimized falsely positive associations 
that could be obtained merely by chance. We tested associations for resistance to 
penicillin, trimethoprim, cotrimoxazole, erythromycin, ofloxacin, ciprofloxacin, and 
tobramycin. The statistical associations were performed using PLINK software v1.9 [98], 
and the results visualized as Manhattan and Q-Q plots in R using ‘qqman, hmisc, and 
ggplot2’ packages. To investigate the effect of SNP combinations, a Random Forest (RF) 
classification using the Bioconductor randomForest package 4.6-10 was performed to 
discriminate resistant (R) and susceptible (S) isolates. This classification model, consisting 
of 5000 decision trees was trained on candidate genes and/or SNPs that were determined 
to be predictive of resistance through GWAS analysis. Statistical significance of the genes 
or SNPs that were able to discriminate between the classes were calculated by permuting 
the sample class labels. A normal distribution was determined for mean decrease 
accuracy (mda) values from the 300 permutations using the pnorm package which is part 
of the R version 3.3.0 distribution. Using the same package a p-value was calculated 
comparing the average of mda values for RF 100 analyses with the original sample classes 
(to account for slight differences between RF analyses) to the distribution of permuted 
mda values. 
Candidate resistance loci and a measure of the distance to resistance 
We selected SNPs showing statistically significant associations (p-values < 0.01 at a minor 
allele frequency > 0.01; Bonferroni-adjusted for multiple testing) as candidates for 
subsequent analysis. The percentage distribution of these candidate SNPs within 
resistance isolates relative to the susceptible isolates in each population was computed to 
determine how they vary in each cohort. For each SNP significantly associated with 
antibiotic resistance, we determined the odds ratio (OR) and nature (positive or negative) 
of the correlation. The accumulation of these significant SNPs in each isolate was also 
defined across all test cohorts. Each SNP present in an isolate was represented by the 
logarithmic derivative of the odds ratio; logR10 R(OR): The negative logarithmic values were 
used for SNPs negatively correlated with resistance. Q-Q plots were used to determine a 
more stringent p-value cut-off. The aggregate effect of the SNPs conferring antibiotic 
resistance is the sum of all the logR10R (OR) values for SNPs above the p-value threshold. 
These represented a measure of the level of resistance of an isolate. These aggregate 
values were plotted in GraphPad Prism v6.05 software.   
Supporting data 
Supplementary material for this chapter are available online at: 
https://www.dropbox.com/sh/bnx7vad8qivax1d/AABXGROkQDj0vRQqmRruQqPOa?dl=0 
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Abstract 
Invasive pneumococcal disease (IPD), defined as an infection verified by the isolation of 
Streptococcus pneumoniae from a normally sterile body site, such as the blood and 
cerebrospinal fluid, remains a major burden to global healthcare systems, causing 
approximately 25% of all preventable deaths in children under the age of 5 and more than 
1.3 million infant deaths yearly. The pneumococcus carries various virulence factors that 
help to evade host defenses and persist during colonization. Although these factors are 
involved in colonization, they may also play a role in pneumococcal infectiveness and the 
subsequently clinical manifestation of IPD. Genome-wide association studies (GWAS) are 
undoubtedly an important tool for genetic analysis is humans, aiding the identification of 
various genetic determinants of inherited traits and diseases. However, the application of 
GWAS to identify genotypic variants responsible for important bacterial phenotypes has 
only been made possible recently by the significant advances in next generation genome 
sequencing. Various studies are now utilizing GWAS with diverse study designs that 
incorporate a range of genetic features in the core genome such as single nucleotide 
polymorphisms (SNPs) and small indels, or variations in the accessory or flexible genome 
such as presence and/or absence of a genes to correlate measurable bacterial 
phenotypes. Here, we report the use of GWAS to discover how genetic variation in the 
accessory genomes of 350 S. pneumoniae isolates correlate with various clinical 
contingencies of invasive pneumococcal disease. 
Introduction
Streptococcus pneumoniae remains an important human commensal and an opportunistic
bacterium pathogen. It is the most common cause of acute otitis media in children, and
community-acquired pneumonia, meningitis, and bacteremia in children and adults,
accounting for multiple morbidities and over 1.3 million childhood mortalities worldwide
each year [1]. The burden of invasive pneumococcal disease (IPD) is particularly high in
children under the age of 2 years, adults above 65 years old, and individuals with
predisposing conditions such as asplenia, chronic medical conditions like diabetes, or
immunosuppressive illnesses, particularly HIV and AIDS [2]. 
S. pneumoniae encodes various virulence factors that help promote infections and
pathologies by various means such as adherence and invasion, evasion of host defenses
and nutrient acquisition [3]. Its efficient competence machinery enables rapid
recombination of foreign DNA into its genome [4, 5]. The horizontal transfer of DNA,
either via recombination or via phage transduction begets extensive allelic variations in
the core genome and a broad flexible or accessory genome, which underlie phenotypic
differences in important traits such as virulence and antibiotic resistance. While most
pneumococcal virulence factors have been characterized, their role in invasive
pneumococcal disease remains underexplored.
Genome-wide association studies (GWAS) have over the past decade become the de 
facto approach to identify candidate genetic variations associated with complex inherited
human diseases [6]. Despite being broached nearly a decade ago that tools and
knowledge drawn from eukaryotic GWAS could be employed in bacteriology to
investigate the genotypic etiology of relevant phenotypes [7], GWAS has limitedly been
applied to the pneumococcus. The use of GWAS to identify genetic variants associated
with important bacterial phenotypes has only been made possible recently by advances in
bioinformatics and genome sequencing technologies [8]. Studies employ either alleles
counting or homoplasy counting to compute the key association indicators [9, 10].
The use of GWAS to identify genetic variants associated with disease manifestation still
remains unexplored. A recently published set of 350 draft pneumococcal genomes
isolated from adults admitted with IPD in Nijmegen [11, 12], whose clinical metadata is
available, provided an opportunity to examine the role of genetic diversity in the
accessory genome on the clinical manifestation of IPD. These isolates cover the period
before and after introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in the 
national vaccination program. We performed a GWAS analysis on the accessory genome
using PLINK [13] and corrected for effects of clonal population structure. We identified a
number of genetic factors associated with clinical manifestation of invasive
pneumococcal disease and discuss their potential mode of action in disease.
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either via recombination or via phage transduction begets extensive allelic variations in
the core genome and a broad flexible or accessory genome, which underlie phenotypic
differences in important traits such as virulence and antibiotic resistance. While most
pneumococcal virulence factors have been characterized, their role in invasive
pneumococcal disease remains underexplored.
Genome-wide association studies (GWAS) have over the past decade become the de 
facto approach to identify candidate genetic variations associated with complex inherited 
human diseases [6]. Despite being broached nearly a decade ago that tools and 
knowledge drawn from eukaryotic GWAS could be employed in bacteriology to 
investigate the genotypic etiology of relevant phenotypes [7], GWAS has limitedly been 
applied to the pneumococcus. The use of GWAS to identify genetic variants associated 
with important bacterial phenotypes has only been made possible recently by advances in 
bioinformatics and genome sequencing technologies [8]. Studies employ either alleles 
counting or homoplasy counting to compute the key association indicators [9, 10]. 
The use of GWAS to identify genetic variants associated with disease manifestation still 
remains unexplored. A recently published set of 350 draft pneumococcal genomes 
isolated from adults admitted with IPD in Nijmegen [11, 12], whose clinical metadata is 
available, provided an opportunity to examine the role of genetic diversity in the 
accessory genome on the clinical manifestation of IPD. These isolates cover the period 
before and after introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in the 
national vaccination program. We performed a GWAS analysis on the accessory genome 
using PLINK [13] and corrected for effects of clonal population structure. We identified a 
number of genetic factors associated with clinical manifestation of invasive 
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Table 1. A summary of clinical phenotypes included in the study. 
Type Phenotype Cases Controls Missing Notes 
Binary 
phenotypes 
Empyema 31 317 1 a 
Empyema and pneumonia 30 255 64 a 
Meningitis 30 318 1 a 
Neutrophils (dichotomous) 242 36 71 b 
Pleural effusion 105 130 114 c 
Pneumonia 285 63 1 a 
Renal disease 19 329 1 d 
Systemic Inflammatory 
Response Syndrome (SIRS) on 
Admission 
273 38 38 c 
30 day mortality 37 308 4 c 
Cardiovascular disease 148 200 1 d 
Cancer 75 273 1 d 
Collection during influenza 
season 
207 142 0 d 
Chronic Obstructive Pulmonary 
Disease (COPD) 
76 272 1 d 
Cough 209 102 38 b 
Dicompensatio Cordis 41 307 1 d 
Diabetes Mellitus 60 288 1 d 
Type Phenotype Category Denoted  Count Notes 
Continuous 
phenotypes 
Age 
Data missing -9 1 
d 
0-6 years 0 7 
7-55 years 1 88 
56 years or older 2 253 
Pneumonia Severity Index  (PSI) 
Missing -9 81 
c 
Outpatient 1 9 
Short inpatient 2 96 
Hospitalized 3 106 
ICU 4 58 
C- reactive proteins (CRP)
Missing -9 2 
b 
Normal (<10mg/L) 0 8 
Low risk (10-100mg/L) 1 70 
Average risk (200-300mg/L) 2 111 
High risk (300-500mg/L) 3 117 
Very high risk (>500mg/L) 4 41 
Charlson comorbidity index* 
Missing -9 1 
d 
Normal 0 36 
Myocardial Infarction 1 22 
Congestive Heart Failure 2 22 
Peripheral Vascular Disease 3 47 
Cerebrovascular Disease 4 62 
Dementia 5 56 
COPD 6 30 
Connective Tissue Disease 7 39 
Peptic Ulcer Disease 8 18 
Diabetes Mellitus 9 10 
Kidney Disease 10 5 
Liver Disease 15 1 
Notes: a, type of infection; b, disease characteristics; c, severity of disease; and d, risk factors; 
*http://touchcalc.com/calculators/cci_js. 
Results and discussion
Defining the sequence clusters and the accessory genome
Coding sequences from the 350 isolates have been grouped into a total of 3,021 clusters
of orthologous genes (OGs), of which 1,075 were core; appearing in a single copy in all 
isolates and 1,946 accessory OGs, containing rarer or variable genotypes [12]. Filtering for
OGs containing singletons and genes present in less than 2% (7 isolates) of the isolates
resulted into 1,532 accessory OGs. Analysis of the concatenated variant sites on the core 
OGs using hierarchical BAPS [14] converged at 13 sequence clusters (SCs); 12 largely
monophyletic SCs and a thirteenth comprised of atypical genotypes (Figure 1). After 
collating measures according to the type of pneumococcal disease, severity of disease,
disease characteristics, and underlying risk factors, a total of 16 binary phenotypes and 4
multi-category phenotypes were included in the analysis (Table 1).
Although disease is a highly polygenic phenomenon, disease phenotypes show positive
associations with certain SCs (Fishers p-value <0.05 Bonferroni corrected for multiple
testing), indicating that specific clones are likely to cause more disease that others (Table
2), or that different genetic signatures result in the same disease phenotype. Therefore,
corrections for population structure stratifications is required. For example SC1, SC6, and
SC10 correlate with pneumococcal disease. These SCs respectively consist of serotypes
14, 8, and 1, which have been observed to be the dominant serotypes that cause invasive 
pneumococcal infections [12, 15]. Surprisingly, rarer sequence types (SC2; consisting of
atypical genotypes) also seem to cause more disease. Studies have shown that rarer 
pneumococcal serotypes might be more prevalent in disease than previously thought
[16]. SNPs analysis may be necessary to elucidate if specific polymorphisms in the clones
underlie these associations. Highly recombinogenic bacteria like the pneumococcus
exhibit clonal population structures. The linkage disequilibrium (LD) between gene
presence or absence and phylogenetically informative SNPs. Unfortunately, we lack
sufficient number of genomes with clinical metadata to perform the analyses on the
atypical genotypes.
The Cochran–Mantel–Haenszel statistic was employed to infer associations between
pneumococcal accessory genome and binary phenotypes with sequence cluster-
membership as covariate. The results in Supplementary Table 1 (stratified) and
Supplementary Table 2 (unstratified) show that correcting for population substructure
stratification minimized the inflation of association p-values. Correction was specific to
variation in frequency of candidate OGs across ancestral populations. Without
stratification, there was a substantial systematic inflation of the association test p-values
across all clinical phenotypes. For example, OG 2136 and OG 2380 show significant
association with empyema (p-value <0.05) before stratification but not so after 
population stratification. Therefore, stratification minimizes spurious associations and
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maximizes the power to detect true associations in GWAS studies. Only three phenotypes 
(pneumoniae, meningitis, and 30 day mortality) exhibited significant associations (p-
values < 0.05 Bonferroni adjusted for multiple testing) after correcting for population 
stratification (Figure 1; Table 3). 
Figure 1. A phylogeny of the variable sites from the core genome of all clinical isolates used in study. Clades are 
colored according to the sequence clusters as determined using BAPS (see materials and methods). Presence 
(black) or absence (white) of genes statistically associated with pneumonia, meningitis and 30-day mortality is 
represented by the heatmap. The first column of each disease eventuality shows the phenotype for individual 
isolates; green=control, black = case. 
Table 2. Statistical association between sequence clusters and phenotypes of disease manifestation
Sequence 
cluster
Meningitis + Meningitis -
Others
diseases+
Others
diseases-
p-value
SC1 1 18 29 302 1
SC2 15 57 15 263 0.000155556
SC3 0 25 30 295 0.1487862
SC4 0 13 30 307 0.6133904
SC5 2 21 28 299 1
SC6 3 38 27 282 1
SC7 0 22 30 298 0.2380451
SC8 0 15 30 305 0.6274878
SC9 5 33 25 287 0.3502867
SC10 1 32 29 288 0.3363776
SC11 1 10 29 310 1
SC12 2 16 28 304 0.6596066
SC13 0 20 30 300 0.238468
Pneumonia + Pneumonia -
Others
diseases+
Others
diseases-
p-value
SC1 15 4 270 61 0.7630057
SC2 48 24 237 41 0.000606396
SC3 22 3 263 62 0.5926162
SC4 10 3 275 62 0.7150978
SC5 19 4 266 61 1
SC6 39 2 246 63 0.01691588
SC7 19 3 266 62 0.7774798
SC8 14 1 271 64 0.3212966
SC9 29 9 256 56 0.3814105
SC10 32 1 253 64 0.01615192
SC11 8 3 277 62 0.4351478
SC12 13 5 272 60 0.3468605
SC13 17 3 268 62 1
30-day mortality
+
30-day
mortality -
Others
diseases+
Others
diseases-
p-value
SC1 5 14 23 308 0.0120289
SC2 2 70 26 252 0.08613299
SC3 2 23 26 299 1
SC4 0 13 28 309 0.610641
SC5 3 20 25 302 0.4132743
SC6 5 36 23 286 0.3514003
SC7 2 20 26 302 0.6921759
SC8 0 15 28 307 0.6199427
SC9 1 37 27 285 0.3385618
SC10 1 32 27 290 0.4962165
SC11 0 11 28 311 1
SC12 3 15 25 307 0.1658858
SC13 4 16 24 306 0.06489312
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maximizes the power to detect true associations in GWAS studies. Only three phenotypes 
(pneumoniae, meningitis, and 30 day mortality) exhibited significant associations (p-
values < 0.05 Bonferroni adjusted for multiple testing) after correcting for population 
stratification (Figure 1; Table 3). 
 
 
Figure 1. A phylogeny of the variable sites from the core genome of all clinical isolates used in study. Clades are 
colored according to the sequence clusters as determined using BAPS (see materials and methods). Presence 
(black) or absence (white) of genes statistically associated with pneumonia, meningitis and 30-day mortality is 
represented by the heatmap. The first column of each disease eventuality shows the phenotype for individual 
isolates; green=control, black = case. 
  
 
 
  
Table 2. Statistical association between sequence clusters and phenotypes of disease manifestation 
Sequence 
cluster 
Meningitis + Meningitis  - 
Others 
diseases+ 
Others 
diseases- 
p-value 
SC1 1 18 29 302 1 
SC2 15 57 15 263 0.000155556 
SC3 0 25 30 295 0.1487862 
SC4 0 13 30 307 0.6133904 
SC5 2 21 28 299 1 
SC6 3 38 27 282 1 
SC7 0 22 30 298 0.2380451 
SC8 0 15 30 305 0.6274878 
SC9 5 33 25 287 0.3502867 
SC10 1 32 29 288 0.3363776 
SC11 1 10 29 310 1 
SC12 2 16 28 304 0.6596066 
SC13 0 20 30 300 0.238468 
 
Pneumonia + Pneumonia - 
Others 
diseases+ 
Others 
diseases- 
p-value 
SC1 15 4 270 61 0.7630057 
SC2 48 24 237 41 0.000606396 
SC3 22 3 263 62 0.5926162 
SC4 10 3 275 62 0.7150978 
SC5 19 4 266 61 1 
SC6 39 2 246 63 0.01691588 
SC7 19 3 266 62 0.7774798 
SC8 14 1 271 64 0.3212966 
SC9 29 9 256 56 0.3814105 
SC10 32 1 253 64 0.01615192 
SC11 8 3 277 62 0.4351478 
SC12 13 5 272 60 0.3468605 
SC13 17 3 268 62 1 
 
30-day mortality 
+ 
30-day 
mortality - 
Others 
diseases+ 
Others 
diseases- 
p-value 
SC1 5 14 23 308 0.0120289 
SC2 2 70 26 252 0.08613299 
SC3 2 23 26 299 1 
SC4 0 13 28 309 0.610641 
SC5 3 20 25 302 0.4132743 
SC6 5 36 23 286 0.3514003 
SC7 2 20 26 302 0.6921759 
SC8 0 15 28 307 0.6199427 
SC9 1 37 27 285 0.3385618 
SC10 1 32 27 290 0.4962165 
SC11 0 11 28 311 1 
SC12 3 15 25 307 0.1658858 
SC13 4 16 24 306 0.06489312 
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 Genes associated with pneumonia and meningitis 
Certain proteins or enzymes expressed by the pneumococcus significantly contribute to 
pathogenesis and might be involved in the disease process caused by these pathogen. 
Indeed, several pneumococcal virulence factors including choline binding protein A 
(CbpA) [17], pneumococcal surface antigen A (PsaA) [18], pneumococcal surface protein 
A (PspA) [19], hyaluronate lyase [20], pneumolysin [21], neuraminidases [20], and major 
autolysin (LytA) [20], and their role in pneumococcal pathogenesis have been described. 
These proteins often interact directly with the host tissues and may also be involved in 
camouflaging the pneumococcal surface from the host defenses. 
The capsule polysaccharide (CPS) plays an important role in the virulence of S. 
pneumoniae and provides resistance to phagocytosis. Presence of ‘CDP-glycerol-1-
phosphate biosynthetic protein’ (OG_2278; gct), a gene involved in the biosynthesis of 
lipoteichoic acid precursors of the CPS [22], is underrepresented in pneumonia and 
overrepresented in meningitis; p-values 0.0098 and 0.001 respectively, Bonferroni 
corrected (Table 3). Teichoic acids (TAs) mainly provide rigidity to the cell-wall by 
attracting cations such as magnesium and sodium [23]. Bacterial strains in which 
expression TAs synthesis has been prevented are biologically nonviable and show 
profound morphological aberrations. In addition, TAs may aid also in regulating cell 
growth by limiting autolysins from breaching the β (1-4) bond between N-acetylmuramic 
acid and N-acetylglucosamine. Since the bacteria exhibiting increased cell wall rigidity 
could better resist killing by the host immune defenses, we hypothesize that the TAs may 
play a role in persisting the host protection during invasive infection. Although not 
conclusively supported, studies have also implicated TAs in biofilm formation, host tissue 
adhesion, cell growth, division and morphogenesis, and as receptor molecules for some 
Gram-positive bacteriophages [24-26].  
The abortive infection phage resistance protein (OG_2254) and an uncharacterized phage 
protein (OG_2287; last gene in phage lytic cycle, downstream the phage transcription 
regulator-see figure 3) are overrepresented in isolates that caused pneumonia compared 
to isolates that caused other type of infections. Phages are perhaps the most diversified, 
adaptive and widespread microorganisms [27]. The abortive infection (Abi) systems 
protects the host bacterium against an existing phage infection by promoting cell death 
and limit phage replication [28] and might have additional roles like enabling stabilization 
of integrative and conjugative elements [29], some of which encode virulence and 
resistance genes that are transmissible between Streptococci [30, 31]. The direct role of 
these elements in promoting pneumonia is not clear but phages may carry virulence 
factors which we assume may enhance pathogenesis [32, 33] 
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autolysin (LytA) [20], and their role in pneumococcal pathogenesis have been described. 
These proteins often interact directly with the host tissues and may also be involved in 
camouflaging the pneumococcal surface from the host defenses. 
The capsule polysaccharide (CPS) plays an important role in the virulence of S. 
pneumoniae and provides resistance to phagocytosis. Presence of ‘CDP-glycerol-1-
phosphate biosynthetic protein’ (OG_2278; gct), a gene involved in the biosynthesis of 
lipoteichoic acid precursors of the CPS [22], is underrepresented in pneumonia and 
overrepresented in meningitis; p-values 0.0098 and 0.001 respectively, Bonferroni 
corrected (Table 3). Teichoic acids (TAs) mainly provide rigidity to the cell-wall by 
attracting cations such as magnesium and sodium [23]. Bacterial strains in which 
expression TAs synthesis has been prevented are biologically nonviable and show 
profound morphological aberrations. In addition, TAs may aid also in regulating cell 
growth by limiting autolysins from breaching the β (1-4) bond between N-acetylmuramic 
acid and N-acetylglucosamine. Since the bacteria exhibiting increased cell wall rigidity 
could better resist killing by the host immune defenses, we hypothesize that the TAs may 
play a role in persisting the host protection during invasive infection. Although not 
conclusively supported, studies have also implicated TAs in biofilm formation, host tissue 
adhesion, cell growth, division and morphogenesis, and as receptor molecules for some 
Gram-positive bacteriophages [24-26].  
The abortive infection phage resistance protein (OG_2254) and an uncharacterized phage 
protein (OG_2287; last gene in phage lytic cycle, downstream the phage transcription 
regulator-see figure 3) are overrepresented in isolates that caused pneumonia compared 
to isolates that caused other type of infections. Phages are perhaps the most diversified, 
adaptive and widespread microorganisms [27]. The abortive infection (Abi) systems 
protects the host bacterium against an existing phage infection by promoting cell death 
and limit phage replication [28] and might have additional roles like enabling stabilization 
of integrative and conjugative elements [29], some of which encode virulence and 
resistance genes that are transmissible between Streptococci [30, 31]. The direct role of 
these elements in promoting pneumonia is not clear but phages may carry virulence 
factors which we assume may enhance pathogenesis [32, 33] 
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Figure 2. A schematic overview of eicosanoids biosynthesis 
We identified some proteins, which significantly associated with meningitis, and have 
been previously associated with increased virulence and observed in meningitis. They 
include phospholipase A2; slaA [34], wzy/wzx [22], and UDP-galactopyranose mutase; glf 
[35]. Phospholipase A2, encoded by slaA, has a function in host-pathogen interaction as a 
colonization and pathogenesis promoting factor [36]. In vitro studies have shown that 
SlaA promotes colonization by cleaving epithelial cell membrane phospholipids in the 
nasopharynx releasing arachidonic acid [37]. Current knowledge on meningeal infection 
by pneumococcus implicates platelet-activating factor receptor (PAFR) in binding S. 
pneumoniae, thereby aiding adhesion, uptake and transcytosis through endothelial cells 
[38, 39]. Pneumococcus interacts with PAFR which activates signal transduction 
pathways including phospholipase A2 [40] to release arachidonic acid [41]; a precursor of 
eicosanoids including prostaglandins and leukotrienes (Figure 2). Also, during meningeal 
infection by Group B Streptococci, the host cytosolic phospholipase A₂α facilitates the 
release of arachidonic acid from brain endothelial membrane [34]. Arachidonic acid is 
processed into leukotrienes that regulate permeability of the human brain microvascular 
endothelial cells (HBMEC), which constitute the blood-brain barrier. Penetration of the 
blood-brain barrier is the crucial stage necessary for the development of pneumococcal 
meningitis. It is tempting to speculate that the bacterial SlaA from the pneumococcus 
may also releases arachidonic acid from the brain endothelial membrane, subsequently 
increasing permeability of the blood-brain barrier through leukotriene function. SlaA may 
therefore be a colonization factor that also has an inadvertent function of magnifying 
invasive pneumococcal infections by enabling the microorganism to cross the blood-brain 
barrier. SlaA together with streptococcal pyrogenic exotoxin K (SpeK), are implicated in 
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increased virulence, particularly in the serotype M3 clone of Group A Streptococcus
(GAS) [42, 43]. Interestingly in our genomes, SlaA is neighbored by SpeK, perhaps an
indicator of their function or relatedness as bacteriophage-encoded factors. However,
these hypotheses have not been experimentally confirmed. An arachidonic acid release 
assay using HBMEC cells exposed to SlaA expressing pneumococcus would be of great
benefit. An additional meningitis mouse model with pneumococcal strains expressing
SlaA and isogenic knockouts could be used to conclusively confirm the role of SlaA in
meningitis.
Apart from pneumococcal serotypes 3 and 37 that are synthesized by the synthase
pathway [41, 44-46]; other pneumococcal capsular polysaccharides are generally
synthesized by the Wzx/Wzy-dependent pathway [22]. The Wzy polymerase (wzy), Wzx
flippase (wzx) are localized in the pneumococcal capsular biosynthetic (cps) loci along
with various enzymes that modify the repeat units or add other moieties on capsule. The 
wzy/wzx genes are involved in polymerization and export of the pneumococcal capsule
and are unique to each capsular type [22, 47]. The wzy/wzx genes (OG 2725) associated
with meningitis in the Nijmegen adults’ cohort are all unique to serotypes 18B/C.
Serotype 18C is a highly invasive serotype [48] that has been included in all PCVs owing to 
its high global prevalence [49]. Overall, serogroup 18 has been reported to be among the
most common serogroups causing meningitis which could explain the observed
correlation [50, 51]. 
UDP-galactopyranose (OG 449) is an important constituent of glycoconjugates that
comprise major portions of the cell surface and plays a crucial role in the infectious cycle
[35]. OG 449 codes for UDP-galactopyranose which plays a role in production of vaccine-
type capsules 6C, 7F, 18C, and non-vaccine capsules 6A, 8, 9V, 18B, 19A, 22A/F, 33A/F and
35B. Increased post-vaccine prevalence of vaccine related serotypes like 6A and 19A has
been reported both in carriage [52] and invasive disease [12]. In addition to 7F and 8 were
the dominant causes of post-vaccine invasive disease [12], while other non-vaccine 
serotypes including 11, 12, 15, 22F, 23A, 33F, 24, 34, and 35B are rapidly increasing in
prevalence worldwide [53-57]. This increased prevalence and persistence may correlate to
the increased propensity of these serotypes to infect and progress to meningitis.
Serotype 35B has particularly been reported in infant pneumococcal meningitis [53]
perhaps indicative of the increased invasiveness of this serotype.
Genes associated with 30 days mortality
Some IPD patients do not survive the first 30 days of hospitalization; herein referred to as
30-day mortality. In our dataset, the 30-day mortality phenotype was predominantly
associated with bacteriophage genes (Figure 1). This association was primarily with genes
at the lytic end of the phage (the late region) but also included other genes in the phage 
lytic cluster (Figure 3). Bacteriophages are among the most common and diverse entities
in the atmosphere. They encode as few as four genes, to as many as hundreds of genes.
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Figure 2. A schematic overview of eicosanoids biosynthesis 
 
We identified some proteins, which significantly associated with meningitis, and have 
been previously associated with increased virulence and observed in meningitis. They 
include phospholipase A2; slaA [34], wzy/wzx [22], and UDP-galactopyranose mutase; glf 
[35]. Phospholipase A2, encoded by slaA, has a function in host-pathogen interaction as a 
colonization and pathogenesis promoting factor [36]. In vitro studies have shown that 
SlaA promotes colonization by cleaving epithelial cell membrane phospholipids in the 
nasopharynx releasing arachidonic acid [37]. Current knowledge on meningeal infection 
by pneumococcus implicates platelet-activating factor receptor (PAFR) in binding S. 
pneumoniae, thereby aiding adhesion, uptake and transcytosis through endothelial cells 
[38, 39]. Pneumococcus interacts with PAFR which activates signal transduction 
pathways including phospholipase A2 [40] to release arachidonic acid [41]; a precursor of 
eicosanoids including prostaglandins and leukotrienes (Figure 2). Also, during meningeal 
infection by Group B Streptococci, the host cytosolic phospholipase A₂α facilitates the 
release of arachidonic acid from brain endothelial membrane [34]. Arachidonic acid is 
processed into leukotrienes that regulate permeability of the human brain microvascular 
endothelial cells (HBMEC), which constitute the blood-brain barrier. Penetration of the 
blood-brain barrier is the crucial stage necessary for the development of pneumococcal 
meningitis. It is tempting to speculate that the bacterial SlaA from the pneumococcus 
may also releases arachidonic acid from the brain endothelial membrane, subsequently 
increasing permeability of the blood-brain barrier through leukotriene function. SlaA may 
therefore be a colonization factor that also has an inadvertent function of magnifying 
invasive pneumococcal infections by enabling the microorganism to cross the blood-brain 
barrier. SlaA together with streptococcal pyrogenic exotoxin K (SpeK), are implicated in 
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increased virulence, particularly in the serotype M3 clone of Group A Streptococcus 
(GAS) [42, 43]. Interestingly in our genomes, SlaA is neighbored by SpeK, perhaps an 
indicator of their function or relatedness as bacteriophage-encoded factors. However, 
these hypotheses have not been experimentally confirmed. An arachidonic acid release 
assay using HBMEC cells exposed to SlaA expressing pneumococcus would be of great 
benefit. An additional meningitis mouse model with pneumococcal strains expressing 
SlaA and isogenic knockouts could be used to conclusively confirm the role of SlaA in 
meningitis.  
 Apart from pneumococcal serotypes 3 and 37 that are synthesized by the synthase 
pathway [41, 44-46]; other pneumococcal capsular polysaccharides are generally 
synthesized by the Wzx/Wzy-dependent pathway [22]. The Wzy polymerase (wzy), Wzx 
flippase (wzx) are localized in the pneumococcal capsular biosynthetic (cps) loci along 
with various enzymes that modify the repeat units or add other moieties on capsule. The 
wzy/wzx genes are involved in polymerization and export of the pneumococcal capsule 
and are unique to each capsular type [22, 47]. The wzy/wzx genes (OG 2725) associated 
with meningitis in the Nijmegen adults’ cohort are all unique to serotypes 18B/C.  
Serotype 18C is a highly invasive serotype [48] that has been included in all PCVs owing to 
its high global prevalence [49]. Overall, serogroup 18 has been reported to be among the 
most common serogroups causing meningitis which could explain the observed 
correlation [50, 51].  
UDP-galactopyranose (OG 449) is an important constituent of glycoconjugates that 
comprise major portions of the cell surface and plays a crucial role in the infectious cycle 
[35]. OG 449 codes for UDP-galactopyranose which plays a role in production of vaccine-
type capsules 6C, 7F, 18C, and non-vaccine capsules 6A, 8, 9V, 18B, 19A, 22A/F, 33A/F and 
35B. Increased post-vaccine prevalence of vaccine related serotypes like 6A and 19A has 
been reported both in carriage [52] and invasive disease [12]. In addition to 7F and 8 were 
the dominant causes of post-vaccine invasive disease [12], while other non-vaccine 
serotypes including 11, 12, 15, 22F, 23A, 33F, 24, 34, and 35B are rapidly increasing in 
prevalence worldwide [53-57]. This increased prevalence and persistence may correlate to 
the increased propensity of these serotypes to infect and progress to meningitis. 
Serotype 35B has particularly been reported in infant pneumococcal meningitis [53] 
perhaps indicative of the increased invasiveness of this serotype. 
Genes associated with 30 days mortality 
Some IPD patients do not survive the first 30 days of hospitalization; herein referred to as 
30-day mortality. In our dataset, the 30-day mortality phenotype was predominantly 
associated with bacteriophage genes (Figure 1). This association was primarily with genes 
at the lytic end of the phage (the late region) but also included other genes in the phage 
lytic cluster (Figure 3). Bacteriophages are among the most common and diverse entities 
in the atmosphere. They encode as few as four genes, to as many as hundreds of genes. 
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Figure 3. Lytic and lysogenic clusters of the Spn1 phage. The organization of phage genes was sketched from 
visualization of a whole-genome of an isolate carrying the pblB gene. 
Bacteria are generally believed to acquire virulence properties from bacteriophages [58, 
59]. Phage-encoded proteins have previously been implicated in providing a large gene 
pool for the pneumococcus which facilitate colonization and virulence [33, 60, 61]. 
Jeffrey N. Weiser and colleagues published this bacteriophage (named ‘Spn1’) containing 
63 open reading frames in the pneumococcus [60]. They investigated the effect of Spn1 
phage on colonization in vivo and observed that its presence was associated with reduced 
fitness during competitive colonization. Compared to the strain without the phage, the 
strain carrying Spn1 exhibited a defect in LytA-mediated autolysis in vitro but were 
characterized by an increased chain length of the cell wall, and increased resistance to 
lysis by penicillin. Expression of the phage genes was induced upon exposure to 
mitomycin C, but the treatment did not trigger lysis of the bacterial host [60]. 
The late phage region is expressed as the final step when the phage is induced. Induction 
may be caused by damage of the bacterial host DNA due to various factors, including 
chemical or oxidative compounds, UV irradiation, and halted translation by some 
antibiotics. To maintain the integrity of their genomes, bacteria turns on the DNA repair 
pathways which is governed by the so called ‘SOS response’ [60, 62]. The final step in 
phage replication consists of expression the late region which contains lytic enzymes that 
lyse the bacterial host, thereby releasing newly formed phage particles. However, when 
the bacterial host cells are compromised by the phage replication mediated lysis, 
pneumolysin toxin may also be released. Pneumolysin is a virulence factor that promotes 
adherence during colonization [63], damages host cells and interferes with the host 
immune response during infection [64]. It has no secretion system, but relies on lysis of 
bacterial host to be released in its environment. Therefore, rapid release of pneumolysin 
due to phage mediated lysis may be partly responsible for the increased mortality 
observed in the patients. An initial mitomycin-C phage induction experiment did not
result in phage plaque formation, thereby casting doubt on the lysis hypothesis, similar to
what has been described for Spn1 [60].
We also observed that presence of pblB: a phage-encoded gene is associated with 30-day
mortality. The pblB gene is also encoded in the late region of the same phage discussed
above. PblB has been reported to promote platelet binding in Streptococcus mitis [65, 66]. 
In pneumonia infection, PblB has been reported to significantly enhance the platelet
activating properties of pneumococci [33]. Higher platelet activation has been associated
with myocardial infarction in pneumonia and the formation of microthrombi in other
diseases, which may explain the potential of pneumococci carrying genes encoding PblB
to cause endocarditis, cardiac failure and multi-organ failure, which could lead to death.
Weiser and colleagues recently reported decreased bacterial fitness and increased
resistance to penicillin by pneumococci carrying a phage encoding PblB [60]. Weiser et al.
suggest that due to the use of penicillin, there was a positive selection on carriage of the 
phage, even though it has a fitness effect in carriage [60]. Inadvertently, this may have
resulted in increased carriage of the pathogenicity factors encoded on the phages. To 
experimentally verify if the presence of the phage is associated with higher platelet 
activation, platelet-rich plasma (PRP) and whole blood can be used for in vitro stimulation
assays with strains of the pneumococcus carrying or not carrying the phage. Flow
cytometry can then be used to measure platelet activation and platelet-monocyte
complex formation following induction of the phage.
Effect of vaccination on prevalence of disease associated genes
Significant post-vaccine restructuring of the pneumococcal population has been observed
in both carriage [52, 67] and invasive disease [12, 52, 68]. The reshuffling is characterized
by an initial decrease of a number of different genes within isolates followed by a return
to equilibrium with a similar diversity of genes as in pre-vaccination state. Non-vaccine 
type isolates have become the dominant pneumococcal species after vaccination [12, 52, 
68], virulence related genes may be lost or isolates with specific virulence factors may
have an increased presence following vaccination [11, 69].  It is still unclear whether these
perturbations affect virulence factors and consequently the eventuality of pneumococcal
disease. With the exception of OGs 344, 416, 449, 533, 558, 679, 2034, 2278, 2292 and
2601 which increased in percentage prevalence, we observed a decrease in the 
prevalence of genes associated with disease (Table 3). A possible explanations is that
these factors decrease with vaccine-types upon immunization but return with the
replacing non-vaccine serotypes afterwards. Indeed, post-vaccine re-expansion of the
genome content with genes circulating in population pre-vaccine has been reported [12,
52].
In conclusion, we suggest the use of whole genome sequencing for investigating the
effect of vaccination on the prevalence of disease inflating factors in circulating
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observed in the patients. An initial mitomycin-C phage induction experiment did not 
result in phage plaque formation, thereby casting doubt on the lysis hypothesis, similar to 
what has been described for Spn1 [60].  
We also observed that presence of pblB: a phage-encoded gene is associated with 30-day 
mortality. The pblB gene is also encoded in the late region of the same phage discussed 
above. PblB has been reported to promote platelet binding in Streptococcus mitis [65, 66]. 
In pneumonia infection, PblB has been reported to significantly enhance the platelet 
activating properties of pneumococci [33]. Higher platelet activation has been associated 
with myocardial infarction in pneumonia and the formation of microthrombi in other 
diseases, which may explain the potential of pneumococci carrying genes encoding PblB 
to cause endocarditis, cardiac failure and multi-organ failure, which could lead to death. 
Weiser and colleagues recently reported decreased bacterial fitness and increased 
resistance to penicillin by pneumococci carrying a phage encoding PblB [60]. Weiser et al. 
suggest that due to the use of penicillin, there was a positive selection on carriage of the 
phage, even though it has a fitness effect in carriage [60]. Inadvertently, this may have 
resulted in increased carriage of the pathogenicity factors encoded on the phages. To 
experimentally verify if the presence of the phage is associated with higher platelet 
activation, platelet-rich plasma (PRP) and whole blood can be used for in vitro stimulation 
assays with strains of the pneumococcus carrying or not carrying the phage. Flow 
cytometry can then be used to measure platelet activation and platelet-monocyte 
complex formation following induction of the phage. 
Effect of vaccination on prevalence of disease associated genes 
Significant post-vaccine restructuring of the pneumococcal population has been observed 
in both carriage [52, 67] and invasive disease [12, 52, 68]. The reshuffling is characterized 
by an initial decrease of a number of different genes within isolates followed by a return 
to equilibrium with a similar diversity of genes as in pre-vaccination state. Non-vaccine 
type isolates have become the dominant pneumococcal species after vaccination [12, 52, 
68], virulence related genes may be lost or isolates with specific virulence factors may 
have an increased presence following vaccination [11, 69].  It is still unclear whether these 
perturbations affect virulence factors and consequently the eventuality of pneumococcal 
disease. With the exception of OGs 344, 416, 449, 533, 558, 679, 2034, 2278, 2292 and 
2601 which increased in percentage prevalence, we observed a decrease in the 
prevalence of genes associated with disease (Table 3). A possible explanations is that 
these factors decrease with vaccine-types upon immunization but return with the 
replacing non-vaccine serotypes afterwards. Indeed, post-vaccine re-expansion of the 
genome content with genes circulating in population pre-vaccine has been reported [12, 
52]. 
In conclusion, we suggest the use of whole genome sequencing for investigating the 
effect of vaccination on the prevalence of disease inflating factors in circulating 
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Testing for associations between presence or absence of a gene and clinical
phenotypes
OGs representing the accessory genome were assigned a binary measure of presence (1)
or absence (0) of a representative CDS from each strain. Applying this criterion, the
contribution of each strain to the OGs was therefore denoted by a single numeric value (1
or 0) to represent the presence or absence of a gene, or a group of paralogs in a genome 
accordingly. Clinical phenotypes were classified into two types: binary or dichotomous
phenotypes containing either cases (clinical outcome present) or controls (clinical
outcome absent) for members within the cohort respectively, and multi-category ordinal
phenotypes containing continuous or class-series traits like age and disease severity or 
comorbidity indices.
The Cochran–Mantel–Haenszel statistic, implemented in PLINK [13], was employed to
infer associations between pneumococcal accessory genome and binary phenotypes.
Associations for multi-category (non-binary) phenotypes like age, pneumonia severity
index (PSI), and C-reactive proteins (CRP) were performed using multinomial logistic, and
proportional odds ordinal logistic analyses implemented in Trinculo v0.9
(http://sourceforge.net/projects/trinculo/). All association tests were performed
contingent on the SCs (representing genetic subpopulations within the population) as
covariates of population substructure stratification. OGs showing statistically robust
associations (p-values < 0.05 Bonferroni adjusted for multiple testing) were selected as
putative causative candidates.
Supporting data
Supplementary material for this chapter are available online at:
https://www.dropbox.com/sh/bnx7vad8qivax1d/AABXGROkQDj0vRQqmRruQqPOa?dl=0
pneumococcal strains. This could give a forecast on the course of disease and facilitate 
modelling of future interventions. Additional experiments will be required to corroborate 
the observed statistical associations and possibly characterize the underlying biological 
mechanisms. 
Methods 
Determining the core and accessory genome 
The isolates and clusters of orthologous genes (OGs) used in this analysis were defined 
previously [11, 12]. All putative protein coding sequences (CDSs) were analyzed in an all-
versus-all protein blast using an e-value cut-off of 10e-15 and a BLOSUM90 substitution 
matrix. Orthologs were then grouped using TribeMCL [70] by implementing the Markov 
Clustering (MCL) step with an inflation value of 4. In total, the CDSs were grouped into 
3,021 OGs, 1,075 of which were denominated as ‘core’ as they consisted of proteins 
present in a single copy in each of the 350 isolates. The remaining OGs were denominated 
as the flexible or accessory genome.  
Defining the sequence clusters (SCs) 
Protein coding sequences of the core OGs were aligned with MUSCLE [71] using a the 
default maximum of tree-dependent refinement iterations (16) for realignment until 
convergence was reached. The aligned sequences were then codon translated into 
nucleotide alignments using RevTrans [72]. Sequences in OGs encoding ribosomal 
proteins were then concatenated into a single ‘ribosomal’ alignment. A reference 
maximum likelihood phylogeny was constructed on the ribosomal alignment using 
RAxML v8.2.0 [73]. Phylogenies for each of the remaining core OGs were also constructed 
independently. The Euclidian distances (EuD) of these individual phylogenies were 
plotted against the ribosomal phylogeny resulting into three distinct distributions 
(Supplementary 3). To improve the core phylogeny resolution, sequences in OGs whose 
phylogenies were similar to the ribosomal phylogeny (EuD ≤ 0.03) were concatenated to 
the ribosomal alignment to give a single reduced ‘core’ super-alignment.  
Finally, a maximum likelihood phylogenetic tree was constructed using RAxML and an 
alignment of all the concatenated polymorphic sites from ‘core’ super-alignment. The 
maximum-likelihood ratios were calculated using the general time-reversible model with 
a γ correction for site variation as the nucleotide substitution model. The support for 
nodes on the trees were confirmed using 100 random bootstrap replicates. Resulting 
phylogenetic trees were visualized in iTOL v3.0 [74]. Sequence clusters (SCs) were defined 
by analyzing the core super-alignment using hierarchical BAPS software v6.0 [14]. Two 
runs of 40 and 50 maximum clusters were performed and the consensus was established 
as previously described [12]. 
42613 maati, Frederick.indd   132 04-10-16   16:08
Genetic correlates of IPD manifestation | 133
6
 
 
  
Testing for associations between presence or absence of a gene and clinical 
phenotypes 
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or absence (0) of a representative CDS from each strain. Applying this criterion, the 
contribution of each strain to the OGs was therefore denoted by a single numeric value (1 
or 0) to represent the presence or absence of a gene, or a group of paralogs in a genome 
accordingly. Clinical phenotypes were classified into two types: binary or dichotomous 
phenotypes containing either cases (clinical outcome present) or controls (clinical 
outcome absent) for members within the cohort respectively, and multi-category ordinal 
phenotypes containing continuous or class-series traits like age and disease severity or 
comorbidity indices. 
The Cochran–Mantel–Haenszel statistic, implemented in PLINK [13], was employed to 
infer associations between pneumococcal accessory genome and binary phenotypes. 
Associations for multi-category (non-binary) phenotypes like age, pneumonia severity 
index (PSI), and C-reactive proteins (CRP) were performed using multinomial logistic, and 
proportional odds ordinal logistic analyses implemented in Trinculo v0.9 
(http://sourceforge.net/projects/trinculo/). All association tests were performed 
contingent on the SCs (representing genetic subpopulations within the population) as 
covariates of population substructure stratification. OGs showing statistically robust 
associations (p-values < 0.05 Bonferroni adjusted for multiple testing) were selected as 
putative causative candidates. 
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Abstract 
To improve our understanding about the severity of invasive pneumococcal disease (IPD), 
in this study we investigated the association between the genotype of Streptococcus 
pneumoniae and disease outcome of 349 bacteremic patients. Pneumococcal genome-
wide association (GWAS) analysis demonstrated a strong correlation between 30-day 
mortality and the presence of the phage-derived pblB gene, encoding a platelet-binding 
protein of which consequences on platelet activation was previously unknown. Platelets 
are increasingly recognized as key players of the innate immune system, and in sepsis, 
excessive platelet activation contributes to microvascular obstruction, tissue 
hypoperfusion and finally multi-organ failure leading to mortality. Our in vitro studies 
revealed that pblB expression was induced by fluoroquinolones but not by the beta-
lactam antibiotic Penicillin G. Subsequently, we determined pblB induction and platelet 
activation by incubating whole blood with wild type or knock-out mutant of pblB, in the 
presence or absence of antibiotics commonly administered in our patient cohort. PblB-
dependent enhancement of platelet activation, as measured by increased expression of 
the alpha-granule protein P-selectin, the binding of fibrinogen to the activated αIIbβ3 
receptor and the formation of platelet-monocyte complex, occurred irrespective of the 
antibiotics exposure. In conclusion, the presence of pblB on the pneumococcal 
chromosome potentially leads to increased mortality in patients with an invasive S. 
pneumoniae infection, which may be explained by enhanced platelet activation. This 
study highlights the clinical utility of bacterial GWAS, followed by functional 
characterization to identify bacterial factors involved in disease severity. 
Importance 
The exact mechanisms causing mortality in invasive pneumococcal disease (IPD) patients 
is not completely understood. We examined 349 patients with IPD and found in a 
bacterial genome-wide association study (GWAS) that the presence of the phage-derived 
gene pblB was associated with mortality in the first 30 days after hospitalization. 
Although pblB had been extensively studied in Streptococcus mitis, its consequence on the 
interaction between platelets and Streptococcus pneumoniae is largely unknown. Platelets 
are important in immunity and inflammation, and excessive platelet activation 
contributes to microvascular obstruction and multi-organ failure, leading to mortality. We 
therefore developed this study to assess whether the phage-derived pblB might increase 
the risk for mortality in IPD patients through its effect on enhanced platelet activation. 
This study would also show the value of integrating extensive bacterial genomics and 
clinical data in predicting and understanding pathogen virulence, which in turn will help to 
improve prognosis and therapy. 
Introduction
Streptococcus pneumoniae or the pneumococcus is a frequent colonizer of the
nasopharynx. In a minority of carriers, infection progresses to pneumococcal disease with
an estimated 1.6 million deaths annually [1, 2]. The largest clinical burden of invasive
pneumococcal disease (IPD) is seen in young children and older adults, who present
mostly with sepsis and meningitis. Case mortality rates are estimated to range from 11 to
30% in adults [3-5], with treatment becoming complicated due to the worldwide
emergence of multi-drug resistance [6]. Therefore, it is of utmost importance to fully
understand the pathogenic mechanisms of pneumococcal disease in order to improve 
treatment and prognosis of critically ill patients.
Recently, the utilization of whole genome sequencing and analyses for predicting and
understanding pathogen virulence has been highlighted [7]. In this study, we performed a
genome-wide association analysis (GWAS) on 349 pneumococcal draft genomes of blood
isolates from patients who were admitted with IPD in two Dutch hospitals. We identified
a significant association between 30-day mortality and the presence of pblB, encoding for
a platelet binding protein that was also reported to function in adhesion, which might
explain clonal success [8]. In a subsequent functional study, we investigated the induction
of the phage-derived pblB expression by fluoroquinolones in S. pneumoniae. Lastly, we
simulated the in vivo conditions using an ex vivo whole blood assay demonstrating the
importance of pblB in enhancing platelet activation.
Platelets are an important part of the innate immune system, and can interact with and
be activated by S. pneumoniae. In sepsis, platelet activation and platelet-leukocyte
complex formation contribute to microvascular obstruction, tissue hypoperfusion and
finally multi-organ failure [9]. The role of this phage-derived gene in the clinical outcome
and severity of IPD patients and its consequences for platelet activation warrant further
study.
Figure 1. Flowchart of computational method used to identify the association of presence of the pblB gene with
30-day mortality
350 clinical S.
pneumoniae isolates
GWAS:
Plink v1.07
Binary matrix of
presence (1) or absence
(0) of PblB
30-day mortality
phenotype (case; 1,
control; 0, missing;-9)
Orthologs clustering:
TribeMCL
Sequencing and annotation
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To improve our understanding about the severity of invasive pneumococcal disease (IPD),
in this study we investigated the association between the genotype of Streptococcus
pneumoniae and disease outcome of 349 bacteremic patients. Pneumococcal genome-
wide association (GWAS) analysis demonstrated a strong correlation between 30-day
mortality and the presence of the phage-derived pblB gene, encoding a platelet-binding
protein of which consequences on platelet activation was previously unknown. Platelets
are increasingly recognized as key players of the innate immune system, and in sepsis,
excessive platelet activation contributes to microvascular obstruction, tissue
hypoperfusion and finally multi-organ failure leading to mortality. Our in vitro studies
revealed that pblB expression was induced by fluoroquinolones but not by the beta-
lactam antibiotic Penicillin G. Subsequently, we determined pblB induction and platelet
activation by incubating whole blood with wild type or knock-out mutant of pblB, in the 
presence or absence of antibiotics commonly administered in our patient cohort. PblB-
dependent enhancement of platelet activation, as measured by increased expression of
the alpha-granule protein P-selectin, the binding of fibrinogen to the activated αIIbβ3
receptor and the formation of platelet-monocyte complex, occurred irrespective of the
antibiotics exposure. In conclusion, the presence of pblB on the pneumococcal
chromosome potentially leads to increased mortality in patients with an invasive S.
pneumoniae infection, which may be explained by enhanced platelet activation. This
study highlights the clinical utility of bacterial GWAS, followed by functional 
characterization to identify bacterial factors involved in disease severity.
Importance
The exact mechanisms causing mortality in invasive pneumococcal disease (IPD) patients
is not completely understood. We examined 349 patients with IPD and found in a
bacterial genome-wide association study (GWAS) that the presence of the phage-derived
gene pblB was associated with mortality in the first 30 days after hospitalization.
Although pblB had been extensively studied in Streptococcus mitis, its consequence on the
interaction between platelets and Streptococcus pneumoniae is largely unknown. Platelets
are important in immunity and inflammation, and excessive platelet activation
contributes to microvascular obstruction and multi-organ failure, leading to mortality. We
therefore developed this study to assess whether the phage-derived pblB might increase
the risk for mortality in IPD patients through its effect on enhanced platelet activation.
This study would also show the value of integrating extensive bacterial genomics and
clinical data in predicting and understanding pathogen virulence, which in turn will help to 
improve prognosis and therapy.
Introduction 
Streptococcus pneumoniae or the pneumococcus is a frequent colonizer of the 
nasopharynx. In a minority of carriers, infection progresses to pneumococcal disease with 
an estimated 1.6 million deaths annually [1, 2]. The largest clinical burden of invasive 
pneumococcal disease (IPD) is seen in young children and older adults, who present 
mostly with sepsis and meningitis. Case mortality rates are estimated to range from 11 to 
30% in adults [3-5], with treatment becoming complicated due to the worldwide 
emergence of multi-drug resistance [6]. Therefore, it is of utmost importance to fully 
understand the pathogenic mechanisms of pneumococcal disease in order to improve 
treatment and prognosis of critically ill patients.  
Recently, the utilization of whole genome sequencing and analyses for predicting and 
understanding pathogen virulence has been highlighted [7]. In this study, we performed a 
genome-wide association analysis (GWAS) on 349 pneumococcal draft genomes of blood 
isolates from patients who were admitted with IPD in two Dutch hospitals. We identified 
a significant association between 30-day mortality and the presence of pblB, encoding for 
a platelet binding protein that was also reported to function in adhesion, which might 
explain clonal success [8]. In a subsequent functional study, we investigated the induction 
of the phage-derived pblB expression by fluoroquinolones in S. pneumoniae. Lastly, we 
simulated the in vivo conditions using an ex vivo whole blood assay demonstrating the 
importance of pblB in enhancing platelet activation. 
Platelets are an important part of the innate immune system, and can interact with and 
be activated by S. pneumoniae. In sepsis, platelet activation and platelet-leukocyte 
complex formation contribute to microvascular obstruction, tissue hypoperfusion and 
finally multi-organ failure [9]. The role of this phage-derived gene in the clinical outcome 
and severity of IPD patients and its consequences for platelet activation warrant further 
study. 
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Results 
PblB is an independent determinant of 30-day mortality in IPD patients 
We conducted an unbiased association study for the presence or absence of genes and 
mortality within the first 30 days of hospitalization (Figure 1). Analysis was performed 
using 349 pneumococcal strains collected from a clinical IPD cohort in Nijmegen which 
comprised of strains from multiple lineages [10]. The overall 30-day mortality within this 
IPD cohort was 11% (37/346, outcome unknown for 3 cases). We observed that out of the 
1946 orthologous genes (OGs) of the pneumococcal accessory genome, the presence of 
the phage-encoded gene pblB (OG_17), was positively associated with 30-day mortality in 
IPD patients (GWAS stratified for population structure with BAPS, p=0.00034 Bonferroni 
corrected for multiple testing) [11]. All the OGs associated with 30-day mortality with 
corrected p-values <0.05 are listed in Table S1. The pblB gene was present in 48% of the 
349 clinical strains and co-occurred with other genes predicted to encode for phage 
components or hypothetical proteins. However, we identified pblB as the phage-derived 
gene having the strongest statistical correlation with 30-day mortality.  
Among the IPD cases caused by pneumococci containing the pblB gene (pblB P+ P), 27 out of 
165 died within 30 days (16.4%), compared to only 10 out of 181 (5.5%) caused by 
pneumococci not containing the pblB gene (pblBP-P) (p=0.0011; OR 3.3). In a sub-analysis of 
cases who died without any limitations of medical treatment, 30-day mortality was 15/165 
(9.1%) in pblB P+ P and 6/171 (3.3%) in pblBP-P cases, which remained statistically significant 
(p=0.022; OR 2.8). For all cases, the presence of pblB was an independent determinant of 
30-day mortality (OR 3.4, 95% CI: 1.5-7.6), next to Charlson comorbidity index score (OR
1.5, 95% CI: 1.2-1.7) and meningitis (OR 4.6, 95% CI: 1.6-13.7). For pneumonia cases
separately, in addition to PSI score (OR 1.4, 95% CI: 1.1-1.7) and Charlson comorbidity
score (OR 1.02, 95% CI: 1.01-1.04), both designed to predict mortality, the presence of
pblB was an independent risk factor for 30-day mortality (OR 3.4, 95% CI: 1.2-9.5).
Fluoroquinolones induced the expression of pblB 
It was unknown whether pblB-containing temperate pneumophages are specifically 
induced by this group of antibiotics in vitro. Therefore, different doses of ciprofloxacin 
(CPX) and levofloxacin (LVX; both belonging to the fluoroquinolone group of antibiotics), 
mitomycin C (MitC) and penicillin G (PenG; a beta-lactam antibiotic) were tested on three 
pblB-containing pneumococcal strains (PBCN0103, PBCN0226, PBCN0239) in THY 
medium to determine the sublethal dose of the four antibiotics (data not shown). To 
confirm that the selected doses were not bactericidal, the number colony forming units 
(CFU) were determined after exposure of MitC, PenG and the fluoroquinolones for two 
hours at 37 °C and 5% COR2 R(Figure 2A). At the same time point, the difference in 
expression of pblB, relative to gyrA, was measured. The DNA cross-linking agent MitC 
was included as positive control. Both the fluoroquinolones CPX and LVX induced the 
expression of pblB, the latter being the strongest inducer, which appeared specific for this
group of antibiotics, as the beta-lactam antibiotic PenG did not induce the expression.
Furthermore, strong variation was found between the different pneumococcal strains
(Figure 2B).
Simulation of the clinical conditions in a whole blood ex vivo assay
Of the 312 patients with sequenced strains and known empirical treatment, 28% (n=88)
received only beta-lactam, 4% (n=11) received only fluoroquinolones, and 44% received a
combination of a beta-lactam and a fluoroquinolone. To simulate the aforementioned
clinical conditions, we incubated live pneumococci strain PBCN0162 containing a
mutationally inactivated pblB gene (∆pblB) or wild type (wt), with and without antibiotics
(PenG, CPX, and a combination of PenG and CFX) in whole blood, determined the
expression of pblB using qPCR (Figure 3A) and measured in the same samples the
activation of platelets. We were able to measure pblB expression of the wt pneumococci
in the whole blood samples without antibiotics and its increase in the presence of
antibiotics (mean CQ value 30.6, 95% confidence interval 29.5-31.7). We first analyzed
whether the different antibiotics significantly affect the wt-/∆pblB-bacteria-mediated
platelet activation state in whole blood using a liner mixed model. We found that in all 
cases, stronger activation of platelets was observed with wt pneumococci as compared to
∆pblB, which clearly indicates that PblB induces enhanced platelet activation irrespective
of the exposure to antibiotics (Figures 3B).
Figure 2. Sublethal doses of antibiotics
induced pneumococcal expression of 
the pblB phage in culture medium.
Average CFU values were determined
after incubation of the three clinical
pneumococcal strains (PBCN0103,
PBCN0226, PBCN0239) for two hours
at 37°C and 5% COR2 Rin THY medium 
with sub-lethal doses of antibiotics;
mitomycin C (MitC), penicillin G
(PenG), ciprofloxacin (CPX) and
levofloxacin (LVX). The condition 
without antibiotics (-) was included as 
negative control (A). Induction of pblB
expression after two hours of
incubation with sub-lethal doses of 
antibiotics were determined by qRT-
PCR measuring levels of mRNA relative
to the control gyrA (B). The data shown
represent the means with standard
deviations of three independently
performed experiments.
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Results
PblB is an independent determinant of 30-day mortality in IPD patients
We conducted an unbiased association study for the presence or absence of genes and
mortality within the first 30 days of hospitalization (Figure 1). Analysis was performed
using 349 pneumococcal strains collected from a clinical IPD cohort in Nijmegen which
comprised of strains from multiple lineages [10]. The overall 30-day mortality within this
IPD cohort was 11% (37/346, outcome unknown for 3 cases). We observed that out of the
1946 orthologous genes (OGs) of the pneumococcal accessory genome, the presence of 
the phage-encoded gene pblB (OG_17), was positively associated with 30-day mortality in
IPD patients (GWAS stratified for population structure with BAPS, p=0.00034 Bonferroni
corrected for multiple testing) [11]. All the OGs associated with 30-day mortality with
corrected p-values <0.05 are listed in Table S1. The pblB gene was present in 48% of the 
349 clinical strains and co-occurred with other genes predicted to encode for phage 
components or hypothetical proteins. However, we identified pblB as the phage-derived
gene having the strongest statistical correlation with 30-day mortality.
Among the IPD cases caused by pneumococci containing the pblB gene (pblB P+ P), 27 out of 
165 died within 30 days (16.4%), compared to only 10 out of 181 (5.5%) caused by
pneumococci not containing the pblB gene (pblBP-P) (p=0.0011; OR 3.3). In a sub-analysis of
cases who died without any limitations of medical treatment, 30-day mortality was 15/165
(9.1%) in pblB P+ P and 6/171 (3.3%) in pblBP-P cases, which remained statistically significant
(p=0.022; OR 2.8). For all cases, the presence of pblB was an independent determinant of
30-day mortality (OR 3.4, 95% CI: 1.5-7.6), next to Charlson comorbidity index score (OR
1.5, 95% CI: 1.2-1.7) and meningitis (OR 4.6, 95% CI: 1.6-13.7). For pneumonia cases
separately, in addition to PSI score (OR 1.4, 95% CI: 1.1-1.7) and Charlson comorbidity
score (OR 1.02, 95% CI: 1.01-1.04), both designed to predict mortality, the presence of
pblB was an independent risk factor for 30-day mortality (OR 3.4, 95% CI: 1.2-9.5). 
Fluoroquinolones induced the expression of pblB
It was unknown whether pblB-containing temperate pneumophages are specifically
induced by this group of antibiotics in vitro. Therefore, different doses of ciprofloxacin
(CPX) and levofloxacin (LVX; both belonging to the fluoroquinolone group of antibiotics),
mitomycin C (MitC) and penicillin G (PenG; a beta-lactam antibiotic) were tested on three
pblB-containing pneumococcal strains (PBCN0103, PBCN0226, PBCN0239) in THY
medium to determine the sublethal dose of the four antibiotics (data not shown). To 
confirm that the selected doses were not bactericidal, the number colony forming units
(CFU) were determined after exposure of MitC, PenG and the fluoroquinolones for two 
hours at 37 °C and 5% COR2 R(Figure 2A). At the same time point, the difference in
expression of pblB, relative to gyrA, was measured. The DNA cross-linking agent MitC
was included as positive control. Both the fluoroquinolones CPX and LVX induced the
expression of pblB, the latter being the strongest inducer, which appeared specific for this 
group of antibiotics, as the beta-lactam antibiotic PenG did not induce the expression. 
Furthermore, strong variation was found between the different pneumococcal strains 
(Figure 2B).  
Simulation of the clinical conditions in a whole blood ex vivo assay 
Of the 312 patients with sequenced strains and known empirical treatment, 28% (n=88) 
received only beta-lactam, 4% (n=11) received only fluoroquinolones, and 44% received a 
combination of a beta-lactam and a fluoroquinolone. To simulate the aforementioned 
clinical conditions, we incubated live pneumococci strain PBCN0162 containing a 
mutationally inactivated pblB gene (∆pblB) or wild type (wt), with and without antibiotics 
(PenG, CPX, and a combination of PenG and CFX) in whole blood, determined the 
expression of pblB using qPCR (Figure 3A) and measured in the same samples the 
activation of platelets. We were able to measure pblB expression of the wt pneumococci 
in the whole blood samples without antibiotics and its increase in the presence of 
antibiotics (mean CQ value 30.6, 95% confidence interval 29.5-31.7). We first analyzed 
whether the different antibiotics significantly affect the wt-/∆pblB-bacteria-mediated 
platelet activation state in whole blood using a liner mixed model. We found that in all 
cases, stronger activation of platelets was observed with wt pneumococci as compared to 
∆pblB, which clearly indicates that PblB induces enhanced platelet activation irrespective 
of the exposure to antibiotics (Figures 3B). 
Figure 2. Sublethal doses of antibiotics 
induced pneumococcal expression of 
the pblB phage in culture medium. 
Average CFU values were determined 
after incubation of the three clinical 
pneumococcal strains (PBCN0103, 
PBCN0226, PBCN0239) for two hours 
at 37°C and 5% COR2 Rin THY medium 
with sub-lethal doses of antibiotics; 
mitomycin C (MitC), penicillin G 
(PenG), ciprofloxacin (CPX) and 
levofloxacin (LVX). The condition 
without antibiotics (-) was included as 
negative control (A). Induction of pblB 
expression after two hours of 
incubation with sub-lethal doses of 
antibiotics were determined by qRT-
PCR measuring levels of mRNA relative 
to the control gyrA (B). The data shown 
represent the means with standard 
deviations of three independently 
performed experiments. 
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Whilst PenG did not strongly induce expression of pblB in THY-medium-grown 
pneumococci (Figure 2B), we observed PenG-dependent induction (∼3-fold) of 
expression in whole blood (Figure 3A). This might be caused by an indirect effect as a 
consequence of the bactericidal effect of PenG leading to the production of reactive 
oxygen species (ROS) which has DNA damaging effects, inducing the expression of pblB. 
Despite the fact that expression of pblB was much stronger in whole blood containing 
CPX, platelet activation is not increased accordingly, indicating a close to maximum 
activation under these conditions 
Figure 3. Live wild type pneumococci in an ex vivo 
whole blood assay showed increased expression of 
pblB upon exposure to fluoroquinolones and 
induced higher platelet activation as compared to 
the pblB knock-out mutant, irrespective of 
antibiotics exposure. Live pneumococci (strain 
PBCN0162) containing a mutationally inactivated 
pblB gene (∆pblB) or wild type (WT pblB) were 
incubated in whole blood in the presence or 
absence (as controls) of antibiotics. After two 
hours of incubation at 37 °C and 5 % COR2R the 
expression of pblB was determined using qRT-PCR 
measuring levels of mRNA relative to the control 
samples. One extreme outlier value, as determined 
by the Grubbs’ test, in the CPX-exposed sample 
was excluded from the figure (A). Platelet 
expression of P-selectin, platelet-fibrinogen 
binding and PMC formation were measured in the 
same samples using flow cytometry and expressed 
in percentage of positivity (B).  Data presented are 
means with 95% confidence interval from three 
independent experiments with blood derived from 
a total of 6 human volunteers. Differences were 
analyzed using a linear mixed model, with the 
Bonferroni correction for multiple testing. p<0.05 
was considered statistically significant. PenG, 
Penicillin G; CPX, ciprofloxacin.  
Discussion
In the present study, GWAS was performed, in an unbiased manner, using the sequences
of 349 S. pneumoniae invasive disease isolates to test for associations between the
presence or absence of genes in the pneumococcal accessory genome and 30-day
mortality.
The presence of the phage-encoded pblB gene was positively associated with 30-day
mortality in patients with IPD. This finding suggested the role of pblB in the pathogenesis
and expected cause of death of IPD. The presence of the pblB phage gene as risk factor
remained after adjustment for the local pneumococcal population structure. We
therefore speculate that similar studies in other areas with different pneumococcal
populations would yield similar findings, although this requires confirmation by other
studies. Interestingly, the pblB phage in our cohort was barely present in serotypes 1 and
7F, which are associated with a lower risk of death than other serotypes [12]. 
Up to 75% of pneumococcal clinical isolates have been shown to carry bacteriophages
(pneumophages) [13], which may be distributed among pneumococcal isolates with
different capsular serotypes, indicating that these mobile genetic elements are widely
spread among clinically relevant pneumococcal strains [14]. The hypothesis that bacteria
acquire virulence properties from phages is widely accepted [15], however, there has
been a paucity of data supporting the role of bacteriophages in the pathogenesis of S.
pneumoniae-caused diseases.
The PblB protein was first characterized in S. mitis as a surface protein encoded by a
lysogenic bacteriophage (SM1) and described to mediate the binding to human platelets
[16]. In S. mitis, induction of the lytic cycle leads to permeabilization of the cell wall with
subsequent release and expression of PblB on the cell surface, allowing the interaction
with and propagation of platelet activation. The expression of PblB in S. mitis was also
found to contribute to virulence in an in vivo rabbit model of infective endocarditis [17]. 
These findings demonstrate that pblB might have an important role in endovascular
infection and recently, PblB was reported to mediate pneumococcal adhesion to platelets
and lung epithelial cells [8]. However, the functional consequences of pblB expression in 
S. pneumoniae and its role in the pathogenesis of pneumococcal disease is largely
unknown.
Most patients in this cohort were treated with a combination of penicillin and
ciprofloxacin, which represents a common first line empiric antibiotic regime for severe
community acquired pneumonia in the Netherlands [18]. We therefore proceeded with ex 
vivo experiments in which live pneumococci were incubated in whole blood
supplemented with penicillin or ciprofloxacin or a combination of the two, to simulate the
clinical conditions. The wild type pneumococci clearly demonstrated enhanced platelet 
activation. Interestingly, there were differences in platelet activation between knock-out 
mutant and wild type pneumococci even in the absence of high pblB induction by the
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Whilst PenG did not strongly induce expression of pblB in THY-medium-grown
pneumococci (Figure 2B), we observed PenG-dependent induction (∼3-fold) of 
expression in whole blood (Figure 3A). This might be caused by an indirect effect as a
consequence of the bactericidal effect of PenG leading to the production of reactive
oxygen species (ROS) which has DNA damaging effects, inducing the expression of pblB. 
Despite the fact that expression of pblB was much stronger in whole blood containing
CPX, platelet activation is not increased accordingly, indicating a close to maximum
activation under these conditions
Figure 3. Live wild type pneumococci in an ex vivo
whole blood assay showed increased expression of
pblB upon exposure to fluoroquinolones and
induced higher platelet activation as compared to 
the pblB knock-out mutant, irrespective of
antibiotics exposure. Live pneumococci (strain
PBCN0162) containing a mutationally inactivated
pblB gene (∆pblB) or wild type (WT pblB) were 
incubated in whole blood in the presence or
absence (as controls) of antibiotics. After two
hours of incubation at 37 °C and 5 % COR2R the
expression of pblB was determined using qRT-PCR 
measuring levels of mRNA relative to the control
samples. One extreme outlier value, as determined
by the Grubbs’ test, in the CPX-exposed sample
was excluded from the figure (A). Platelet
expression of P-selectin, platelet-fibrinogen 
binding and PMC formation were measured in the
same samples using flow cytometry and expressed
in percentage of positivity (B).  Data presented are 
means with 95% confidence interval from three 
independent experiments with blood derived from
a total of 6 human volunteers. Differences were
analyzed using a linear mixed model, with the
Bonferroni correction for multiple testing. p<0.05
was considered statistically significant. PenG,
Penicillin G; CPX, ciprofloxacin.
Discussion 
In the present study, GWAS was performed, in an unbiased manner, using the sequences 
of 349 S. pneumoniae invasive disease isolates to test for associations between the 
presence or absence of genes in the pneumococcal accessory genome and 30-day 
mortality.  
The presence of the phage-encoded pblB gene was positively associated with 30-day 
mortality in patients with IPD. This finding suggested the role of pblB in the pathogenesis 
and expected cause of death of IPD. The presence of the pblB phage gene as risk factor 
remained after adjustment for the local pneumococcal population structure. We 
therefore speculate that similar studies in other areas with different pneumococcal 
populations would yield similar findings, although this requires confirmation by other 
studies.  Interestingly, the pblB phage in our cohort was barely present in serotypes 1 and 
7F, which are associated with a lower risk of death than other serotypes [12].  
Up to 75% of pneumococcal clinical isolates have been shown to carry bacteriophages 
(pneumophages) [13], which may be distributed among pneumococcal isolates with 
different capsular serotypes, indicating that these mobile genetic elements are widely 
spread among clinically relevant pneumococcal strains [14]. The hypothesis that bacteria 
acquire virulence properties from phages is widely accepted [15], however, there has 
been a paucity of data supporting the role of bacteriophages in the pathogenesis of S. 
pneumoniae-caused diseases. 
The PblB protein was first characterized in S. mitis as a surface protein encoded by a 
lysogenic bacteriophage (SM1) and described to mediate the binding to human platelets 
[16]. In S. mitis, induction of the lytic cycle leads to permeabilization of the cell wall with 
subsequent release and expression of PblB on the cell surface, allowing the interaction 
with and propagation of platelet activation. The expression of PblB in S. mitis was also 
found to contribute to virulence in an in vivo rabbit model of infective endocarditis [17]. 
These findings demonstrate that pblB might have an important role in endovascular 
infection and recently, PblB was reported to mediate pneumococcal adhesion to platelets 
and lung epithelial cells [8]. However, the functional consequences of pblB expression in 
S. pneumoniae and its role in the pathogenesis of pneumococcal disease is largely
unknown. 
Most patients in this cohort were treated with a combination of penicillin and 
ciprofloxacin, which represents a common first line empiric antibiotic regime for severe 
community acquired pneumonia in the Netherlands [18]. We therefore proceeded with ex 
vivo experiments in which live pneumococci were incubated in whole blood 
supplemented with penicillin or ciprofloxacin or a combination of the two, to simulate the 
clinical conditions. The wild type pneumococci clearly demonstrated enhanced platelet 
activation. Interestingly, there were differences in platelet activation between knock-out 
mutant and wild type pneumococci even in the absence of high pblB induction by the 
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antibiotics. This may be explained by a constitutive expression of pblB, which despite its 
low level was sufficient to induce platelet activation, as had been described in S. mitis [17].  
S. pneumoniae has been shown to directly activate platelets mainly through TLR2 [19],
with FcγRIIA and integrin αIIbβ3 being involved in the amplification of bacteria-
induced platelet activation [20]. This leads to platelet degranulation and subsequently the
release of an array of chemokines and inflammatory mediators which may modulate not
only their own function but also cells around them [21, 22]. Our findings that whole blood
exposure to WT pneumococci result in higher platelet activation compared to the pblB 
knock-out mutant may explain why bacteremic patients, infected with pneumococci
containing the pblB gene, have a higher chance to die within 30 days. An approximate of
20% increase from baseline values in platelet P-selectin expression and PMC has been
associated with adverse cardiovascular events and the acute phase of ischaemic stroke
[23, 24]. The increase in platelet activation associated with pblB in our ex vivo assays 
exceeded this aforementioned value. By causing enhanced platelet activation, bacteria
can become engulfed in a septic thrombus and protected from other cells of the immune 
system, allowing them to persist in the circulation [25]. We speculate that the pblB-
enhanced platelet activation may confer this survival advantage for S. pneumoniae. On
the other hand, the resulting excess of platelet activation together with platelet
clumping, platelet-leukocyte and platelet-endothelium aggregation and increased fibrin
formation result in enhanced thrombo-inflammatory responses, microvascular
obstruction, tissue hypoperfusion and finally multi-organ failure in sepsis [26, 27]. The
increase of PMC formation predicts mortality in older septic patients [28], and platelet
consumption associated with platelet activation in sepsis patients leads to
thrombocytopenia, which has been shown to increase the risk of mortality [29-31].
Our results have several potential clinical implications. Firstly, that pblB is associated with 
30-day mortality suggests the potential of bacterial GWAS for improvement of clinical
management of IPD patients. Secondly, our results demonstrated that fluoroquinolones
induce higher pblB expression. However, the presence of fluoroquinolones was not
required by the pblB-expressing wild type pneumococci to enhance platelet activation
when compared with the knock-out mutant. Given that fluoroquinolones are frequently
used in the management of community-acquired pneumonia for the coverage of atypical
pathogens [32], sufficiently-powered studies are needed to investigate the clinical
outcomes of the interplay between antibiotics regimen and pblB before drawing any
conclusions. Thirdly, our study further highlights the importance of platelet-bacterial 
interaction and platelet activation, both in providing a survival advantage for bacteria and
in posing increased risk of mortality in patients. There is more and more data on the use 
of platelet function inhibitors in sepsis, however, these results at times contradict [9]. 
Platelet inhibition by the P2YR12 Rreceptor antagonists reduces the release of pro-
inflammatory mediators from the platelet α-granules [33]. Taken together with our 
findings, the role of anti-platelet agents as adjunctive therapy in sepsis warrants further
investigation. To the best of our knowledge, this is the only patient-based study which
independently and in an unbiased manner reveal the role of pblB in the pathogenesis of
IPD based on a vast analysis of both genomics and clinical data, adding substantial
evidence to only two recent studies on pneumococcal pblB in vitro and in mice [8, 34].  
In conclusion, we have integrated genome sequencing and GWAS with functional 
characterization to investigate the clinical role of pblB in the mortality of patients with
IPD. Bacterial GWAS may be an important tool to study the potential predictive value of
certain virulence genes. As genomic sequencing is increasingly being utilized, we believe 
that this integrated approach will assist greatly in elucidating the mechanisms of bacterial
pathogenesis leading to the development of novel diagnostics and new therapeutic
approaches.
Materials and Methods
Study population
Consecutive patients hospitalized with a bacteremic pneumococcal infection at two 
Dutch hospitals between 2001 and 2011 were included in the study. Detailed clinical data
were obtained on patient characteristics, clinical severity, treatment and the course of
disease. Corresponding blood culture isolates of S. pneumoniae were collected and
serotyped as described before [10]. For 349 of the isolated strains, sequencing, assembly
of draft genomes and annotation was determined as previously described [35]. This study
was reviewed and approved by the Local Medical Ethical Committees. All adult patients
and healthy volunteers involved in this study provided written informed consent.
Orthologous clustering and GWAS
Orthologous genes (OGs) from S. pneumoniae used in this study have previously been
described by our group [35]. Putative protein coding sequences were investigated using
an “all-versus-all” protein BLAST (blastP), with a 10e-15 e-value cut-off and a BLOSUM90
substitution matrix. The results were subsequently clustered into clusters of orthologous
groups using TribeMCL [35, 36], resulting into a total of 3021 orthologous genes (OGs),
1075 of which were conserved in all isolates in a single copy. The population (sub)-
structure (sequence clusters; SCs) used for population stratification in the study have also 
been previously characterized [35]. Basing disease severity on mortality within the first 30
days of admission to the hospital, the pneumococcal isolates were categorized into three
categories: derived from patients who died (n=37), from patients who survived (n=309),
and from patients of whom the data was not captured (n=3). The Cochran-Mantel-
Haenszel (CMH) association statistics was employed to test the associations between the
presence or absence of pneumococcal OGs and 30-day mortality, conditional on the
bacterial population substructure as proposed by BAPS [11]. All associations were
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antibiotics. This may be explained by a constitutive expression of pblB, which despite its
low level was sufficient to induce platelet activation, as had been described in S. mitis [17]. 
S. pneumoniae has been shown to directly activate platelets mainly through TLR2 [19], 
with FcγRIIA and integrin αIIbβ3 being involved in the amplification of bacteria-
induced platelet activation [20]. This leads to platelet degranulation and subsequently the 
release of an array of chemokines and inflammatory mediators which may modulate not 
only their own function but also cells around them [21, 22]. Our findings that whole blood
exposure to WT pneumococci result in higher platelet activation compared to the pblB
knock-out mutant may explain why bacteremic patients, infected with pneumococci 
containing the pblB gene, have a higher chance to die within 30 days. An approximate of
20% increase from baseline values in platelet P-selectin expression and PMC has been
associated with adverse cardiovascular events and the acute phase of ischaemic stroke 
[23, 24]. The increase in platelet activation associated with pblB in our ex vivo assays
exceeded this aforementioned value. By causing enhanced platelet activation, bacteria
can become engulfed in a septic thrombus and protected from other cells of the immune 
system, allowing them to persist in the circulation [25]. We speculate that the pblB-
enhanced platelet activation may confer this survival advantage for S. pneumoniae. On 
the other hand, the resulting excess of platelet activation together with platelet 
clumping, platelet-leukocyte and platelet-endothelium aggregation and increased fibrin
formation result in enhanced thrombo-inflammatory responses, microvascular
obstruction, tissue hypoperfusion and finally multi-organ failure in sepsis [26, 27]. The 
increase of PMC formation predicts mortality in older septic patients [28], and platelet 
consumption associated with platelet activation in sepsis patients leads to 
thrombocytopenia, which has been shown to increase the risk of mortality [29-31]. 
Our results have several potential clinical implications. Firstly, that pblB is associated with
30-day mortality suggests the potential of bacterial GWAS for improvement of clinical
management of IPD patients. Secondly, our results demonstrated that fluoroquinolones
induce higher pblB expression. However, the presence of fluoroquinolones was not
required by the pblB-expressing wild type pneumococci to enhance platelet activation
when compared with the knock-out mutant. Given that fluoroquinolones are frequently
used in the management of community-acquired pneumonia for the coverage of atypical 
pathogens [32], sufficiently-powered studies are needed to investigate the clinical
outcomes of the interplay between antibiotics regimen and pblB before drawing any
conclusions. Thirdly, our study further highlights the importance of platelet-bacterial
interaction and platelet activation, both in providing a survival advantage for bacteria and
in posing increased risk of mortality in patients. There is more and more data on the use 
of platelet function inhibitors in sepsis, however, these results at times contradict [9]. 
Platelet inhibition by the P2YR12 Rreceptor antagonists reduces the release of pro-
inflammatory mediators from the platelet α-granules [33]. Taken together with our 
findings, the role of anti-platelet agents as adjunctive therapy in sepsis warrants further 
investigation. To the best of our knowledge, this is the only patient-based study which
independently and in an unbiased manner reveal the role of pblB in the pathogenesis of 
IPD based on a vast analysis of both genomics and clinical data, adding substantial 
evidence to only two recent studies on pneumococcal pblB in vitro and in mice [8, 34].   
In conclusion, we have integrated genome sequencing and GWAS with functional 
characterization to investigate the clinical role of pblB in the mortality of patients with 
IPD. Bacterial GWAS may be an important tool to study the potential predictive value of 
certain virulence genes. As genomic sequencing is increasingly being utilized, we believe 
that this integrated approach will assist greatly in elucidating the mechanisms of bacterial 
pathogenesis leading to the development of novel diagnostics and new therapeutic 
approaches. 
Materials and Methods 
Study population 
Consecutive patients hospitalized with a bacteremic pneumococcal infection at two 
Dutch hospitals between 2001 and 2011 were included in the study. Detailed clinical data 
were obtained on patient characteristics, clinical severity, treatment and the course of 
disease. Corresponding blood culture isolates of S. pneumoniae were collected and 
serotyped as described before [10]. For 349 of the isolated strains, sequencing, assembly 
of draft genomes and annotation was determined as previously described [35]. This study 
was reviewed and approved by the Local Medical Ethical Committees. All adult patients 
and healthy volunteers involved in this study provided written informed consent. 
Orthologous clustering and GWAS 
Orthologous genes (OGs) from S. pneumoniae used in this study have previously been 
described by our group [35]. Putative protein coding sequences were investigated using 
an “all-versus-all” protein BLAST (blastP), with a 10e-15 e-value cut-off and a BLOSUM90 
substitution matrix. The results were subsequently clustered into clusters of orthologous 
groups using TribeMCL [35, 36], resulting into a total of 3021 orthologous genes (OGs), 
1075 of which were conserved in all isolates in a single copy. The population (sub)-
structure (sequence clusters; SCs) used for population stratification in the study have also 
been previously characterized [35]. Basing disease severity on mortality within the first 30 
days of admission to the hospital, the pneumococcal isolates were categorized into three 
categories: derived from patients who died (n=37), from patients who survived (n=309), 
and from patients of whom the data was not captured (n=3). The Cochran-Mantel-
Haenszel (CMH) association statistics was employed to test the associations between the 
presence or absence of pneumococcal OGs and 30-day mortality, conditional on the 
bacterial population substructure as proposed by BAPS [11]. All associations were 
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determined using PLINK [37]. Candidate OGs were selected based on association test 
with p <0.05 (Bonferroni adjusted for multiple testing). 
Adjustment for covariates of mortality 
Certain patients had predetermined limitations of medical treatments, for example, 
opted not to be transferred to the intensive care unit. Therefore, the relation between 
OGs and 30-day mortality was also established separately for those who died after fully-
applied treatment. Potentially interesting covariates of 30-day mortality, in addition to 
the pneumococcal OG, were selected by their distribution in relation to 30-day mortality. 
The variables considered were gender, age, year of inclusion, comorbidities (i.e. cancer, 
COPD, diabetes mellitus, liver-, renal-, cardiovascular- and cerebrovascular disease, 
Charlson comorbidity index score), clinical diagnosis, blood C-reactive protein level, 
presence of Systemic Inflammatory Response Syndrome (SIRS) and pleural effusion, 
Pneumonia Severity Index (PSI) score, and class of antibiotics administered. The final 
model for 30-day mortality as a dependent variable was constructed via binary logistic 
regression analysis by likelihood ratio based backward modeling, entering the 
pneumococcal OG plus identified possible covariates as explaining variables. Analyses of 
covariates were performed using IBM SPSS statistics 23. 
Induction of pblB expression by antibiotics 
Three isolates derived from the group of deceased patients, containing the pblB gene, 
were selected: PBCN0103, PBCN0226 and PBCN0239. Different concentrations of 
mitomycin C, penicillin G, ciprofloxacin and levofloxacin (all purchased from Sigma-
Aldrich, Zwijndrecht, The Netherlands) were tested to determine the sub-lethal doses. 
The pneumococci were grown in THY medium to midlog (OD 0.3), then diluted to OD 0.1, 
supplemented with 0.132 µg/ml mitomycin C, 0.0125 µg/ml penicillin G, 0.533 µg/ml 
ciprofloxacin or 0.533 µg/ml levofloxacin, and grown for an additional two hours at 37°C 
with 5% COR2R. Subsequently, serial dilutions were incubated on blood agar plates (BD) and 
incubated overnight at 37°C with 5% COR2R. Experiments were performed in triplicate to 
determine the expression of pblB. Mitomycin C was included as positive control, as it was 
previously shown to induce pblB expression [38]. Penicillin G was included as negative 
control. After two hours of growth, pneumococci were harvested by centrifugation. The 
supernatant was discarded and a 2:1 volume of RNA protect (Qiagen, Hilden, Germany) 
was added to the pellet. RNA was isolated using the RNeasy kit (Qiagen, Hilden, 
Germany), following the manufacturer’s instructions. Residual DNA was removed with a 
DNAse treatment using the Ambion Turbo DNA-free kit according to manufacturer’s 
instructions (Ambion, Austin, TX, USA). The qRT-PCR was performed as previously 
described by DeBardeleben et al. [38] using the following primers: HBgyrAF: 
AATGAACGGGAACCCTTGGT, HBgyrAR: CCATCCCAACCGCGATAC, pblB_F: 
TACAGCTGTGAAAGCCTTGG, pblB_R: GATAGCCATCTGGATTCTCAGG. 
Construction of S. pneumoniae strain PBCN0162ΔpblB
A directed gene deletion mutant of S. pneumoniae strain PBCN0162 was generated by
allelic exchange of the target gene (pblB) with a spectinomycin resistance cassette
(obtained from pR412T7), using the megaprimer polymerase chain reaction method, this
resulted in PBCN0162ΔpblB. Briefly, flanking regions of ∼500 bp, containing less than 150
bp of the coding sequence of the target genes, were amplified by PCR, with chromosomal
DNA as the template. For each flanking region, the primer closest to the target gene 
(extension plus _L2 or _R2) contained an additional sequence complementary to primer
PBpR412_L or PBpR412_R. In a second PCR, the PCR products of the two flanking regions
and the antibiotic resistance cassette were combined, leading to incorporation of the
antibiotic resistance cassette between the two flanking regions of the target gene, as
previously described by Burghout et al., 2007 [39]. The primer sequences are provided in
Table S1 in the supplemental material. Subsequently, the megaprimer PCR product was
used for transformation of competent PBCN0162. Mutants, selected on blood agar plates
containing spectinomycin, were assessed by colony PCR for recombination at the desired
location on the chromosome. Chromosomal DNA was isolated from the mutants and
used for transformation of competent strain PBCN0162. Gene inactivation was confirmed
by quantitative real-time PCR gene expression analyses as described above (see 
‘Induction of pblB expression by antibiotics’).
Ex vivo (whole blood) assays
Whole blood was obtained from healthy volunteers (n=6) after informed consent using
3.2% citrate-anticoagulated tubes (BD Vacutainer, Becton Dickinson, Plymouth, UK) and
exposed to 1x10 P7P CFU/ml ∆pblB or wt pneumococci for 30 minutes at 37°C. Subsequently,
either medium, penG (0.0125 ug/ml), CPX (0.533 ug/ml), or a combination of penG and
CPX were added, and samples were incubated for 2 hrs at 37°C. RNA isolation and qRT-
PCR was performed as described in the previous section. These whole blood samples
were also collected for measurement of platelet activation and PMC by flow cytometry.
Measurement of platelet activation and platelet-monocyte (PMC) complex formation
by flow cytometry
Platelet activation was measured by whole blood flow cytometry as previously described 
[40] by quantifying the platelet membrane expression of the α-granule protein P-selectin
(CD62P) and the binding of fibrinogen to the activated αIIbβ3 receptor (GPIIbIIIa
complex). The following antibodies were used to incubate samples from the whole blood 
ex vivo assay: PE-labelled anti-CD62P (Bio-Legend, San Diego, CA, USA), FITC-labelled
anti-fibrinogen (F0111-FITC; DAKO Ltd., High Wycombe, UK) and PC7-labelled anti-CD61 
(platelet glycoprotein IIIa, Beckman Coulter, Miami, FL, USA), the latter as platelet
identification marker. The percentage of CD62P and fibrinogen on CD61-positive events
were determined. Formation of PMC was measured by incubating samples with PC7-
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determined using PLINK [37]. Candidate OGs were selected based on association test
with p <0.05 (Bonferroni adjusted for multiple testing).
Adjustment for covariates of mortality
Certain patients had predetermined limitations of medical treatments, for example,
opted not to be transferred to the intensive care unit. Therefore, the relation between
OGs and 30-day mortality was also established separately for those who died after fully-
applied treatment. Potentially interesting covariates of 30-day mortality, in addition to 
the pneumococcal OG, were selected by their distribution in relation to 30-day mortality.
The variables considered were gender, age, year of inclusion, comorbidities (i.e. cancer,
COPD, diabetes mellitus, liver-, renal-, cardiovascular- and cerebrovascular disease,
Charlson comorbidity index score), clinical diagnosis, blood C-reactive protein level,
presence of Systemic Inflammatory Response Syndrome (SIRS) and pleural effusion,
Pneumonia Severity Index (PSI) score, and class of antibiotics administered. The final
model for 30-day mortality as a dependent variable was constructed via binary logistic
regression analysis by likelihood ratio based backward modeling, entering the
pneumococcal OG plus identified possible covariates as explaining variables. Analyses of
covariates were performed using IBM SPSS statistics 23.
Induction of pblB expression by antibiotics
Three isolates derived from the group of deceased patients, containing the pblB gene,
were selected: PBCN0103, PBCN0226 and PBCN0239. Different concentrations of
mitomycin C, penicillin G, ciprofloxacin and levofloxacin (all purchased from Sigma-
Aldrich, Zwijndrecht, The Netherlands) were tested to determine the sub-lethal doses.
The pneumococci were grown in THY medium to midlog (OD 0.3), then diluted to OD 0.1,
supplemented with 0.132 µg/ml mitomycin C, 0.0125 µg/ml penicillin G, 0.533 µg/ml 
ciprofloxacin or 0.533 µg/ml levofloxacin, and grown for an additional two hours at 37°C
with 5% COR2R. Subsequently, serial dilutions were incubated on blood agar plates (BD) and
incubated overnight at 37°C with 5% COR2R. Experiments were performed in triplicate to
determine the expression of pblB. Mitomycin C was included as positive control, as it was
previously shown to induce pblB expression [38]. Penicillin G was included as negative
control. After two hours of growth, pneumococci were harvested by centrifugation. The 
supernatant was discarded and a 2:1 volume of RNA protect (Qiagen, Hilden, Germany)
was added to the pellet. RNA was isolated using the RNeasy kit (Qiagen, Hilden,
Germany), following the manufacturer’s instructions. Residual DNA was removed with a
DNAse treatment using the Ambion Turbo DNA-free kit according to manufacturer’s
instructions (Ambion, Austin, TX, USA). The qRT-PCR was performed as previously
described by DeBardeleben et al. [38] using the following primers: HBgyrAF:
AATGAACGGGAACCCTTGGT, HBgyrAR: CCATCCCAACCGCGATAC, pblB_F:
TACAGCTGTGAAAGCCTTGG, pblB_R: GATAGCCATCTGGATTCTCAGG.
Construction of S. pneumoniae strain PBCN0162ΔpblB 
A directed gene deletion mutant of S. pneumoniae strain PBCN0162 was generated by 
allelic exchange of the target gene (pblB) with a spectinomycin resistance cassette 
(obtained from pR412T7), using the megaprimer polymerase chain reaction method, this 
resulted in PBCN0162ΔpblB. Briefly, flanking regions of ∼500 bp, containing less than 150 
bp of the coding sequence of the target genes, were amplified by PCR, with chromosomal 
DNA as the template. For each flanking region, the primer closest to the target gene 
(extension plus _L2 or _R2) contained an additional sequence complementary to primer 
PBpR412_L or PBpR412_R. In a second PCR, the PCR products of the two flanking regions 
and the antibiotic resistance cassette were combined, leading to incorporation of the 
antibiotic resistance cassette between the two flanking regions of the target gene, as 
previously described by Burghout et al., 2007 [39]. The primer sequences are provided in 
Table S1 in the supplemental material. Subsequently, the megaprimer PCR product was 
used for transformation of competent PBCN0162. Mutants, selected on blood agar plates 
containing spectinomycin, were assessed by colony PCR for recombination at the desired 
location on the chromosome. Chromosomal DNA was isolated from the mutants and 
used for transformation of competent strain PBCN0162. Gene inactivation was confirmed 
by quantitative real-time PCR gene expression analyses as described above (see 
‘Induction of pblB expression by antibiotics’). 
Ex vivo (whole blood) assays 
Whole blood was obtained from healthy volunteers (n=6) after informed consent using 
3.2% citrate-anticoagulated tubes (BD Vacutainer, Becton Dickinson, Plymouth, UK) and 
exposed to 1x10 P7P CFU/ml ∆pblB or wt pneumococci for 30 minutes at 37°C. Subsequently, 
either medium, penG (0.0125 ug/ml), CPX (0.533 ug/ml), or a combination of penG and 
CPX were added, and samples were incubated for 2 hrs at 37°C. RNA isolation and qRT-
PCR was performed as described in the previous section. These whole blood samples 
were also collected for measurement of platelet activation and PMC by flow cytometry. 
Measurement of platelet activation and platelet-monocyte (PMC) complex formation 
by flow cytometry 
Platelet activation was measured by whole blood flow cytometry as previously described 
[40] by quantifying the platelet membrane expression of the α-granule protein P-selectin
(CD62P) and the binding of fibrinogen to the activated αIIbβ3 receptor (GPIIbIIIa 
complex). The following antibodies were used to incubate samples from the whole blood 
ex vivo assay: PE-labelled anti-CD62P (Bio-Legend, San Diego, CA, USA), FITC-labelled
anti-fibrinogen (F0111-FITC; DAKO Ltd., High Wycombe, UK) and PC7-labelled anti-CD61 
(platelet glycoprotein IIIa, Beckman Coulter, Miami, FL, USA), the latter as platelet
identification marker. The percentage of CD62P and fibrinogen on CD61-positive events
were determined. Formation of PMC was measured by incubating samples with PC7-
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labelled anti-CD61 and PE-labelled anti-CD14 (a-glycosylphosphatidylinositol (GPI)-linked 
membrane glycoprotein; Bio-Legend). After 20 min incubation, Optilyse B (Beckman 
Coulter, Fullerton CA, USA) was added to lyse erythrocytes. PMC formation was 
determined by quantifying the MFI of CD14+ cells that were also positive for the platelet 
identification marker CD61. All samples were measured using a FC500 flow cytometer 
(Beckman Coulter). 
Statistical Analyses 
Results from independent experiments (involving n = 6 donors) were pooled, data are 
provided as means with 95% confidence interval. For data from the ex vivo whole blood 
assay, we used a linear mixed model approach to analyze the effects of the interaction 
between bacterial exposure and the different antibiotics on platelet activation (SPSS, 
Chicago IL, USA). The level of significance was set at p<0.05. 
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Streptococcus pneumoniae (the pneumococcus) asymptomatically colonizes the
nasopharynx of healthy carriers but, can transition into a significant respiratory tract 
pathogen that is a major cause of global morbidity and mortality. The world health
organization estimates that around 1.6 million people die each year worldwide from
pneumococcal infections [1]. This burden of invasive pneumococcal disease (IPD)
necessitates our constant attention. Imprudent use of antibiotics to manage IPD has led
to the development and spread of multidrug resistance, thus demanding a search for 
novel antimicrobial drugs. Preventive interventions with pneumococcal conjugate
vaccines (PCV) have reduced episodes of pneumococcal infections caused by covered
vaccine serotypes [2, 3]. However, due to their limited serotype coverage, PCVs also have 
triggered rapid serotype replacement of vaccine serotypes with non-vaccine serotypes [4, 
5]. Recombination events in the capsular loci may give rise to novel ‘capsule switched’
lineages capable of vaccine-escape [6, 7]. As a result, there is a need for continued
surveillance after vaccine introduction to fully understand their impact on pneumococcal 
populations. Over the past years, our knowledge of high-throughput sequencing
technologies and their applications in pneumococcal microbiology has steadily advanced.
The aim of this thesis was to further our comprehension of the etiology and epidemiology
of S. pneumoniae using in silico analyses combined with in vivo and in vitro assays. We
performed in-depth studies on genomes of relevant pneumococcal isolates and
corresponding clinical metadata to better understand their population genomics, and
relate their genetic profiles as well as genotypic diversity with: (i) causation of IPD, (ii)
clinical manifestation of pneumococcal disease and (iii) antibiotic resistance.
Furthermore, we studied the possibility of finding novel antibiotics that target the
pneumococcus as well as Haemophilus influenzae and Moraxella catarrhalis, which 
together with the S. pneumoniae constitute the major bacterial causes of respiratory tract 
infections. This chapter summarizes the findings of our studies and discusses their
allusions in the light of the current state of literature and future healthcare and research
applications.
High throughput discovery of potential drug targets
“A post-antibiotic era means, in effect, an end to modern medicine as we know it.” Dr. 
Margaret Chan [8]
The specter of antibiotic resistance is not a new phenomenon. The founder of antibiotics,
Sir Alexander Fleming, had observed that exposing microbes to penicillin concentrations
not sufficient to kill them lead to resistance. In his 1945 Nobel Prize winner's lecture [9] he 
said: “It is not difficult to make microbes resistant to penicillin in the laboratory by
exposing them to concentrations not sufficient to kill them, and the same thing has
occasionally happened in the body. The time may come when penicillin can be bought by
anyone in the shops. Then there is the danger that the ignorant man may easily
underdose himself and by exposing his microbes to non-lethal quantities of the drug
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Streptococcus pneumoniae (the pneumococcus) asymptomatically colonizes the 
nasopharynx of healthy carriers but, can transition into a significant respiratory tract 
pathogen that is a major cause of global morbidity and mortality. The world health 
organization estimates that around 1.6 million people die each year worldwide from 
pneumococcal infections [1]. This burden of invasive pneumococcal disease (IPD) 
necessitates our constant attention. Imprudent use of antibiotics to manage IPD has led 
to the development and spread of multidrug resistance, thus demanding a search for 
novel antimicrobial drugs. Preventive interventions with pneumococcal conjugate 
vaccines (PCV) have reduced episodes of pneumococcal infections caused by covered 
vaccine serotypes [2, 3]. However, due to their limited serotype coverage, PCVs also have 
triggered rapid serotype replacement of vaccine serotypes with non-vaccine serotypes [4, 
5]. Recombination events in the capsular loci may give rise to novel ‘capsule switched’ 
lineages capable of vaccine-escape [6, 7]. As a result, there is a need for continued 
surveillance after vaccine introduction to fully understand their impact on pneumococcal 
populations. Over the past years, our knowledge of high-throughput sequencing 
technologies and their applications in pneumococcal microbiology has steadily advanced. 
The aim of this thesis was to further our comprehension of the etiology and epidemiology 
of S. pneumoniae using in silico analyses combined with in vivo and in vitro assays. We 
performed in-depth studies on genomes of relevant pneumococcal isolates and 
corresponding clinical metadata to better understand their population genomics, and 
relate their genetic profiles as well as genotypic diversity with: (i) causation of IPD, (ii) 
clinical manifestation of pneumococcal disease and (iii) antibiotic resistance. 
Furthermore, we studied the possibility of finding novel antibiotics that target the 
pneumococcus as well as Haemophilus influenzae and Moraxella catarrhalis, which 
together with the S. pneumoniae constitute the major bacterial causes of respiratory tract 
infections. This chapter summarizes the findings of our studies and discusses their 
allusions in the light of the current state of literature and future healthcare and research 
applications. 
High throughput discovery of potential drug targets 
“A post-antibiotic era means, in effect, an end to modern medicine as we know it.” Dr. 
Margaret Chan [8] 
The specter of antibiotic resistance is not a new phenomenon. The founder of antibiotics, 
Sir Alexander Fleming, had observed that exposing microbes to penicillin concentrations 
not sufficient to kill them lead to resistance. In his 1945 Nobel Prize winner's lecture [9] he 
said: “It is not difficult to make microbes resistant to penicillin in the laboratory by 
exposing them to concentrations not sufficient to kill them, and the same thing has 
occasionally happened in the body. The time may come when penicillin can be bought by 
anyone in the shops. Then there is the danger that the ignorant man may easily 
underdose himself and by exposing his microbes to non-lethal quantities of the drug 
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make them resistant.” True to his word, antimicrobial resistance is inexorably on the rise 
and it is already threatening most if not all first-line antimicrobials including penicillin [10-
13]. The inevitable spread could reverse decades of medical progress and enfeeble 
healthcare systems globally. Unless action is taken, experts are warning of a “post-
antibiotic era [8]” when simple, currently treatable infections, will once again kill 
unabated. Thus far, antibiotic resistance has been counteracted by administering a 
combination of antibiotics, and by chemically modifying current antibiotics or isolating 
derivatives that are less easily degraded or extruded by the bacteria. While antibiotic 
resistance is common in most pathogenic bacteria, resistant S. pneumoniae are 
particularly rampant that in approximately thirty percent of severe IPD cases in the USA, 
the bacterium is fully resistant to one or more clinically relevant antibiotics [14]. 
Additionally, the pneumococcus is a highly recombinogenic and competent bacteria that 
readily takes up resistance-conferring DNA fragments [15], and can adjust its 
transformation rates in response to various environmental stimuli, including vaccines and 
antibiotics [7, 15, 16]. To curb resistance and effectively manage IPD, development of new 
classes of antimicrobials is necessary. Identification of genes essential for bacterial 
growth and viability is prerequisite to discovery of molecular targets upon which drugs 
could subsequently be developed. Next generation sequencing technologies have 
granted access to higher levels of genome organization making it easier to identify gene 
function and potentially essential genes. 
In Chapter 3, we explore a proof-of-concept study for the discovery of essential genes in 
the pneumococcus which form promising molecular targets upon which antimicrobial 
drugs could be developed. We employed various in vitro and in silico analyses to address 
caveats in traditional drug discovery pipelines that hamper speed and precision. 
Identification of essential genes is a prerequisite to the discovery of drug target. This 
process customarily relied on rigorous analysis of fitness defects of single mutants 
through appropriate in vitro or in vivo conditions with techniques that were far from high-
throughput. Signature Tagged Mutagenesis; STM marked the first step towards high-
throughput screening for essential genes [17]. In STM, single mutants in a pool of up to 96 
tagged mutants are screened before and after a conditional challenge by detecting 
mutant-specific DNA tags using southern hybridization. STM, owing to the DNA tag, is 
highly specific but could only screen a few mutants at a time. The advent of microarray-
based methods like Genomic Array Footprinting; GAF and Transposon Site Hybridization; 
TraSH [18-20] further improved on the throughput but, these methods were prone to low 
resolution and inaccurate results due to cross-hybridization, impreciseness of locating the 
insertion site, and inherent drawbacks of the microarray platform such as skewed signals.  
With the recently developed technologies like Tn-seq [21], TraDIS [22], INSeq [23], and 
HITS [24] that rely on high-throughput sequencing of transposon insertion sites, 
transposon mutant libraries can now be screened at higher resolutions in tracking 
insertion sites. We exploited an integrative approach that uses genome-wide transposon 
mutagenesis, high-throughput transposon sequencing and analysis with the Tn-seq 
schema [21] implemented in the ESSENTIALS pipeline [25], and comparative genomics;
to discover essential genes and prioritize drug targets in certain strains of Streptococcus
pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis: these are the most
prevalent bacteria that cause respiratory tract infections; RTI [26]. This approach explores
the exhaustive power of transposon insertions sequencing (Tn-seq) complemented with
in silico tracking to rapidly identify essential genes. Like in previous essentiality screens, it
was observed that approximately 20% of all genes in these species are essential to
growth and viability. Candidate essential genes were further subjected to a comparative 
selection criterion to identify a subset of 249 potential target proteins that have no
homologues in the human host and human microbiota. This subset constituted of 67
genes that are verified target to 75 FDA-approved antimicrobial and 35 other small 
molecule inhibitors. The capacity to identify some verity was likely to increase confidence
in moving these targets into drug development. In that respect, we experimentally
validated the inhibition of bacterial growth using commercially available small-molecule 
inhibitors of four novel targets using Kirby-Bauer disk diffusion susceptibility test [27]. 
This approach relied on literature for known inhibitors and assumed that the inhibitor
molecule did not target alternative pathways to cause the lethal phenotype. Therefore, it 
was not unequivocally conclusive on the inhibited function. Nonetheless, the small-scale
laboratory assays we performed have provided leads on which analogous active
compound could be synthesized and optimized. We further tested for the toxicity of
these inhibitors on human cell-lines and computed their effective inhibitory
concentrations. This approach addresses issues that hamper accurate and fast discovery
of drug targets, and could speed up the process of rational drug design.
High throughput genome sequencing and computational approaches are already used as
an addendum to circumvent the tedious laboratory screens conventionally used to screen
for essential genes and prioritize drug targets [28-32]. As reviewed in Chapter 2, 
transposon insertion sequencing methods, including Tn-seq, show a remarkable degree 
of accuracy and sensitivity in predicting gene essentiality. Nonetheless, for these
methods to be reliable, they demand saturated mutant libraries and precise deep
sequencing making them costly and laborious. This was evident in the number of
essential genes we identified in each strain relative to the corresponding transposon
mutant libraries. The more saturated libraries of S. pneumoniae R6 and TIGR4 strains led
to a small but perhaps more accurate set of essential genes; 325 and 414 respectively.
These were expected to contain less false positives as compared with H. influenzae 86-
028NP which had 532 essential genes from a mutant library that was less saturated.
Other ab initio computational approaches developed to predict essential genes and drug
targets are feeble in terms of predicting conditionally essential genes, scaling to different
organisms or experimental conditions, and they often require seed biological or
biophysicochemical information which is difficult to obtain [33, 34]. Experimental
validation of gene function in also expected. This was traditionally achieved by gene-
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make them resistant.” True to his word, antimicrobial resistance is inexorably on the rise 
and it is already threatening most if not all first-line antimicrobials including penicillin [10-
13]. The inevitable spread could reverse decades of medical progress and enfeeble 
healthcare systems globally. Unless action is taken, experts are warning of a “post-
antibiotic era [8]” when simple, currently treatable infections, will once again kill 
unabated. Thus far, antibiotic resistance has been counteracted by administering a 
combination of antibiotics, and by chemically modifying current antibiotics or isolating 
derivatives that are less easily degraded or extruded by the bacteria. While antibiotic 
resistance is common in most pathogenic bacteria, resistant S. pneumoniae are 
particularly rampant that in approximately thirty percent of severe IPD cases in the USA, 
the bacterium is fully resistant to one or more clinically relevant antibiotics [14]. 
Additionally, the pneumococcus is a highly recombinogenic and competent bacteria that 
readily takes up resistance-conferring DNA fragments [15], and can adjust its 
transformation rates in response to various environmental stimuli, including vaccines and 
antibiotics [7, 15, 16]. To curb resistance and effectively manage IPD, development of new 
classes of antimicrobials is necessary. Identification of genes essential for bacterial 
growth and viability is prerequisite to discovery of molecular targets upon which drugs 
could subsequently be developed. Next generation sequencing technologies have 
granted access to higher levels of genome organization making it easier to identify gene 
function and potentially essential genes. 
In Chapter 3, we explore a proof-of-concept study for the discovery of essential genes in 
the pneumococcus which form promising molecular targets upon which antimicrobial 
drugs could be developed. We employed various in vitro and in silico analyses to address 
caveats in traditional drug discovery pipelines that hamper speed and precision. 
Identification of essential genes is a prerequisite to the discovery of drug target. This 
process customarily relied on rigorous analysis of fitness defects of single mutants 
through appropriate in vitro or in vivo conditions with techniques that were far from high-
throughput. Signature Tagged Mutagenesis; STM marked the first step towards high-
throughput screening for essential genes [17]. In STM, single mutants in a pool of up to 96 
tagged mutants are screened before and after a conditional challenge by detecting 
mutant-specific DNA tags using southern hybridization. STM, owing to the DNA tag, is 
highly specific but could only screen a few mutants at a time. The advent of microarray-
based methods like Genomic Array Footprinting; GAF and Transposon Site Hybridization; 
TraSH [18-20] further improved on the throughput but, these methods were prone to low 
resolution and inaccurate results due to cross-hybridization, impreciseness of locating the 
insertion site, and inherent drawbacks of the microarray platform such as skewed signals.  
With the recently developed technologies like Tn-seq [21], TraDIS [22], INSeq [23], and 
HITS [24] that rely on high-throughput sequencing of transposon insertion sites, 
transposon mutant libraries can now be screened at higher resolutions in tracking 
insertion sites. We exploited an integrative approach that uses genome-wide transposon 
 
 
  
mutagenesis, high-throughput transposon sequencing and analysis with the Tn-seq 
schema [21] implemented in the ESSENTIALS pipeline [25], and comparative genomics; 
to discover essential genes and prioritize drug targets in certain strains of Streptococcus 
pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis: these are the most 
prevalent bacteria that cause respiratory tract infections; RTI [26]. This approach explores 
the exhaustive power of transposon insertions sequencing (Tn-seq) complemented with 
in silico tracking to rapidly identify essential genes. Like in previous essentiality screens, it 
was observed that approximately 20% of all genes in these species are essential to 
growth and viability. Candidate essential genes were further subjected to a comparative 
selection criterion to identify a subset of 249 potential target proteins that have no 
homologues in the human host and human microbiota. This subset constituted of 67 
genes that are verified target to 75 FDA-approved antimicrobial and 35 other small 
molecule inhibitors. The capacity to identify some verity was likely to increase confidence 
in moving these targets into drug development. In that respect, we experimentally 
validated the inhibition of bacterial growth using commercially available small-molecule 
inhibitors of four novel targets using Kirby-Bauer disk diffusion susceptibility test [27]. 
This approach relied on literature for known inhibitors and assumed that the inhibitor 
molecule did not target alternative pathways to cause the lethal phenotype. Therefore, it 
was not unequivocally conclusive on the inhibited function. Nonetheless, the small-scale 
laboratory assays we performed have provided leads on which analogous active 
compound could be synthesized and optimized. We further tested for the toxicity of 
these inhibitors on human cell-lines and computed their effective inhibitory 
concentrations. This approach addresses issues that hamper accurate and fast discovery 
of drug targets, and could speed up the process of rational drug design. 
High throughput genome sequencing and computational approaches are already used as 
an addendum to circumvent the tedious laboratory screens conventionally used to screen 
for essential genes and prioritize drug targets [28-32]. As reviewed in Chapter 2, 
transposon insertion sequencing methods, including Tn-seq, show a remarkable degree 
of accuracy and sensitivity in predicting gene essentiality. Nonetheless, for these 
methods to be reliable, they demand saturated mutant libraries and precise deep 
sequencing making them costly and laborious. This was evident in the number of 
essential genes we identified in each strain relative to the corresponding transposon 
mutant libraries. The more saturated libraries of S. pneumoniae R6 and TIGR4 strains led 
to a small but perhaps more accurate set of essential genes; 325 and 414 respectively. 
These were expected to contain less false positives as compared with H. influenzae 86-
028NP which had 532 essential genes from a mutant library that was less saturated. 
Other ab initio computational approaches developed to predict essential genes and drug 
targets are feeble in terms of predicting conditionally essential genes, scaling to different 
organisms or experimental conditions, and they often require seed biological or 
biophysicochemical information which is difficult to obtain [33, 34]. Experimental 
validation of gene function in also expected. This was traditionally achieved by gene-
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knockout or gene silencing, and subsequently observing the ensuing phenotype, a 
process that often takes a lot of time and resources to accomplish. Luckily, there is 
optimism around the future of computer-guided drug-discovery. Recently developed 
high-throughput molecular docking (HTMD) approaches have become increasingly 
important tool for drug discovery [35]. Compared with traditional experimental 
approaches, HTMD allows for a more direct and rational screening of millions of 
compounds for leads at low cost and high effectiveness. Because most HTMD methods 
require structural information of the target proteins and a database of chemicals, we did 
not perform these assays. We anticipate that future research will take advantage of these 
high-throughput methods and identify promising clinical candidates that target the 
essential pathways we have reported. 
Overall, advances in high-throughput approaches have permitted a deeper understanding 
of gene function. This chapter demonstrates that genome sequencing technologies and 
high-throughput genomic screens could reliably be incorporated into rational drug design 
to improve on speed, precision, and robustness. Most importantly, we have improved the 
general understanding of bacterial pathogens of the respiratory tract, and identified 
novel drug targets and putative inhibitors that form a solid basis for experimental 
validation. It is our hope that a follow-up studies will lead to the development of novel 
antimicrobial drugs against major bacterial pathogens of the respiratory tract. 
The post-vaccine population genomics of invasive pneumococci  
The efficient competence machinery of the pneumococcus enables this microorganism to 
readily accept exogenous genetic material and evolve rapidly [36, 37]. Strategies to 
control IPD continue being deployed despite the evident dearth of a detailed 
understanding of how the pneumococcus evolves in response to these clinical 
interventions. It is therefore critical to precisely monitor circulating pneumococcal strains 
and evaluate emerging evolutionary patterns in response to clinical interventions. 
Chapter 4 has contributed to our understanding of the post-vaccine population dynamics 
of invasive pneumococcus in adults through ‘herd protection’. This is a form of indirect 
protection that occurs when a large percentage of a population has been vaccinated. In 
such a population where the majority is immune to an infection, the chain of infection is 
disrupted thereby stopping or slowing the spread of disease and providing a measure of 
protection for the few individuals who are not vaccinated [38]. We elucidated the genetic 
variations that occurred in sequenced genomes of 350 pneumococcal isolates from adult 
IPD patients during the years between 2000 and 2011, the period before and after the 
introduction of 7-valent PCV (PCV7) in the Netherlands: PCV7 was introduced into the 
Dutch National Immunization program for pediatrics in 2007. The ‘core genome’ 
phylogeny; represented by genes present in single copies in all 350 isolates, revealed a 
tight clustering of clades according to the capsular serotypes, indicating a correlation 
between genotype and serotype. Like in nasopharyngeal carriage [7], a steady decrease 
 
 
  
in adulthood IPD cases caused by vaccine-types was observed after the introduction of 
PCV7. This reduction in cases of IPD in unimmunized adults following a mass pediatric 
immunization supports the herd protection (cross-protection) effect of PCV. Also, there 
was a massive serotype replacement of vaccine-types with non-vaccine serotypes in our 
disease cohorts. Post-vaccine S. pneumoniae infections were dominated by strains 
expressing non-vaccine capsular types mainly serotypes 1, 3, 7F, and 8, which have 
surprisingly been reported to be less frequent in asymptomatic carriage [39]. 
The selective pressure induced by pneumococcal conjugate vaccines has been implicated 
in causing capsular switches although in rare occasions [7]. Research has, however, 
reported that the existence of capsular switch singly should not considerably impact the 
efficacy of PCV on IPD incidence [40]. Nonetheless, recombination of capsular 
polysaccharide synthesis genes has been recognized as the main driver of structural and 
antigenic heterogeneity of capsule types. Therefore, the significant PCV-induced 
recombination may directly lead to vaccine-escape when a vaccine-type takes up and 
expresses a non-vaccine capsule [6], or trigger the development of chimeric serotypes 
that may diverge in their interaction with the host immune system [41]. In our 
unvaccinated adults, capsular switches -typified by the presence of an eccentric serotype 
within an otherwise monophyletic clade- involved the acquisition of both vaccine and 
non-vaccine capsular serotypes, and were only found in isolates collected before the 
introduction of PCV7. This precludes adaptation to vaccine-pressure as the driver of these 
capsule switches. 
The introduction of PCV7 also caused a sharp drop in the diversity the core and accessory 
genome shortly after 2007. However, subsequent years saw a considerable re-expansion 
of the genomes and a return towards equilibrium which was mainly contributed by genes 
extant pre-vaccination. This tendency of the strains to recover the genes after 
perturbation by vaccines perhaps points to the importance of these genes to the 
pneumococci for thriving during carriage and invasive disease. Alternatively, strains 
carrying these genes may have previously existed, albeit unsuccessful in outcompeting 
the vaccine-types in the absence of vaccine pressure. This dynamic post-vaccine 
reshuffling of the pneumococcal genome could actually enlarge the repertoire of 
virulence factors subsequently altering strains invasiveness potential. For example, 
Cremers et al [42] observed in their IPD cohort that patients infected by pneumococcal 
strains expressing zinc metalloproteinase C (ZmpC) in their genome often presented 
more severe clinical symptoms and more frequently required intensive care as compared 
to patients infected with stains lacking zmpC. These findings demonstrate that presence 
of certain pneumococcal genetic factors may therefore be useful in monitoring the 
clinical manifestation and predict predicting the course of IPD. 
The rollout of massive immunization programs with PCV around the world has 
remarkably reduced episodes of IPD caused by vaccine types both in vaccinated 
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knockout or gene silencing, and subsequently observing the ensuing phenotype, a 
process that often takes a lot of time and resources to accomplish. Luckily, there is 
optimism around the future of computer-guided drug-discovery. Recently developed 
high-throughput molecular docking (HTMD) approaches have become increasingly 
important tool for drug discovery [35]. Compared with traditional experimental 
approaches, HTMD allows for a more direct and rational screening of millions of 
compounds for leads at low cost and high effectiveness. Because most HTMD methods 
require structural information of the target proteins and a database of chemicals, we did 
not perform these assays. We anticipate that future research will take advantage of these 
high-throughput methods and identify promising clinical candidates that target the 
essential pathways we have reported. 
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to improve on speed, precision, and robustness. Most importantly, we have improved the 
general understanding of bacterial pathogens of the respiratory tract, and identified 
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validation. It is our hope that a follow-up studies will lead to the development of novel 
antimicrobial drugs against major bacterial pathogens of the respiratory tract. 
The post-vaccine population genomics of invasive pneumococci  
The efficient competence machinery of the pneumococcus enables this microorganism to 
readily accept exogenous genetic material and evolve rapidly [36, 37]. Strategies to 
control IPD continue being deployed despite the evident dearth of a detailed 
understanding of how the pneumococcus evolves in response to these clinical 
interventions. It is therefore critical to precisely monitor circulating pneumococcal strains 
and evaluate emerging evolutionary patterns in response to clinical interventions. 
Chapter 4 has contributed to our understanding of the post-vaccine population dynamics 
of invasive pneumococcus in adults through ‘herd protection’. This is a form of indirect 
protection that occurs when a large percentage of a population has been vaccinated. In 
such a population where the majority is immune to an infection, the chain of infection is 
disrupted thereby stopping or slowing the spread of disease and providing a measure of 
protection for the few individuals who are not vaccinated [38]. We elucidated the genetic 
variations that occurred in sequenced genomes of 350 pneumococcal isolates from adult 
IPD patients during the years between 2000 and 2011, the period before and after the 
introduction of 7-valent PCV (PCV7) in the Netherlands: PCV7 was introduced into the 
Dutch National Immunization program for pediatrics in 2007. The ‘core genome’ 
phylogeny; represented by genes present in single copies in all 350 isolates, revealed a 
tight clustering of clades according to the capsular serotypes, indicating a correlation 
between genotype and serotype. Like in nasopharyngeal carriage [7], a steady decrease 
 
 
  
in adulthood IPD cases caused by vaccine-types was observed after the introduction of 
PCV7. This reduction in cases of IPD in unimmunized adults following a mass pediatric 
immunization supports the herd protection (cross-protection) effect of PCV. Also, there 
was a massive serotype replacement of vaccine-types with non-vaccine serotypes in our 
disease cohorts. Post-vaccine S. pneumoniae infections were dominated by strains 
expressing non-vaccine capsular types mainly serotypes 1, 3, 7F, and 8, which have 
surprisingly been reported to be less frequent in asymptomatic carriage [39]. 
The selective pressure induced by pneumococcal conjugate vaccines has been implicated 
in causing capsular switches although in rare occasions [7]. Research has, however, 
reported that the existence of capsular switch singly should not considerably impact the 
efficacy of PCV on IPD incidence [40]. Nonetheless, recombination of capsular 
polysaccharide synthesis genes has been recognized as the main driver of structural and 
antigenic heterogeneity of capsule types. Therefore, the significant PCV-induced 
recombination may directly lead to vaccine-escape when a vaccine-type takes up and 
expresses a non-vaccine capsule [6], or trigger the development of chimeric serotypes 
that may diverge in their interaction with the host immune system [41]. In our 
unvaccinated adults, capsular switches -typified by the presence of an eccentric serotype 
within an otherwise monophyletic clade- involved the acquisition of both vaccine and 
non-vaccine capsular serotypes, and were only found in isolates collected before the 
introduction of PCV7. This precludes adaptation to vaccine-pressure as the driver of these 
capsule switches. 
The introduction of PCV7 also caused a sharp drop in the diversity the core and accessory 
genome shortly after 2007. However, subsequent years saw a considerable re-expansion 
of the genomes and a return towards equilibrium which was mainly contributed by genes 
extant pre-vaccination. This tendency of the strains to recover the genes after 
perturbation by vaccines perhaps points to the importance of these genes to the 
pneumococci for thriving during carriage and invasive disease. Alternatively, strains 
carrying these genes may have previously existed, albeit unsuccessful in outcompeting 
the vaccine-types in the absence of vaccine pressure. This dynamic post-vaccine 
reshuffling of the pneumococcal genome could actually enlarge the repertoire of 
virulence factors subsequently altering strains invasiveness potential. For example, 
Cremers et al [42] observed in their IPD cohort that patients infected by pneumococcal 
strains expressing zinc metalloproteinase C (ZmpC) in their genome often presented 
more severe clinical symptoms and more frequently required intensive care as compared 
to patients infected with stains lacking zmpC. These findings demonstrate that presence 
of certain pneumococcal genetic factors may therefore be useful in monitoring the 
clinical manifestation and predict predicting the course of IPD. 
The rollout of massive immunization programs with PCV around the world has 
remarkably reduced episodes of IPD caused by vaccine types both in vaccinated 
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pediatrics and in unvaccinated adults through herd protection. However, the full effects 
of mass vaccination with PCVs are not well understood. Studies have reported a risk of 
the emergence of replacement invasive vaccine-escape strains. Continuous surveillance is 
therefore necessary to better understand the effects of mass vaccination on circulating 
pneumococcal strains. This study revealed the herd immunity effect and the 
perturbations of pediatric immunization with PCV7 on the population epidemiology of 
invasive pneumococci in adults. Furthermore, the chapter presents whole-genome 
sequencing as a powerful tool for molecular epidemiological surveillance of 
pneumococcal strains at a genomic level resolution. These advances will significantly 
influence the modelling of future interventions. 
Correlating pneumococcal genetic profiles with phenotypes of antibiotic resistance 
and clinical manifestation of IPD 
Because the capsule is known to be vital for virulence and is the target for the PCV-
induced serotype-specific protection against IPD, there has been little focus on other 
genotypic factors in development of vaccines. Until now, the pneumococcal invasiveness 
has been entirely based on the capsular serotypes. However, it is highly unlikely that 
capsular serotype solitarily outlines pneumococcal pathogenicity [43]. If this was the case, 
genetically divergent strains expressing identical capsular serotype should have a similar 
potential for invasiveness. Other genetic factors, but the capsule, have been shown to 
determine variations in pneumococcal pathogenicity [43-46]. Therefore, sequence types 
will perhaps be insufficient to explain the invasiveness of individual strains especially 
within a highly recombinogenic species such as the pneumococcus. Whole-genome 
sequencing holds the key to understanding the interplay between ecology and genetic 
adaptation, and identifying other genes outside the capsular loci, or genetic variations 
that confer invasiveness [46, 47].  
Chapters 5 and 6 explore the use of whole-genome sequencing and genome-wide 
association studies (GWAS) to give insight into how pneumococcal genotypic variants 
give rise to antimicrobial resistance and clinical eventuality of invasive pneumococcal 
disease respectively. Research has strived in identifying variations, especially single 
nucleotide polymorphisms (SNP) and presence or absence of certain genes, in genomes 
of bacterial pathogens - including the pneumococcus - that confer resistance to various 
antibiotics [48-50]. In a world in which antibiotics are widely used, we need to know much 
more in general about development of inexorable antibiotic resistance and the 
emergence of multi-drug resistant invasive strains of S. pneumoniae, to help improve 
diagnosis and choice of antibiotic(s) [51]. A recently published study explores the use of 
de Bruijn graphs on genome sequence data to identify species and detect antibiotic 
resistance profiles in clinical samples of Staphylococcus aureus and Mycobacterium 
tuberculosis in silico [48]. The model showed over 99% sensitivity and specificity across 12 
antibiotics for S. aureus, and a slightly lower specificity (98.5%) at 82.6% sensitivity for M. 
 
 
  
tuberculosis: these values are comparable to gold-standard phenotypic methods, 
demonstrating the feasibility of using genome sequencing data with in silico approaches 
in rapid diagnostics. 
In Chapter 5, we investigated the distance to antimicrobial resistance using 1682 
literature and in-house S. pneumoniae genomes. First we identified resistance-conferring 
SNPs using GWAS. The clonal nature of pneumococcal lineages and their high rates of 
recombination demand a correction for population stratification to break the strong 
linkage disequilibrium which often inflates the association test p-values obscuring true 
causal variants among ‘hitch-hikers’ in association studies. Population stratification can 
be performed using genomic control [52]; whereby all p-values are normalized with a 
single inflation factor λ or through inference of ancestry by identifying genetic 
subpopulations within the overall population and testing for associations conditional on 
these subpopulations. Population substructures are heuristically inferred using various 
approached, for example Bayesian Analysis of Population Structure; BAPS [53], principal 
component analysis; PCA in EIGENSTRAT [54] and multi-dimensional scaling in PLINK 
[55]. Starting with a concatenated super-alignment of all variant regions on the core 
genome of 1682 pneumococcal isolates, we determined subpopulations as sequence 
clusters; SCs using BAPS. Also, we generated a phylogeny on the alignment and inferred 
SCs using a clustering method proposed by Prosperi et al [56] which partitions 
phylogenies. We tested for associations between whole-genome SNPs and resistance to 
antibiotics (penicillin, trimethoprim, co-trimoxazole, erythromycin, ofloxacin, 
ciprofloxacin, and tobramycin) conditional on these SCs. Resistance-conferring mutations 
(SNPs) were localized mainly in genes previously associated with resistance against the 
classes of antibiotics we tested. They include penicillin binding proteins (pbp1A, pbp2A, 
and pbpX); pneumococcal surface protein (pspA, pspC); multi-drug resistance efflux pump 
(pmrA); dihydrofolate reductase (dyr); and dihydropteroate synthase (folP/sulA). Other 
mutations however appeared in novel putative resistance genes like transcription factor 
(rarA) and heme exporter protein A (ccmA) for fluoroquinolone resistance, and the cell 
division proteins (gpsB, ftsL, ftsX) for penicillin resistance.  
A plasmid-borne efflux pump oqxAB in Escherichia coli confers resistance to quinolones 
[57]. More recently studies have shown that mutations in an oqxAB homolog in Klebsiella 
pneumoniae (oqxR) led to overexpression of rarA, which encodes the oqxAB 
transcriptional regulator, eliciting cross-resistance to quinolones [58-61]. RarA may 
therefore be implicated in up-regulation or down-regulation of the expression of the 
oqxAB drug efflux pumps. More studies will be required to characterize the exact 
mechanisms, whether direct or indirect, through which the mutations seen on rarA 
influence quinolone resistance in the pneumococcus. While dissemination of conjugative 
plasmid-derived antibiotic resistance genes is common in bacteria [62-64], to our 
knowledge, mutational-driven resistance by plasmid-borne genes has not been reported 
yet. CcmA on the other hand is implicated in biofilm formation in Streptococcus gordonii. 
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pediatrics and in unvaccinated adults through herd protection. However, the full effects 
of mass vaccination with PCVs are not well understood. Studies have reported a risk of 
the emergence of replacement invasive vaccine-escape strains. Continuous surveillance is 
therefore necessary to better understand the effects of mass vaccination on circulating 
pneumococcal strains. This study revealed the herd immunity effect and the 
perturbations of pediatric immunization with PCV7 on the population epidemiology of 
invasive pneumococci in adults. Furthermore, the chapter presents whole-genome 
sequencing as a powerful tool for molecular epidemiological surveillance of 
pneumococcal strains at a genomic level resolution. These advances will significantly 
influence the modelling of future interventions. 
Correlating pneumococcal genetic profiles with phenotypes of antibiotic resistance 
and clinical manifestation of IPD 
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induced serotype-specific protection against IPD, there has been little focus on other 
genotypic factors in development of vaccines. Until now, the pneumococcal invasiveness 
has been entirely based on the capsular serotypes. However, it is highly unlikely that 
capsular serotype solitarily outlines pneumococcal pathogenicity [43]. If this was the case, 
genetically divergent strains expressing identical capsular serotype should have a similar 
potential for invasiveness. Other genetic factors, but the capsule, have been shown to 
determine variations in pneumococcal pathogenicity [43-46]. Therefore, sequence types 
will perhaps be insufficient to explain the invasiveness of individual strains especially 
within a highly recombinogenic species such as the pneumococcus. Whole-genome 
sequencing holds the key to understanding the interplay between ecology and genetic 
adaptation, and identifying other genes outside the capsular loci, or genetic variations 
that confer invasiveness [46, 47].  
Chapters 5 and 6 explore the use of whole-genome sequencing and genome-wide 
association studies (GWAS) to give insight into how pneumococcal genotypic variants 
give rise to antimicrobial resistance and clinical eventuality of invasive pneumococcal 
disease respectively. Research has strived in identifying variations, especially single 
nucleotide polymorphisms (SNP) and presence or absence of certain genes, in genomes 
of bacterial pathogens - including the pneumococcus - that confer resistance to various 
antibiotics [48-50]. In a world in which antibiotics are widely used, we need to know much 
more in general about development of inexorable antibiotic resistance and the 
emergence of multi-drug resistant invasive strains of S. pneumoniae, to help improve 
diagnosis and choice of antibiotic(s) [51]. A recently published study explores the use of 
de Bruijn graphs on genome sequence data to identify species and detect antibiotic 
resistance profiles in clinical samples of Staphylococcus aureus and Mycobacterium 
tuberculosis in silico [48]. The model showed over 99% sensitivity and specificity across 12 
antibiotics for S. aureus, and a slightly lower specificity (98.5%) at 82.6% sensitivity for M. 
 
 
  
tuberculosis: these values are comparable to gold-standard phenotypic methods, 
demonstrating the feasibility of using genome sequencing data with in silico approaches 
in rapid diagnostics. 
In Chapter 5, we investigated the distance to antimicrobial resistance using 1682 
literature and in-house S. pneumoniae genomes. First we identified resistance-conferring 
SNPs using GWAS. The clonal nature of pneumococcal lineages and their high rates of 
recombination demand a correction for population stratification to break the strong 
linkage disequilibrium which often inflates the association test p-values obscuring true 
causal variants among ‘hitch-hikers’ in association studies. Population stratification can 
be performed using genomic control [52]; whereby all p-values are normalized with a 
single inflation factor λ or through inference of ancestry by identifying genetic 
subpopulations within the overall population and testing for associations conditional on 
these subpopulations. Population substructures are heuristically inferred using various 
approached, for example Bayesian Analysis of Population Structure; BAPS [53], principal 
component analysis; PCA in EIGENSTRAT [54] and multi-dimensional scaling in PLINK 
[55]. Starting with a concatenated super-alignment of all variant regions on the core 
genome of 1682 pneumococcal isolates, we determined subpopulations as sequence 
clusters; SCs using BAPS. Also, we generated a phylogeny on the alignment and inferred 
SCs using a clustering method proposed by Prosperi et al [56] which partitions 
phylogenies. We tested for associations between whole-genome SNPs and resistance to 
antibiotics (penicillin, trimethoprim, co-trimoxazole, erythromycin, ofloxacin, 
ciprofloxacin, and tobramycin) conditional on these SCs. Resistance-conferring mutations 
(SNPs) were localized mainly in genes previously associated with resistance against the 
classes of antibiotics we tested. They include penicillin binding proteins (pbp1A, pbp2A, 
and pbpX); pneumococcal surface protein (pspA, pspC); multi-drug resistance efflux pump 
(pmrA); dihydrofolate reductase (dyr); and dihydropteroate synthase (folP/sulA). Other 
mutations however appeared in novel putative resistance genes like transcription factor 
(rarA) and heme exporter protein A (ccmA) for fluoroquinolone resistance, and the cell 
division proteins (gpsB, ftsL, ftsX) for penicillin resistance.  
A plasmid-borne efflux pump oqxAB in Escherichia coli confers resistance to quinolones 
[57]. More recently studies have shown that mutations in an oqxAB homolog in Klebsiella 
pneumoniae (oqxR) led to overexpression of rarA, which encodes the oqxAB 
transcriptional regulator, eliciting cross-resistance to quinolones [58-61]. RarA may 
therefore be implicated in up-regulation or down-regulation of the expression of the 
oqxAB drug efflux pumps. More studies will be required to characterize the exact 
mechanisms, whether direct or indirect, through which the mutations seen on rarA 
influence quinolone resistance in the pneumococcus. While dissemination of conjugative 
plasmid-derived antibiotic resistance genes is common in bacteria [62-64], to our 
knowledge, mutational-driven resistance by plasmid-borne genes has not been reported 
yet. CcmA on the other hand is implicated in biofilm formation in Streptococcus gordonii. 
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Loss of expression could have a variety of effects on metabolic activity, and on protein 
and peptide secretion and trafficking [65]. Moreover, ccmA mutants show a phenotype of 
aberrant cell wall morphology [66], indicating that this gene may be involved in cell-wall 
biogenesis. Biofilm formation is a simple strategy of microbial survival and persistence. 
The biofilm formation process itself is complex, involving a variety of genes, and 
influenced by several environmental factors [67, 68]. Bacteria in biofilm communities 
exhibit an inherent tolerance to antibiotics and host immunity [69]. Biofilm formation in 
pneumococci has been shown to enhance strains fitness and virulence [67, 68]. Of 
particular interest is the ability of antibiotic-susceptible strains to form thicker biofilms 
compared to resistant strains [70], perhaps as a strategy to resist antibiotics. The 
functions played by ccmA in promoting bacterial sessility may be suggestive of its 
importance in antibiotic resistance. Donati et al [71] predicted a fast-growing 
pneumococcal pan-genome characterized by a large gene repertoire, and postulated that 
the microorganism remains open to novel evolutionary possibilities by rapidly acquiring 
and integrating novel genes.  
In recent years, creating antimicrobial compounds designed to inhibit the bacterial 
divisome has been recognized as a promising strategy for antibiotic attack [72, 73]. 
Interfering with proteins involved in bacterial cell division blocks the pathogen’s 
proliferation leading death. GpsB and ftsL play a role in cell division and are essential for 
complete cell wall formation. FtsL forms a complex with other essential genes that co-
localize at the division site to regulate the cell-division [74]; deletion of one or more 
components destabilizes this complex hampering the cell division apparatus [74-76]. On 
the other hand, mutants of GpsB show phenotypes of cell deformation similar to those 
observed in methicillin-mediated inhibition of the penicillin binding protein (Pbp2x) [77]. 
Whether these cell division proteins potentially interact with pbp genes, either directly or 
indirectly through regulation or participation in cell wall formation remains unclear. It will 
be interesting and important for future studies to experimentally elucidate and 
characterize the mechanisms of how alterations in transcription regulation, biofilm 
formation, and cell division factors influence resistance to quinolone and beta-lactams 
respectively. All in all, by aggregating the odds ratios (ORs) effect of candidate SNPs for 
each genome, we were able to partition the resistance phenotypes and identify resistant 
strains in each population. 
Whole-genome sequencing technologies have great potential, in the future, in simplifying 
the diagnostic laboratory workflow thus becoming a part of routine clinical practice. 
Currently, the phenotypic tests used to determine antibiograms take days to complete. 
There is a shift towards rapid sequencing-based diagnostics, but the link between 
genotype and phenotype has not been perfected yet. Studies like this one should results 
into a model that allows the prediction of antibiograms from genome sequencing data. It 
is also noteworthy that the NCBI has started a database; National Database of Antibiotic 
Resistant Organisms (NDARO), which collates and makes publicly available the resistance 
 
 
  
phenotypes and corresponding genome sequences of infectious organisms. Such 
initiatives will provide a unique platform for rapid assessment of the presence of 
resistance genes using assembled genomes. At present however, sequencing-based 
diagnostics require optimizations to eliminate methodological and technical errors from 
sample collection, sequencing and analysis because these generally lead to false positive 
results. Nonetheless, these technologies have aided in understanding the evolutionary 
variations and observing their dynamics in evolving pneumococcal lineages. This study 
shows that whole-genome sequencing could be employed to develop novel easy-to-use 
clinical diagnostic assays that may provide consistent results in rapid detection of drug-
resistant pneumococcal strains. Moreover, the data generated here is invaluable for 
evaluating pneumococcal selection to antibiotic resistance and evolution of strains in 
response to antimicrobial drugs. This information could inform future drug development 
and enhance surveillance of circulating pneumococcal strains to be vigilant on the 
emergence of novel resistance mechanisms. 
Chapter 6 improves our understanding on how pneumococcal genotypic variations affect 
the severity of IPD. The utilization of whole-genome sequencing and analysis 
technologies to predict and characterize pathogen virulence has been emphasized in 
recent times [78, 79]. To discover genetic variants that associate with clinical 
manifestation of IPD, we analyzed the accessory genome (the flexible gene pool) of 350 
invasive pneumococci isolated from patients admitted with pneumococcal disease in two 
hospitals in Nijmegen, the Netherlands. Generally, IPD patients exhibit a plethora of 
diverse clinical outcomes, begging the question whether certain pneumococcal genotypic 
traits contribute to these outcomes. If indeed there are essential pneumococcal traits 
linked to disease manifestation, they have important implications for prevention of IPD. 
In this study, we identified genes significantly associated with pneumonia, meningitis, 
and 30-day mortality. They included genes previously associated with these clinical 
phenotypes and novel genes that required experimental validation. Extensive vaccination 
with current vaccines which target a limited number of circulating pneumococcal strains 
has led to significant serotype replacement that rescinds the benefits of pneumococcal 
vaccination. The possibility still exists of identifying proteins conferring invasiveness or 
contributing to clinical eventuality of disease, and using them as candidate targets for 
future vaccine. In this study, most of the disease-associated factors we identified changed 
in percentage prevalence following the introduction of PCV7. They include CDP-Glycerol-
1-Phosphate Biosynthetic Protein (gct) and phospholipase A2 (slaA) that have been 
implicated in meningitis and pblB which is implicated in promoting mortality. It is still 
unclear whether these perturbations affect virulence factors and consequently the 
eventuality of pneumococcal disease. However, research has shown that some genotypic 
factors associated with the replacing non-vaccine strains might play a role in exacerbating 
the clinical manifestation of pneumococcal disease [42] and promoting antibiotic 
resistance [80]. Unfortunately, we lacked a second cohort with relevant metadata to 
validate our findings and increase confidence in verity. It is our hope that as the costs for 
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phenotypes and corresponding genome sequences of infectious organisms. Such 
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shows that whole-genome sequencing could be employed to develop novel easy-to-use 
clinical diagnostic assays that may provide consistent results in rapid detection of drug-
resistant pneumococcal strains. Moreover, the data generated here is invaluable for 
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response to antimicrobial drugs. This information could inform future drug development 
and enhance surveillance of circulating pneumococcal strains to be vigilant on the 
emergence of novel resistance mechanisms. 
Chapter 6 improves our understanding on how pneumococcal genotypic variations affect 
the severity of IPD. The utilization of whole-genome sequencing and analysis 
technologies to predict and characterize pathogen virulence has been emphasized in 
recent times [78, 79]. To discover genetic variants that associate with clinical 
manifestation of IPD, we analyzed the accessory genome (the flexible gene pool) of 350 
invasive pneumococci isolated from patients admitted with pneumococcal disease in two 
hospitals in Nijmegen, the Netherlands. Generally, IPD patients exhibit a plethora of 
diverse clinical outcomes, begging the question whether certain pneumococcal genotypic 
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linked to disease manifestation, they have important implications for prevention of IPD. 
In this study, we identified genes significantly associated with pneumonia, meningitis, 
and 30-day mortality. They included genes previously associated with these clinical 
phenotypes and novel genes that required experimental validation. Extensive vaccination 
with current vaccines which target a limited number of circulating pneumococcal strains 
has led to significant serotype replacement that rescinds the benefits of pneumococcal 
vaccination. The possibility still exists of identifying proteins conferring invasiveness or 
contributing to clinical eventuality of disease, and using them as candidate targets for 
future vaccine. In this study, most of the disease-associated factors we identified changed 
in percentage prevalence following the introduction of PCV7. They include CDP-Glycerol-
1-Phosphate Biosynthetic Protein (gct) and phospholipase A2 (slaA) that have been 
implicated in meningitis and pblB which is implicated in promoting mortality. It is still 
unclear whether these perturbations affect virulence factors and consequently the 
eventuality of pneumococcal disease. However, research has shown that some genotypic 
factors associated with the replacing non-vaccine strains might play a role in exacerbating 
the clinical manifestation of pneumococcal disease [42] and promoting antibiotic 
resistance [80]. Unfortunately, we lacked a second cohort with relevant metadata to 
validate our findings and increase confidence in verity. It is our hope that as the costs for 
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genome-sequencing decreases, more data will be made available for similar studies. 
Overall, our results suggest that modeling of future pneumococcal vaccines requires 
diversification from exclusively targeting the capsular serotypes and capitalize on 
tailoring for other disease inflating genetic factors in circulating pneumococcal strains. By 
increasing the range of vaccine targets, the selective pressure on the pneumococcal 
populations in general could be reduced, subsequently limiting the undesirable serotype 
replacement and capsular switches thus enhancing the efficacy of future vaccines. The 
findings in this chapter also recap the biological significance of genetic factors that lie 
beneath the capsule since the replacement strains may exhibit different virulence 
potential. The study also reinforces that perhaps more studies need to be performed in 
this realm to monitor the emerging genotypic and phenotypic patterns following clinical 
interventions. 
Chapter 7 further explores the clinical role of a phage-encoded gene pblB (OG_ 17) in the 
mortality of patients with IPD. The majority of clinically relevant pneumococcal isolates 
have been shown to carry bacteriophages [81]. It is also widely accepted that bacteria 
could acquire virulence properties from these mobile genetic elements [82]; however, the 
role of bacteriophages in pathogenesis of IPD remains largely unknown. A GWAS analysis 
of 350 pneumococcal genomes revealed that pblB was positively associated (p-value = 
0.00034 Bonferroni corrected for multiple testing) with ‘all-cause’ mortality in IPD 
patients within the first 30 days of hospitalization (30-day mortality). PblB, phage-
encoded surface protein, was shown to partly mediate in vitro platelets binding by 
Streptococcus mitis [83, 84]. More recent studies on pneumophages have shown the 
importance of pblB in promoting persistence and fitness both in the nasopharynx and the 
lungs, and in facilitating pneumococcal adhesion to platelets and epithelial cells [85, 86]. 
The adhesion is thought to promote pneumococcal clonal success and pathogenicity. For 
instance, an in vivo mouse model showed that pblB deletion resulted in reduced 
adherence, biofilm formation, reduced initial infection within the lungs, and a reduction in 
the number of circulating platelets [87].  
We observed an inclination towards later fatality among IPD cases involving pneumococci 
carrying the pblB gene; pblB+ (mean 6.6 vs 3.0 days, p-value 0.09). Even though 
expression of prophage genes was known to be induced by antibiotics, it was unknown 
whether pneumophages could specifically be induced by fluoroquinolones. In our study 
sub-lethal doses of ciprofloxacin and levofloxacin were optimal for the induction of pblB, 
whereas beta-lactam antibiotic penicillin G did not induce the expression. However, there 
were no differences in 30-day mortality between patients who were treated with 
fluoroquinolones and those who were not. Perhaps a larger cohort, preferably from a 
different country where fluoroquinolones are used to manage IPD, would be necessary to 
verify these findings. Platelet activation occurs in patients with pneumonia or sepsis and 
has previously been shown to enhance development of hyperinflammation, 
microthrombosis, myocardial infarction and multiple organ failure [88, 89]. Increased 
 
 
  
platelet activation has also been shown to be a predictor of mortality in older septic 
patients [90]. In our study after the induction of pblB with levofloxacin, the pneumococci 
triggered higher platelet surface expression of P-selectin and platelet monocyte complex 
formation. This study highlights the clinical utility of bacterial GWAS, followed by 
functional characterization in identifying bacterial factors involved in disease severity. 
Concluding remarks 
The next-generation genome sequencing (NGS) and analysis technologies such as 
metagenomics-based screening are very likely to become an alternative to the 
conventional laboratory methods used for bacteriology. In fact, the technology is already 
being used to complement traditional experimental approaches for molecular 
diagnostics, rational vaccine and antibiotic design, molecular epidemiology and mapping 
of disease outbreaks [91-93]. In addition, NGS is likely to transform our insight on 
mechanisms of infection, sanctioning rational preventive measures [94] thus reducing the 
risk of unwarranted interventions [95]. NGS and metagenomics-based screens have also 
allowed for a means to circumvent culturing steps, and determine the presence of 
particular ‘risky’ functionalities, including virulence factors and antibiotic resistance 
markers, collectively transforming the way we do microbial research. Presently however, 
the different NGS techniques have different attributes impeding the development of a 
universal methodology for data management and analysis. Software developers are also 
facing challenges to cope with the escalating amount of genomes and genome-
sequencing data, and ensure harmonized integration with relevant metadata as well as 
prudent stewardship and sharing. Additionally NGS is not cost-effective for routine and 
offers only predictions: phenotypic validations might still be necessary. Nonetheless, 
efforts are currently being made to create a universal database, dubbed global 
pneumococcal sequencing project; GPS that collates pneumococcal isolates, their genome 
sequences, and the associated clinical metadata [96]. In addition, the National Institutes 
of Health has financed, to a tune of $10 million, a multidisciplinary team of researchers to 
study the role of the immune system in the emergence of antibiotic-resistant bacteria. 
The team will apply cutting-edge high-throughput genomics applications and methods to 
elucidate the interplay between bacterial genetic adaptation, host immunity and clinical 
intervention. Already, genome sequencing and bioinformatics have proven to be pivotal 
in these ventures and they have provided critical insights into the biology of the 
pneumococcus. When completed, these studies will provide platforms for observing the 
genomic diversity and genetic adaptations of S. pneumoniae strains in response to current 
clinical interventions and the host immune response. The aim is to guide modelling of 
better next-generation interventions that avoid escape and resistance. Most of the data 
analyzed in this thesis will be integrated into the global database adding new data-points 
to the repository.  
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to the repository.  
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Largely, the findings presented in this thesis have broadened our understanding in the 
utilization of whole-genome sequencing and bioinformatics in rational designing of 
antimicrobial drugs, assessment of the drug resistance profiles in strains and designing of 
novel diagnostic assays; monitoring the dynamics of population genomics and adaptation 
to clinical intervention; characterizing pneumococcal virulence repertoires; and surveying 
the acquisition and/or dissemination of virulence factors to provide a future trajectory of 
the invasiveness potential of circulating strains. Our methods and findings also dovetail 
neatly with current technological and literature advances, and they open up new avenues 
for future pneumococcal research. As such, this thesis puts to the forefront the important 
practical applications of bioinformatics and NGS in augmenting and furthering 
pneumococcal bacteriology. 
  
 
 
  
References 
1. World Health Organization. Pneumococcal vaccines. Weekly epidemiological record 78, 
110-119 (2003). 
2. Bogaert, D., Hermans, P.W.M., Adrian, P.V., Rümke, H.C. & de Groot, R. Pneumococcal 
vaccines: an update on current strategies. Vaccine 22, 2209-2220 (2004). 
3. van Deursen, A.M., van Mens, S.P., Sanders, E.A., Vlaminckx, B.J., de Melker, H.E., 
Schouls, L.M., de Greeff, S.C. & van der Ende, A. Invasive pneumococcal disease and 7-
valent pneumococcal conjugate vaccine, the Netherlands. Emerg Infect Dis 18, 1729-37 
(2012). 
4. Hanage, W.P., Finkelstein, J.A., Huang, S.S., Pelton, S.I., Stevenson, A.E., Kleinman, K., 
Hinrichsen, V.L. & Fraser, C. Evidence that pneumococcal serotype replacement in 
Massachusetts following conjugate vaccination is now complete. Epidemics 2, 80-84 
(2010). 
5. Cremers, A.J.H., Mobegi, F.M., de Jonge, M.I., van Hijum, S.A.F.T., Meis, J.F., Hermans, 
P.W.M., Ferwerda, G., Bentley, S.D. & Zomer, A.L. The post-vaccine microevolution of 
invasive Streptococcus pneumoniae. Scientific Reports 5, 14952 (2015). 
6. Brueggemann, A.B., Pai, R., Crook, D.W. & Beall, B. Vaccine Escape Recombinants 
Emerge after Pneumococcal Vaccination in the United States. PLoS Pathog 3, e168 
(2007). 
7. Croucher, N.J., Finkelstein, J.A., Pelton, S.I., Mitchell, P.K., Lee, G.M., Parkhill, J., Bentley, 
S.D., Hanage, W.P. & Lipsitch, M. Population genomics of post-vaccine changes in 
pneumococcal epidemiology. Nat Genet 45, 656-63 (2013). 
8. Dr Margaret Chan. Antimicrobial resistance in the European Union and the world: The 
EU’s contributions to the solutions of the global antimicrobial resistance problem. in Keynote 
address at the Conference on Combating Antimicrobial Resistance: time for action (14 March 
2012) (Copenhagen, Denmark, 2012). 
9. Fleming, A., Chain, E.B. & Florey, H. Penicillin: Nobel Lecture, December 11, 1945. Vol. 
2016 (The Nobel Foundation, Stockholm, Sweden, 1945). 
10. Alvares, J.R., Mantese, O.C., Paula, A.d., Wolkers, P.C.B., Almeida, V.V.P., Almeida, 
S.C.G., Guerra, M.L.L.S. & Brandileone, M.C.d.C. Prevalence of pneumococcal serotypes 
and resistance to antimicrobial agents in patients with meningitis: ten-year analysis. 
Brazilian Journal of Infectious Diseases 15, 22-27 (2011). 
11. Davidson, R., Cavalcanti, R., Brunton, J.L., Bast, D.J., de Azavedo, J.C.S., Kibsey, P., 
Fleming, C. & Low, D.E. Resistance to Levofloxacin and Failure of Treatment of 
Pneumococcal Pneumonia. New England Journal of Medicine 346, 747-750 (2002). 
12. Descheemaeker, P., Chapelle, S., Lammens, C., Hauchecorne, M., Wijdooghe, M., 
Vandamme, P., Ieven, M. & Goossens, H. Macrolide resistance and erythromycin 
resistance determinants among Belgian Streptococcus pyogenes and Streptococcus 
pneumoniae isolates. Journal of Antimicrobial Chemotherapy 45, 167-173 (2000). 
13. Feikin, D.R., Schuchat, A., Kolczak, M., Barrett, N.L., Harrison, L.H., Lefkowitz, L., 
McGeer, A., Farley, M.M., Vugia, D.J., Lexau, C., Stefonek, K.R., Patterson, J.E. & 
Jorgensen, J.H. Mortality from invasive pneumococcal pneumonia in the era of antibiotic 
resistance, 1995-1997. Am J Public Health 90, 223-9 (2000). 
14. U.S. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the 
United States, 2013. (2014). 
42613 maati, Frederick.indd   168 04-10-16   16:08
General discussion | 169
8
 
 
  
Largely, the findings presented in this thesis have broadened our understanding in the 
utilization of whole-genome sequencing and bioinformatics in rational designing of 
antimicrobial drugs, assessment of the drug resistance profiles in strains and designing of 
novel diagnostic assays; monitoring the dynamics of population genomics and adaptation 
to clinical intervention; characterizing pneumococcal virulence repertoires; and surveying 
the acquisition and/or dissemination of virulence factors to provide a future trajectory of 
the invasiveness potential of circulating strains. Our methods and findings also dovetail 
neatly with current technological and literature advances, and they open up new avenues 
for future pneumococcal research. As such, this thesis puts to the forefront the important 
practical applications of bioinformatics and NGS in augmenting and furthering 
pneumococcal bacteriology. 
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Dutch summary (Samenvatting) 
Streptococcus pneumoniae, ook wel de pneumokok genoemd, is een Gram positieve 
bacterie met een ronde (-coccus) vorm die zich het beste thuis voelt in de neusholte 
(nasopharynx) van gezonde mensen. In sommige gevallen kan de bacterie infiltreren in 
plekken die normaal gesproken steriel zijn zoals de longen, het midden-oor, het bloed en 
de hersenen. Hier veroorzaakt de bacterie ernstige ziektes zoals longontsteking, 
oorontsteking en hersenvliesontsteking. De pneumokok is daarom een van de 
belangrijkste oorzaken van ziekenhuis opname en sterfte, meer dan 1 miljoen mensen 
overlijden aan infecties van deze bacterie per jaar. De belasting die invasieve 
pneumokokken infecties op de wereld gezondheid veroorzaakt behoeft onze aandacht. 
Onze kennis van genoom sequencing om het genetische materiaal van een organisme in 
kaart te brengen en de toepassingen hiervan in de microbiologie zijn sterk toegenomen in 
de afgelopen jaren. Het doel van dit proefschrift was om deze sequencing technologieën 
te combineren met bioinformatische analyses en lab experimenten om zo ons begrip over 
S. pneumoniae te verbeteren. Dit werk heeft geresulteerd in uitgebreide studies van de 
genoom sequenties van honderden pneumokokken, geïsoleerd in de omgeving van 
Nijmegen over een periode van 10 jaar. Tezamen met de klinische informatie over ziekten 
veroorzaakt door deze bacterie en de vaccinatie status van de bevolking is onderzoek 
gedaan naar de opmaak van de genetische structuur van de populatie van pneumokokken 
en het effect op ziekte. Met deze informatie hebben wij gekeken naar hoe de genetische 
eigenschappen van de pneumokok ervoor zorgen dat deze ziekte wordt veroorzaakt, hoe 
deze ziekte zich manifesteert en hoe antibiotica resistentie zich ontwikkeld en verspreid. 
Verder is onderzocht hoe we nieuwe aangrijpingspunten voor antibiotica ontwikkeling 
kunnen ontdekken voor behandeling van ziekte veroorzaakt door de pneumokok. 
Identificatie van nieuwe antibiotica 
Resistentie tegen antibiotica stijgt aldoor en bedreigt de meeste, zo dan niet alle, 
eerstelijns antibiotica, inclusief penicilline. Als hier niets aan gedaan wordt, zullen 
simpele, behandelbare infecties niet meer te stoppen zijn. Om antibiotica resistentie bij 
invasieve pneumokokken infecties effectief te voorkomen zijn nieuwe antibiotica nodig. 
Voor het vinden van nieuwe antibiotica zullen nieuwe aangrijpingspunten geïdentificeerd 
moeten worden die essentieel zijn voor de groei en levensvatbaarheid van de 
pneumokok. In hoofdstuk 2 wordt het gebruik van high throughput technieken en 
computationele benaderingen beschreven als alternatief voor tijdrovende en kostbare 
laboratorium technieken. Next generation sequencing methoden zouden een toevoeging 
of alternatief kunnen zijn voor traditionele kweek gebaseerde methodes om essentiële 
genen te vinden die gebruikt kunnen worden als aangrijpingspunten voor de ontwikkeling 
van nieuwe antibiotica. In hoofdstuk 3 wordt een concept studie beschreven waarin we 
essentiële genen in pneumokokken ontdekken die als aangrijpingspunt voor nieuwe 
antibiotica kunnen dienen. Normaal gesproken is het ontwikkelen van nieuwe antibiotica 
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erg tijdrovend en duur, maar door slimme combinaties van genoom sequencing, 
bioinformatica en traditionele technieken hebben we 249 potentiele aangrijpingspunten 
ontdekt. Hieronder zitten 67 bekende eiwitten en hun producten, waarop de 75 FDA 
(Amerikaanse food and drug agency)-toegekende antibiotica voor zijn ontwikkeld. De 
nieuw gevonden eiwitten zouden kunnen worden als aangrijpingspunt voor ontwikkeling 
van nieuwe antibiotica. We hebben vier van deze nieuwe aangrijpingspunten 
experimenteel gevalideerd door gebruik te maken van commercieel beschikbare kleine 
moleculen die zouden moeten binden aan de eiwitten gevonden in deze studie. Deze 
methode zou antibiotica ontwikkeling in een stroomversnelling kunnen brengen. 
Evolutie van de pneumokok tijdens een actief vaccinatiebeleid 
Van de pneumokok is bekend dat deze zeer gemakkelijk DNA kan opnemen van uit zijn 
omgeving. Hierdoor kan hij snel nieuwe eigenschappen verkrijgen die helpen bij zijn 
overleving. Voor de behandeling van invasieve pneumokokken infectie zou meer kennis 
beschikbaar moeten zijn over hoe de pneumokok zich handhaaft tijdens interventies 
zoals vaccinatie. In hoofdstuk 4 hebben we de genoom sequenties van 350 
pneumokokken, geïsoleerd van volwassen patiënten uit 2 ziekenhuizen in Nijmegen, 
onderzocht om de genetische verschillen in de pneumokokken populatie te onderzoeken 
voor en na de invoering van een landelijk pediatrisch pneumokokken vaccin. We 
observeerden dat stammen met dezelfde genetische achtergrond vaak hetzelfde kapsel 
(suikers die een soort ‘schild’ vormen om pneumokok cellen) hebben. Ook zagen we dat 
ziekte veroorzakende stammen die een kapsel hadden waartegen gevaccineerd wordt 
verdwenen na introductie van het vaccin. Deze vermindering van ziekte bij volwassenen 
door stammen met dit kapsel suggereert dat er zogenaamde kudde immuniteit optreed 
door vaccinatie van kinderen. Het totaal aantal ziekte gevallen bij volwassenen bleef 
echter gelijk. Dit kwam door de toename van pneumokokken met een kapsel type dat 
niet in het vaccin zat. Twee mechanismen zijn hiervoor mogelijk: 1. verandering van 
kapsel van de bestaande pneumokokken populatie door opname van DNA of 2: toename 
van andere pneumokokken met een ander kapsel type. Wij observeerden bijna alleen 
situatie 2, toename van andere pneumokokken stammen. Genetische modificatie van het 
kapsel van de bestaande pneumokokken populatie werd niet veroorzaakt door het vaccin. 
We zagen echter wel een zeer drastische daling van de genetische diversiteit 1 jaar na 
introductie van het vaccin. Deze diversiteit keerde echter zeer snel terug naar een 
equilibrium in ziekte veroorzakende pneumokokken. Deze herordening van de diversiteit 
zou het wellicht mogelijk maken dat andere ziekte versterkende genen zich nestelen in de 
nieuwe populatie van pneumokokken, hiervoor zijn echter meer studies nodig. Dit 
onderzoek heeft ons begrip vergroot over hoe vaccinatie effect heeft op de 
pneumokokken populatie en laat zien dat genoom sequencen een belangrijke 
surveillance methode zou kunnen zijn om deze effecten in kaart te brengen hetgeen 
belangrijk is als nieuwe vaccins worden toegepast. 
 
  
 
De relatie tussen genetische blauwdruk van de pneumokok, antibiotica resistentie en 
manifestatie van ziekte 
In de toekomst zou het mogelijk kunnen zijn om zeer snel diagnostiek te kunnen 
toepassen op microbiële infecties door middel van genoom sequencing. Huidige 
fenotypische testen op antibiotica resistentie kosten enkele dagen, wat wellicht te lang is 
voor een adequate behandeling. Genotypische testen, waarbij het genoom van de 
infectie veroorzakende bacterie wordt gebruikt om te voorspellen welke resistentie deze 
heeft zijn nog niet uitontwikkeld. In hoofdstukken 5 en 6 wordt het gebruik van genoom 
sequencing behandelt om inzichten te krijgen in welke genetische factoren de 
pneumokok gebruikt om resistent te worden en waarom bepaalde infecties een ernstiger 
verloop hebben dan anderen. In hoofdstuk 5 hebben we de optelsom van de mutaties 
bepaald die nodig zijn voor volledige resistenties aan de hand van 1682 genoom 
sequenties van pneumokokken. We hebben mutaties gevonden die betrokken zijn bij 
resistenties tegen penicilline, trimethoprim, co-trimoxazole, erythromycine, ofloxacine, 
ciprofloxacine, and tobramycine. Resistentie werd veroorzaakt door mutaties in sleutel 
genen die betrokken zijn bij essentiële cellulaire processen. Ook vonden we enkele genen 
die, mits aanwezig, een verhoogde antibiotica resistentie geven. We laten zien dat een 
catalogus van deze resistentie veroorzakende mutaties en genen gebruikt kan worden 
om de mate van resistentie te voorspellen in meerdere pneumokokken. De studie in 
hoofdstuk 5 laat zien dat genoom sequencing gebruikt zou kunnen worden om nieuwe 
diagnostische testen te ontwikkelen waarbij snelle detectie van antibiotica resistentie 
centraal staat.  
Invasieve pneumokokken infectie uit zich op veel verschillende manieren. De relatie 
tussen de genetische blauwdruk van de pneumokok en het ziektebeeld is een logisch 
verband om te onderzoeken gezien de diversiteit in het kapsel en de virulentie factoren in 
de pneumokokken populatie. Als er inderdaad genen zijn die betrokken zijn bij het 
verloop van de ziekte, zou informatie over de prevalentie in de pneumokokken populatie 
van belang zijn. In hoofdstuk 6 worden alle genen van 350 invasieve pneumokokken 
onderzocht en welke relatie zij hebben met het veroorzaken van longontsteking, 
hersenvlies ontsteking en sterfte binnen 30 dagen na ziekenhuisopname. Onze 
bevindingen suggereren dat bepaalde genen inderdaad geassocieerd zijn met het ziekte 
beeld. Het moleculaire mechanisme hiervan is echter onbekend. In hoofdstuk 7 
behandelen wij één van deze associaties van een pneumokokken gen dat mogelijk 
betrokken is bij binding aan bloedplaatjes. Dit gen bevindt zich op een bacteriofaag 
ingenesteld in het genoom van de pneumokok. We observeerden dat mensen die 
geïnfecteerd zijn door pneumokokken met dit gen een sterk verhoogd risico op sterfte 
binnen 30 dagen hebben. Interessant genoeg blijkt de bacteriofaag, met het gen dat 
betrokken is bij betere binding van de pneumokok aan bloedplaatjes, ingeschakeld te 
worden bij bepaalde antibiotica behandelingen. We observeerden dat de pneumokokken 
veel meer van het bloedplaatjes bindende eiwit tot expressie brachten na blootstelling 
aan fluoroquinolonen, een bepaalde klasse antibiotica. Evenwel zagen we geen verschil in 
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sterfte zelf na behandeling met deze antibiotica. Dit kan echter komen doordat het 
cohort van patiënten te klein is om deze verschillen op te merken. Over-activatie van 
bloedplaatjes gebeurt in patiënten met longontsteking en sepsis. In het verleden is 
aangetoond dat dit orgaan falen veroorzaakt, hetgeen veelal een doodsoorzaak is in 
patiënten die binnen 30 dagen overlijden. Identificatie van pneumokokken die een 
dergelijk gen bij zich dragen zou kunnen bijdragen aan het kiezen van een adequate 
behandelingsmethode. 
Next generation sequencing en verdere bioinformatische analyses zijn technieken die 
uitermate geschikt zijn om de kennis over de pneumokok uit te breiden. Dit proefschrift 
benadrukt de noodzaak om dit soort nieuwe technieken te ontwikkelen om ziekte 
veroorzaakt door de pneumokok in kaart te brengen en in te dammen. 
  
 
  
 
Author affiliation 
Aldert L. Zomer P1,2,11P, Amelieke J.H. Cremers P1,4 P, Andre J. van der Ven P3P, Christa E. Gaast de 
JonghP1P, Elles SimonettiP1P, Fredrick M. MobegiP1,2,12 P, Gerben Ferwerda P1P, Hester J. 
Bootsma P1,13P, Jacques F. Meis P4,5 P, Jeroen Langereis P1P, Marien I. de JongeP1P, Nel RoeleveldP6,7P, 
Peter Burghout P1,14 P, Peter W.M. Hermans P1,15 P, Quirijn de Mast P3P, Rahajeng N. TunjungputriP3,8 P, 
Sacha A.F.T. van Hijum P2,9P, Stefan P.W. de Vries P1, 16P, Stephen D. Bentley P10 P. 
 
P
1 
PLaboratory of Pediatric Infectious Diseases, Department of Pediatrics, Radboud Institute for 
Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands. 
P
2 
PCenter for Molecular and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences, 
Radboud University Medical Center, Nijmegen, The Netherlands.  
P
3 
PDepartment of Internal Medicine, Radboud Institute for Molecular Life Sciences, Radboud 
University Medical Center, Nijmegen, The Netherlands. 
P
4 
PDepartment of Medical Microbiology, Radboud Institute for Molecular Life Sciences, Radboud 
University Medical Center, Nijmegen, The Netherlands. 
P
5 
PCanisius-Wilhelmina Hospital, Department of Medical Microbiology and Infectious Diseases, 
Nijmegen, The Netherlands. 
P
6 
PDepartment for Health Evidence, Radboud Institute for Health Sciences, Radboud university 
medical center, Nijmegen, The Netherlands.  
P
7 
PDepartment of Pediatrics, Radboud Amalia Children's Hospital, Radboud University Medical 
Center, Nijmegen, The Netherlands.  
P
8 
PCenter for Tropical and Infectious Diseases, Faculty of Medicine Diponegoro University - Dr. Karzai 
Hospital, Semarang, Indonesia.  
P
9 
PNIZO food research, Ede 6710 BA, The Netherlands 
P
10
P Pathogen Genomics Group, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, 
Hinxton Cambridge, United Kingdom. 
 
Current address 
P
11 
PDepartment of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht 
University, Utrecht, The Netherlands. 
P
12 
PDivision of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The 
Netherlands 
P
13 
PNational Institute of Public Health and the Environment (RIVM), Beethoven, The Netherlands. 
P
14 
PCrucell-Johnson and Johnson, Janssen Pharmaceutical Companies of Johnson & Johnson, Leiden, 
The Netherlands  
P
15 
PJanssen Research and Development, Janssen Pharmaceutical Companies of Johnson & Johnson, 
Beerse, Belgium. 
P
16 
PDepartment of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom 
  
42613 maati, Frederick.indd   182 04-10-16   16:08
A 
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